ID,Imprinted Gene,Gene,Paternal/Maternal,Variant and risk allele,P-value,P-value annotation,RAF,OR,Beta,CI,Mapped gene,Reported trait,Trait(s),Study accession,Location,Grouping
465,GLI3,GLI3,Paternal,rs4724100-<b>C</b>,2 x 10-6,,0.45,1.14,'-,[1.08-1.21],GLI3,Allergic rhinitis,seasonal allergic rhinitis,GCST001310,7:42225080,Allergy
464,GLI3,GLI3,Paternal,rs10233459-<b>G</b>,4 x 10-6,(African),0.05,1.57,'-,[1.30‐1.91],GLI3,Asthma,asthma,GCST005212,7:42001387,Allergy
634,GLIS3,GLIS3,Paternal,rs10814853-<b>T</b>,3 x 10-8,,0.311041,'-,0.053840246 unit decrease,[0.035-0.073],GLIS3,"Medication use (adrenergics, inhalants)",Inhalant adrenergic use measurement,GCST007941,9:4144996,Allergy
729,DIRAS3,GNG12-AS1,Paternal,rs74574132-<b>T</b>,9 x 10-6,,NR,'-,0.0470779 unit decrease,[0.026-0.068],GNG12-AS1,Itch intensity from mosquito bite adjusted by bite size,"mosquito bite reaction itch intensity measurement, mosquito bite reaction size measurement",GCST004862,1:67938637,Allergy
730,DIRAS3,GNG12-AS1,Paternal,rs11209185-<b>G</b>,4 x 10-6,(women),NR,'-,0.0209418 unit decrease,[0.012-0.03],GNG12-AS1,Itch intensity from mosquito bite adjusted by bite size,"mosquito bite reaction itch intensity measurement, mosquito bite reaction size measurement",GCST004862,1:67956491,Allergy
731,DIRAS3,GNG12-AS1,Paternal,rs74664319-<b>G</b>,2 x 10-6,,NR,'-,0.0583796 unit increase,[0.034-0.083],GNG12-AS1,Itch intensity from mosquito bite,mosquito bite reaction itch intensity measurement,GCST004861,1:67979464,Allergy
2540,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,4 x 10-6,,NR,'-,'-,'-,PLAGL1,Asthma (adult onset),adult onset asthma,GCST009842,6:143977063,Allergy
2541,PLAGL1,PLAGL1,Paternal,rs17073303-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,PLAGL1,Peanut allergy (maternal genetic effects),"peanut allergy measurement, parental genotype effect measurement",GCST005723,6:144034900,Allergy
2564,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,5 x 10-10,,NR,'-,'-,'-,PLAGL1,Adult onset asthma and/or BMI,"adult onset asthma, body mass index",GCST009868,6:143977063,Allergy
3211,ZIM2,ZIM2,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Allergy
3226,ZIM2,ZIM2-AS1,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Allergy
52,CCDC71L,CCDC71L,Paternal,rs2286149-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,"CCDC71L, AC004917.1",Waist-hip ratio,waist-hip ratio,GCST007067,7:106659346,Anthropometric
130,DIO3,DIO3,Paternal,rs1955614-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,"DIO3, LINC02320",Height,body height,GCST007841,14:101586438,Anthropometric
199,DLK1,DLK1,Paternal,rs28473022-<b>A</b>,1 x 10-9,,0.0506,'-,0.03446812 unit increase,[0.023-0.046],"DLK1, AL132711.1",Predicted visceral adipose tissue,visceral adipose tissue measurement,GCST008744,14:100695518,Anthropometric
200,DLK1,DLK1,Paternal,rs11160601-<b>?</b>,2 x 10-7,,NR,'-,0.1998 unit increase,[0.12-0.28],"DLK1, AL132711.1",Fat-free mass,lean body mass,GCST007063,14:100720304,Anthropometric
201,DLK1,DLK1,Paternal,rs11160601-<b>?</b>,2 x 10-9,(female),NR,'-,0.25359 unit increase,[0.17-0.34],"DLK1, AL132711.1",Fat-free mass,lean body mass,GCST007063,14:100720304,Anthropometric
202,DLK1,DLK1,Paternal,rs11160601-<b>?</b>,4 x 10-11,,NR,'-,'-,'-,"DLK1, AL132711.1",Body mass index,body mass index,GCST009871,14:100720304,Anthropometric
203,DLK1,DLK1,Paternal,rs117182230-<b>?</b>,1 x 10-18,,NR,'-,0.049768448 unit decrease,[0.039-0.061],DLK1,Height,body height,GCST008839,14:100729932,Anthropometric
204,DLK1,DLK1,Paternal,rs3783350-<b>?</b>,1 x 10-19,,NR,'-,'-,'-,DLK1,Height,body height,GCST007841,14:100732685,Anthropometric
205,DLK1,DLK1,Paternal,rs78420139-<b>G</b>,4 x 10-8,,0.944649,'-,0.0170415 unit increase,[0.011-0.023],DLK1,Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,14:100735350,Anthropometric
279,DNMT1,DNMT1,Paternal,rs117952191-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,"DNMT1, EIF3G",Heel bone mineral density,heel bone mineral density,GCST007066,19:10122946,Anthropometric
280,DNMT1,DNMT1,Paternal,rs78333947-<b>?</b>,8 x 10-39,,NR,'-,'-,'-,DNMT1,Height,body height,GCST007841,19:10143085,Anthropometric
281,DNMT1,DNMT1,Paternal,rs55818584-<b>A</b>,3 x 10-7,,0.2312,'-,0.0122 unit decrease,[0.0075-0.0169],"S1PR2, DNMT1",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST008994,19:10221871,Anthropometric
316,DSCAM,DSCAM,Paternal,rs2837398-<b>A</b>,5 x 10-9,,0.595776,'-,0.00819988 unit decrease,[0.0055-0.0109],DSCAM,Adult body size,body height,GCST010988,21:40055241,Anthropometric
317,DSCAM,DSCAM,Paternal,rs2837398-<b>?</b>,9 x 10-10,,NR,'-,'-,'-,DSCAM,Body mass index,body mass index,GCST009871,21:40055241,Anthropometric
318,DSCAM,DSCAM,Paternal,rs2837398-<b>A</b>,1 x 10-10,,0.6075,'-,0.0112 unit decrease,[0.0079-0.0145],DSCAM,Body mass index,body mass index,GCST009004,21:40055241,Anthropometric
319,DSCAM,DSCAM,Paternal,rs2249498-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,DSCAM,Body mass index,body mass index,GCST007039,21:40059947,Anthropometric
320,DSCAM,DSCAM,Paternal,rs7282525-<b>?</b>,1 x 10-11,,NR,'-,'-,'-,DSCAM,Height,body height,GCST007841,21:40088485,Anthropometric
321,DSCAM,DSCAM,Paternal,rs3804024-<b>G</b>,3 x 10-6,(Height z-score ),0.035,'-,0.03 SD increase,[NR],"DSCAM-IT1, DSCAM",Obesity-related traits,body height,GCST001762,21:40621781,Anthropometric
322,DSCAM,DSCAM,Paternal,rs3804024-<b>G</b>,9 x 10-7,(Arm span ),0.035,'-,0.03 cm increase,[NR],"DSCAM-IT1, DSCAM",Obesity-related traits,arm span,GCST001762,21:40621781,Anthropometric
339,DSCAM,DSCAM,Paternal,rs2249498-<b>?</b>,5 x 10-7,,'-,'-,'-,'-,DSCAM,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A,"Charcot-Marie-Tooth disease type 1A, foot muscle strength measurement",GCST008539,21:40059947,Anthropometric
340,DSCAM,DSCAM,Paternal,rs774787160-<b>A</b>,1 x 10-8,,0.73,'-,0.0983 unit increase,'-,"DSCAM-IT1, DSCAM",Low hand grip strength (60 years and older) (EWGSOP),grip strength measurement,GCST90007528,21:40624759,Anthropometric
354,DSCAM,DSCAM-IT1,Paternal,rs3804024-<b>G</b>,3 x 10-6,(Height z-score ),0.035,'-,0.03 SD increase,[NR],"DSCAM-IT1, DSCAM",Obesity-related traits,body height,GCST001762,21:40621781,Anthropometric
355,DSCAM,DSCAM-IT1,Paternal,rs3804024-<b>G</b>,9 x 10-7,(Arm span ),0.035,'-,0.03 cm increase,[NR],"DSCAM-IT1, DSCAM",Obesity-related traits,arm span,GCST001762,21:40621781,Anthropometric
357,DSCAM,DSCAM-IT1,Paternal,rs774787160-<b>A</b>,1 x 10-8,,0.73,'-,0.0983 unit increase,'-,"DSCAM-IT1, DSCAM",Low hand grip strength (60 years and older) (EWGSOP),grip strength measurement,GCST90007528,21:40624759,Anthropometric
466,GLI3,GLI3,Paternal,rs2237422-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,GLI3,Height,body height,GCST007841,7:42061332,Anthropometric
467,GLI3,GLI3,Paternal,rs10269139-<b>?</b>,9 x 10-8,,NR,'-,0.13109 unit increase,[0.083-0.179],GLI3,Fat-free mass,lean body mass,GCST007063,7:42108589,Anthropometric
468,GLI3,GLI3,Paternal,rs10269139-<b>?</b>,3 x 10-8,(male),NR,'-,0.21545 unit increase,[0.14-0.29],GLI3,Fat-free mass,lean body mass,GCST007063,7:42108589,Anthropometric
469,GLI3,GLI3,Paternal,rs57734857-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,GLI3,Height,body height,GCST007841,7:42179969,Anthropometric
470,GLI3,GLI3,Paternal,rs76990766-<b>?</b>,2 x 10-24,,NR,'-,'-,'-,"LINC01448, GLI3",Heel bone mineral density,heel bone mineral density,GCST007066,7:42567314,Anthropometric
471,GLI3,GLI3,Paternal,rs76990766-<b>?</b>,1 x 10-23,,NR,'-,0.0469767 unit decrease,[0.038-0.056],"LINC01448, GLI3",Heel bone mineral density,heel bone mineral density,GCST006433,7:42567314,Anthropometric
472,GLI3,GLI3,Paternal,rs76990766-<b>C</b>,3 x 10-28,,0.94847,'-,0.0452763 unit decrease,[0.037-0.053],"LINC01448, GLI3",Heel bone mineral density,heel bone mineral density,GCST006979,7:42567314,Anthropometric
473,GLI3,GLI3,Paternal,rs1568799-<b>?</b>,3 x 10-11,,NR,'-,'-,'-,"LINC01448, GLI3",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,7:42628277,Anthropometric
474,GLI3,GLI3,Paternal,rs1568799-<b>?</b>,1 x 10-12,,NR,'-,'-,'-,"LINC01448, GLI3",Waist-hip ratio,waist-hip ratio,GCST007067,7:42628277,Anthropometric
475,GLI3,GLI3,Paternal,rs13223303-<b>T</b>,9 x 10-7,,0.7073,'-,0.0106 unit increase,[0.0063-0.0149],"LINC01448, GLI3",Waist-hip ratio,waist-hip ratio,GCST008997,7:42653112,Anthropometric
476,GLI3,GLI3,Paternal,rs13223303-<b>T</b>,1 x 10-10,,0.7072,'-,0.014 unit increase,[0.0097-0.0183],"LINC01448, GLI3",Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST008994,7:42653112,Anthropometric
477,GLI3,GLI3,Paternal,rs2330627-<b>?</b>,1 x 10-18,,NR,'-,0.0232084 unit decrease,[0.018-0.028],"LINC01448, GLI3",Heel bone mineral density,heel bone mineral density,GCST006433,7:42656903,Anthropometric
504,GLI3,GLI3,Paternal,rs77640775-<b>A</b>,9 x 10-6,,0.137,'-,0.262 unit decrease,[0.15-0.38],GLI3,Digit length ratio (right hand),digit length ratio,GCST005748,7:42151115,Anthropometric
505,GLI3,GLI3,Paternal,rs77640775-<b>A</b>,4 x 10-8,,0.137,'-,0.291 unit decrease,[0.19-0.39],GLI3,Digit length ratio,digit length ratio,GCST005750,7:42151115,Anthropometric
506,GLI3,GLI3,Paternal,rs77640775-<b>A</b>,2 x 10-6,,0.136,'-,0.241 unit decrease,[0.14-0.34],GLI3,Digit length ratio (left hand),digit length ratio,GCST005749,7:42151115,Anthropometric
507,GLI3,GLI3,Paternal,rs77640775-<b>A</b>,2 x 10-6,(EA),0.137,'-,0.252 unit decrease,[0.15-0.36],GLI3,Digit length ratio (left hand),digit length ratio,GCST005749,7:42151115,Anthropometric
512,GLIS3,GLIS3,Paternal,rs702266-<b>T</b>,4 x 10-8,,0.871444,'-,0.055043 unit increase,[0.035-0.075],GLIS3,Appendicular lean mass,appendicular lean mass,GCST009577,9:3917685,Anthropometric
513,GLIS3,GLIS3,Paternal,rs927315-<b>T</b>,6 x 10-6,,0.474,'-,0.0291 unit increase,[0.017-0.042],GLIS3,Height,body height,GCST008163,9:4117713,Anthropometric
514,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,1 x 10-6,,0.6011,'-,0.0338 unit decrease,[0.02-0.047],GLIS3,Height,body height,GCST008163,9:4118111,Anthropometric
515,GLIS3,GLIS3,Paternal,rs12554350-<b>T</b>,3 x 10-6,,0.3045,'-,0.0328 unit increase,[0.019-0.047],GLIS3,Height,body height,GCST008163,9:4154004,Anthropometric
516,GLIS3,GLIS3,Paternal,rs1983753-<b>?</b>,3 x 10-10,,NR,'-,'-,'-,GLIS3,Height,body height,GCST007841,9:4160364,Anthropometric
517,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,7 x 10-7,,0.4938,'-,0.0008 unit increase,[-0.0005-0.0021],GLIS3,Fasting blood glucose (BMI interaction),"body mass index, fasting blood glucose measurement",GCST001527,9:4289050,Anthropometric
518,GLIS3,GLIS3,Paternal,rs10974438-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,GLIS3,Height,body height,GCST007841,9:4291928,Anthropometric
609,GLIS3,GLIS3,Paternal,rs1403785912-<b>AT</b>,4 x 10-9,,0.52,'-,0.0765 unit increase,'-,GLIS3,Low hand grip strength (60 years and older) (FNIH),grip strength measurement,GCST90007529,9:4284961,Anthropometric
732,DIRAS3,GNG12-AS1,Paternal,rs1938434-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,GNG12-AS1,Height,body height,GCST007841,1:67918991,Anthropometric
733,DIRAS3,GNG12-AS1,Paternal,rs12119450-<b>?</b>,1 x 10-13,,NR,'-,0.0185227 unit decrease,[0.013-0.024],GNG12-AS1,Heel bone mineral density,heel bone mineral density,GCST006433,1:67938520,Anthropometric
734,DIRAS3,GNG12-AS1,Paternal,rs12127020-<b>?</b>,2 x 10-14,,NR,'-,'-,'-,GNG12-AS1,Heel bone mineral density,heel bone mineral density,GCST007066,1:67938708,Anthropometric
735,DIRAS3,GNG12-AS1,Paternal,rs4397637-<b>G</b>,6 x 10-20,,0.813715,'-,0.0388858 unit decrease,[0.03-0.047],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006288,1:68137448,Anthropometric
736,DIRAS3,GNG12-AS1,Paternal,rs4397637-<b>G</b>,2 x 10-11,(women),0.812718,'-,0.0383038 unit decrease,[0.027-0.05],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006288,1:68137448,Anthropometric
737,DIRAS3,GNG12-AS1,Paternal,rs4397637-<b>G</b>,7 x 10-10,(men),0.814856,'-,0.0384775 unit decrease,[0.025-0.051],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006288,1:68137448,Anthropometric
738,DIRAS3,GNG12-AS1,Paternal,rs4397637-<b>?</b>,5 x 10-43,,NR,'-,0.035059 unit decrease,[0.03-0.04],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,1:68137448,Anthropometric
739,DIRAS3,GNG12-AS1,Paternal,rs983034-<b>C</b>,2 x 10-31,,0.60349,'-,0.0225488 unit increase,[0.019-0.026],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006979,1:68137903,Anthropometric
740,DIRAS3,GNG12-AS1,Paternal,rs983034-<b>?</b>,8 x 10-45,,NR,'-,0.0279837 unit increase,[0.024-0.032],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006433,1:68137903,Anthropometric
741,DIRAS3,GNG12-AS1,Paternal,rs1430742-<b>C</b>,3 x 10-13,,0.21,'-,0.11 s.d. increase,[0.07-0.14],"GNG12-AS1, WLS",Bone mineral density (spine),bone density,GCST000494,1:68169392,Anthropometric
742,DIRAS3,GNG12-AS1,Paternal,rs2566755-<b>C</b>,2 x 10-12,,0.21,'-,0.1 s.d. increase,[0.07-0.13],"GNG12-AS1, WLS",Bone mineral density (hip),bone density,GCST000495,1:68169707,Anthropometric
743,DIRAS3,GNG12-AS1,Paternal,rs12407028-<b>T</b>,3 x 10-45,,0.6,'-,0.08 unit increase,[NR],"GNG12-AS1, WLS",Lumbar spine bone mineral density,bone density,GCST001482,1:68182033,Anthropometric
744,DIRAS3,GNG12-AS1,Paternal,rs116251444-<b>?</b>,2 x 10-9,,NR,'-,0.0285795 unit decrease,[0.019-0.038],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006433,1:68184950,Anthropometric
745,DIRAS3,GNG12-AS1,Paternal,rs2026749-<b>?</b>,7 x 10-64,,NR,'-,0.0347828 unit increase,[0.031-0.039],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,1:68187806,Anthropometric
746,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>C</b>,3 x 10-9,,0.38,'-,0.16 g/cm2 increase,[0.1-0.22],"WLS, GNG12-AS1",Bone mineral density (spine),spine bone mineral density,GCST003380,1:68191014,Anthropometric
747,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,5 x 10-20,,0.623326,'-,0.0644 unit decrease,[0.051-0.078],"WLS, GNG12-AS1",Femoral neck bone mineral density,femoral neck bone mineral density,GCST005795,1:68191014,Anthropometric
748,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,4 x 10-23,,0.623326,'-,0.0789 unit decrease,[0.063-0.095],"WLS, GNG12-AS1",Lumbar spine bone mineral density,spine bone mineral density,GCST005796,1:68191014,Anthropometric
749,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,7 x 10-31,(European),0.6112,'-,0.0744 unit decrease,'-,"WLS, GNG12-AS1",Total body bone mineral density,bone density,GCST005348,1:68191014,Anthropometric
750,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,1 x 10-11,,0.6056,'-,0.075 unit decrease,'-,"WLS, GNG12-AS1",Total body bone mineral density (age 45-60),bone density,GCST005350,1:68191014,Anthropometric
751,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,2 x 10-14,,0.6119,'-,0.0776 unit decrease,'-,"WLS, GNG12-AS1",Total body bone mineral density (age over 60),bone density,GCST005349,1:68191014,Anthropometric
752,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,3 x 10-54,,0.626833,'-,0.0318699 unit decrease,[0.028-0.036],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006979,1:68191014,Anthropometric
753,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>?</b>,2 x 10-75,,NR,'-,'-,'-,"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST007066,1:68191014,Anthropometric
754,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>T</b>,2 x 10-34,,0.6103,'-,0.0721 unit decrease,'-,"WLS, GNG12-AS1",Total body bone mineral density,bone density,GCST005348,1:68191014,Anthropometric
755,DIRAS3,GNG12-AS1,Paternal,rs2566752-<b>?</b>,4 x 10-73,,NR,'-,0.0385636 unit decrease,[0.034-0.043],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,1:68191014,Anthropometric
756,DIRAS3,GNG12-AS1,Paternal,rs140423501-<b>?</b>,5 x 10-8,,NR,'-,0.08 unit decrease,NR,"WLS, GNG12-AS1",Femoral neck bone mineral density,femoral neck bone mineral density,GCST010268,1:68191125,Anthropometric
757,DIRAS3,GNG12-AS1,Paternal,rs140423501-<b>?</b>,3 x 10-7,,NR,'-,'-,'-,"WLS, GNG12-AS1",Femoral neck bone mineral density and trunk fat mass adjusted by trunk lean mass,"lean mass-adjusted fat body mass, femoral neck bone mineral density",GCST010266,1:68191125,Anthropometric
758,DIRAS3,GNG12-AS1,Paternal,rs1430740-<b>?</b>,1 x 10-11,(spine),NR,'-,'-,'-,"WLS, GNG12-AS1",Bone mineral density,bone density,GCST002276,1:68191827,Anthropometric
759,DIRAS3,GNG12-AS1,Paternal,rs2820501-<b>C</b>,3 x 10-21,,0.0454163,'-,0.0429292 unit increase,[0.034-0.052],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006979,1:68196599,Anthropometric
760,DIRAS3,GNG12-AS1,Paternal,rs78252812-<b>C</b>,2 x 10-10,,0.97214,'-,0.037522 unit decrease,[0.026-0.049],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006979,1:68198221,Anthropometric
761,DIRAS3,GNG12-AS1,Paternal,rs143243230-<b>G</b>,1 x 10-26,,0.463462,'-,0.0368536 unit decrease,[0.03-0.044],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006288,1:68199073,Anthropometric
762,DIRAS3,GNG12-AS1,Paternal,rs143243230-<b>G</b>,1 x 10-17,(women),0.46476,'-,0.0409612 unit decrease,[0.031-0.051],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006288,1:68199073,Anthropometric
763,DIRAS3,GNG12-AS1,Paternal,rs143243230-<b>G</b>,9 x 10-10,(men),0.461976,'-,0.0320586 unit decrease,[0.021-0.043],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006288,1:68199073,Anthropometric
764,DIRAS3,GNG12-AS1,Paternal,rs143243230-<b>?</b>,3 x 10-74,,NR,'-,0.0392969 unit decrease,[0.035-0.044],"GNG12-AS1, WLS",Heel bone mineral density,heel bone mineral density,GCST006433,1:68199073,Anthropometric
765,DIRAS3,GNG12-AS1,Paternal,rs7554551-<b>T</b>,2 x 10-13,,0.65836,'-,0.0155654 unit decrease,[0.011-0.02],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006979,1:68199340,Anthropometric
766,DIRAS3,GNG12-AS1,Paternal,rs7554551-<b>?</b>,2 x 10-36,,NR,'-,0.0275089 unit decrease,[0.023-0.032],"WLS, GNG12-AS1",Heel bone mineral density,heel bone mineral density,GCST006433,1:68199340,Anthropometric
777,GPR1,GPR1,Paternal,rs13011260-<b>?</b>,1 x 10-12,,NR,'-,'-,'-,"EEF1B2, GPR1",Waist-hip ratio,waist-hip ratio,GCST007067,2:206173697,Anthropometric
778,GPR1,GPR1,Paternal,rs114670539-<b>T</b>,5 x 10-8,(EA),NR,'-,0.2699 unit increase,[0.17-0.37],GPR1,Childhood obesity,obesity,GCST009382,2:206199611,Anthropometric
779,GPR1,GPR1,Paternal,rs114670539-<b>T</b>,3 x 10-8,,0.05,'-,0.099 unit increase,[0.064-0.134],GPR1,Childhood body mass index,body mass index,GCST90002409,2:206199611,Anthropometric
780,GPR1,GPR1,Paternal,rs115319174-<b>G</b>,3 x 10-44,,0.942407,'-,0.0423448 unit decrease,[0.036-0.048],GPR1,Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,2:206201750,Anthropometric
876,HECW1,HECW1,Paternal,rs2024125-<b>G</b>,6 x 10-6,(Diet carbohydrate ),0.458,'-,0.02 %energy increase,[NR],"HECW1-IT1, HECW1",Obesity-related traits,energy intake,GCST001762,7:43118878,Anthropometric
877,HECW1,HECW1,Paternal,rs34610745-<b>G</b>,5 x 10-6,,NR,'-,0.2 unit increase,[NR],HECW1,Bone mineral density (Ward's triangle area),femoral neck bone mineral density,GCST003654,7:43294976,Anthropometric
892,HECW1,HECW1-IT1,Paternal,rs2024125-<b>G</b>,6 x 10-6,(Diet carbohydrate ),0.458,'-,0.02 %energy increase,[NR],"HECW1-IT1, HECW1",Obesity-related traits,energy intake,GCST001762,7:43118878,Anthropometric
1237,IGF2,IGF2,Paternal,rs35506085-<b>?</b>,1 x 10-8,(female),NR,'-,0.17954 unit decrease,[0.12-0.24],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1240,IGF2,IGF2,Paternal,rs35506085-<b>?</b>,8 x 10-58,,NR,'-,'-,'-,"INS-IGF2, IGF2-AS",Height,body height,GCST007841,11:2144346,Anthropometric
1247,IGF2,IGF2,Paternal,rs12575480-<b>A</b>,2 x 10-6,(African),0.06211,'-,'-,'-,"IGF2, H19",Pursuit maintenance gain,pursuit maintenance gain measurement,GCST005024,11:2086425,Anthropometric
1275,IGF2,IGF2,Paternal,rs3842763-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,INS-IGF2,Waist-hip ratio,waist-hip ratio,GCST007067,11:2157974,Anthropometric
1292,IGF2,IGF2,Paternal,rs35506085-<b>?</b>,5 x 10-10,,NR,'-,0.17845 unit decrease,[0.12-0.23],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1306,IGF2,IGF2,Paternal,rs7948458-<b>?</b>,4 x 10-7,(weight),NR,'-,0.0137686 unit decrease,[0.0085-0.0191],INS-IGF2,Anthropometric traits,"body weight, body weights and measures",GCST007485,11:2151600,Anthropometric
1307,IGF2,IGF2,Paternal,rs7948458-<b>?</b>,2 x 10-21,,'-,'-,'-,'-,INS-IGF2,Anthropometric traits (multi-trait analysis),body weights and measures,GCST007490,11:2151600,Anthropometric
1316,IGF2,IGF2-AS,Paternal,rs35506085-<b>?</b>,1 x 10-8,(female),NR,'-,0.17954 unit decrease,[0.12-0.24],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1317,IGF2,IGF2-AS,Paternal,rs35506085-<b>?</b>,5 x 10-10,,NR,'-,0.17845 unit decrease,[0.12-0.23],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1319,IGF2,IGF2-AS,Paternal,rs35506085-<b>?</b>,8 x 10-58,,NR,'-,'-,'-,"INS-IGF2, IGF2-AS",Height,body height,GCST007841,11:2144346,Anthropometric
1340,IGF2,INS-IGF2,Paternal,rs7948458-<b>?</b>,4 x 10-7,(weight),NR,'-,0.0137686 unit decrease,[0.0085-0.0191],INS-IGF2,Anthropometric traits,"body weight, body weights and measures",GCST007485,11:2151600,Anthropometric
1341,IGF2,INS-IGF2,Paternal,rs7948458-<b>?</b>,2 x 10-21,,'-,'-,'-,'-,INS-IGF2,Anthropometric traits (multi-trait analysis),body weights and measures,GCST007490,11:2151600,Anthropometric
1353,IGF2,INS-IGF2,Paternal,rs3842763-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,INS-IGF2,Waist-hip ratio,waist-hip ratio,GCST007067,11:2157974,Anthropometric
1355,IGF2,INS-IGF2,Paternal,rs35506085-<b>?</b>,1 x 10-8,(female),NR,'-,0.17954 unit decrease,[0.12-0.24],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1362,IGF2,INS-IGF2,Paternal,rs35506085-<b>?</b>,8 x 10-58,,NR,'-,'-,'-,"INS-IGF2, IGF2-AS",Height,body height,GCST007841,11:2144346,Anthropometric
1384,IGF2,INS-IGF2,Paternal,rs35506085-<b>?</b>,5 x 10-10,,NR,'-,0.17845 unit decrease,[0.12-0.23],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1415,INS,INS,Paternal,rs7948458-<b>?</b>,4 x 10-7,(weight),NR,'-,0.0137686 unit decrease,[0.0085-0.0191],INS-IGF2,Anthropometric traits,"body weight, body weights and measures",GCST007485,11:2151600,Anthropometric
1416,INS,INS,Paternal,rs7948458-<b>?</b>,2 x 10-21,,'-,'-,'-,'-,INS-IGF2,Anthropometric traits (multi-trait analysis),body weights and measures,GCST007490,11:2151600,Anthropometric
1427,INS,INS,Paternal,rs3842763-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,INS-IGF2,Waist-hip ratio,waist-hip ratio,GCST007067,11:2157974,Anthropometric
1428,INS,INS,Paternal,rs35506085-<b>?</b>,1 x 10-8,(female),NR,'-,0.17954 unit decrease,[0.12-0.24],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1431,INS,INS,Paternal,rs35506085-<b>?</b>,8 x 10-58,,NR,'-,'-,'-,"INS-IGF2, IGF2-AS",Height,body height,GCST007841,11:2144346,Anthropometric
1456,INS,INS,Paternal,rs35506085-<b>?</b>,5 x 10-10,,NR,'-,0.17845 unit decrease,[0.12-0.23],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1471,INS,INS-IGF2,Paternal,rs7948458-<b>?</b>,4 x 10-7,(weight),NR,'-,0.0137686 unit decrease,[0.0085-0.0191],INS-IGF2,Anthropometric traits,"body weight, body weights and measures",GCST007485,11:2151600,Anthropometric
1472,INS,INS-IGF2,Paternal,rs7948458-<b>?</b>,2 x 10-21,,'-,'-,'-,'-,INS-IGF2,Anthropometric traits (multi-trait analysis),body weights and measures,GCST007490,11:2151600,Anthropometric
1484,INS,INS-IGF2,Paternal,rs3842763-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,INS-IGF2,Waist-hip ratio,waist-hip ratio,GCST007067,11:2157974,Anthropometric
1486,INS,INS-IGF2,Paternal,rs35506085-<b>?</b>,1 x 10-8,(female),NR,'-,0.17954 unit decrease,[0.12-0.24],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1493,INS,INS-IGF2,Paternal,rs35506085-<b>?</b>,8 x 10-58,,NR,'-,'-,'-,"INS-IGF2, IGF2-AS",Height,body height,GCST007841,11:2144346,Anthropometric
1515,INS,INS-IGF2,Paternal,rs35506085-<b>?</b>,5 x 10-10,,NR,'-,0.17845 unit decrease,[0.12-0.23],"INS-IGF2, IGF2-AS",Fat-free mass,lean body mass,GCST007063,11:2144346,Anthropometric
1522,IRAIN,IRAIN,Paternal,rs191817094-<b>A</b>,1 x 10-6,(African),NR,'-,1.2155 unit increase,[0.72-1.71],"IRAIN, FAM169B",Childhood obesity,obesity,GCST009382,15:98552042,Anthropometric
1523,IRAIN,IRAIN,Paternal,rs28605724-<b>?</b>,2 x 10-19,,NR,'-,'-,'-,"FAM169B, IRAIN",Height,body height,GCST007841,15:98562288,Anthropometric
1524,IRAIN,IRAIN,Paternal,rs9672558-<b>?</b>,7 x 10-63,,NR,'-,0.10059936 unit decrease,[0.089-0.112],"FAM169B, IRAIN",Height,body height,GCST008839,15:98636976,Anthropometric
1525,IRAIN,IRAIN,Paternal,rs56937648-<b>A</b>,1 x 10-11,,0.8495,'-,0.0661 unit increase,[0.047-0.085],"FAM169B, IRAIN",Height,body height,GCST008163,15:98639696,Anthropometric
1526,IRAIN,IRAIN,Paternal,rs1573891-<b>?</b>,1 x 10-14,(male),NR,'-,0.37004 unit decrease,[0.28-0.46],"IRAIN, FAM169B",Fat-free mass,lean body mass,GCST007063,15:98643259,Anthropometric
1527,IRAIN,IRAIN,Paternal,rs1573891-<b>?</b>,2 x 10-18,,NR,'-,0.26621 unit decrease,[0.21-0.33],"IRAIN, FAM169B",Fat-free mass,lean body mass,GCST007063,15:98643259,Anthropometric
2083,LIN28B,LIN28B,Paternal,rs1475120-<b>G</b>,3 x 10-13,,0.452766,'-,0.0133593 unit decrease,[0.0098-0.017],LIN28B,Heel bone mineral density,heel bone mineral density,GCST006979,6:104942078,Anthropometric
2084,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,3 x 10-14,,0.3169,'-,0.0281 unit increase,[0.021-0.035],LIN28B,Waist circumference adjusted for BMI (adjusted for smoking behaviour),"smoking behavior, BMI-adjusted waist circumference",GCST004500,6:104949543,Anthropometric
2085,LIN28B,LIN28B,Paternal,rs314263-<b>T</b>,1 x 10-42,,0.676,'-,0.043 unit decrease,[0.037-0.049],LIN28B,Height,body height,GCST002647,6:104944870,Anthropometric
2086,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,2 x 10-6,"(EA,women)",0.3235,'-,0.0223 unit increase,[0.013-0.032],LIN28B,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST004063,6:104949543,Anthropometric
2087,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,2 x 10-12,"(EA, men)",0.3235,'-,0.0358 unit increase,[0.026-0.046],LIN28B,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST004063,6:104949543,Anthropometric
2088,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,1 x 10-15,(EA),0.3235,'-,0.0288 unit increase,[0.022-0.036],LIN28B,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST004063,6:104949543,Anthropometric
2089,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,3 x 10-6,,0.3169,'-,0.0367 unit increase,[0.021-0.052],LIN28B,Waist circumference adjusted for BMI in smokers,"smoking behavior, BMI-adjusted waist circumference",GCST004503,6:104949543,Anthropometric
2090,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,8 x 10-7,(men),0.3169,'-,0.0548 unit increase,[0.033-0.077],LIN28B,Waist circumference adjusted for BMI in smokers,"smoking behavior, BMI-adjusted waist circumference",GCST004503,6:104949543,Anthropometric
2091,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,2 x 10-11,"(EA, men)",0.3246,'-,0.0438 cm increase,[0.031-0.057],LIN28B,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104949543,Anthropometric
2092,LIN28B,LIN28B,Paternal,rs314276-<b>A</b>,2 x 10-14,,0.3263,'-,0.0553 unit increase,[0.041-0.069],LIN28B,Height,body height,GCST008163,6:104960124,Anthropometric
2093,LIN28B,LIN28B,Paternal,rs62419609-<b>?</b>,2 x 10-11,,NR,'-,'-,'-,LIN28B,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,6:104981636,Anthropometric
2094,LIN28B,LIN28B,Paternal,rs395962-<b>?</b>,1 x 10-175,,NR,'-,'-,'-,LIN28B,Height,body height,GCST007841,6:104949543,Anthropometric
2095,LIN28B,LIN28B,Paternal,rs12207399-<b>?</b>,1 x 10-33,,NR,'-,0.037892476 unit decrease,[0.032-0.044],"LIN28B, LIN28B-AS1",Height,body height,GCST008839,6:104937737,Anthropometric
2096,LIN28B,LIN28B,Paternal,rs11156429-<b>?</b>,3 x 10-15,(EA),0.4566,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104916546,Anthropometric
2097,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,5 x 10-12,(women),0.3414,'-,0.0435 cm increase,[0.031-0.056],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2098,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,4 x 10-11,,0.3303,'-,0.0286 cm increase,[0.02-0.037],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2099,LIN28B,LIN28B,Paternal,rs7759938-<b>?</b>,1 x 10-15,,0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2100,LIN28B,LIN28B,Paternal,rs7759938-<b>?</b>,1 x 10-13,"(EA, men)",0.3209,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2101,LIN28B,LIN28B,Paternal,rs11156429-<b>?</b>,9 x 10-7,"(EA, women)",0.4566,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104916546,Anthropometric
2102,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,5 x 10-8,,0.56,'-,0.031 unit decrease,[0.017-0.045],LIN28B-AS1,Height,body height,GCST002702,6:104931079,Anthropometric
2103,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,2 x 10-6,"(EA, women)",0.6803,'-,0.0231 unit decrease,[0.013-0.033],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2104,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,2 x 10-13,(EA),0.6803,'-,0.0279 unit decrease,[0.02-0.035],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2105,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,1 x 10-9,"(EA,men)",0.6803,'-,0.0331 unit decrease,[0.023-0.044],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2106,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,2 x 10-15,(EA),0.4566,'-,0.0297 cm increase,[0.022-0.037],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104916546,Anthropometric
2107,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,3 x 10-13,(men),0.3303,'-,0.0416 cm increase,[0.03-0.053],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2108,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,2 x 10-6,"(EA, women)",0.4566,'-,0.0232 cm increase,[0.014-0.033],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104916546,Anthropometric
2109,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,2 x 10-13,"(EA, men)",0.3209,'-,0.0436 cm increase,[0.032-0.055],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2110,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,6 x 10-15,(women),0.3303,'-,0.043 cm increase,[0.032-0.054],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2111,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,3 x 10-15,,0.3303,'-,0.0302 cm increase,[0.023-0.038],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2112,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,1 x 10-10,(EA),0.4566,'-,0.0275 cm increase,[0.019-0.036],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104916546,Anthropometric
2113,LIN28B,LIN28B,Paternal,rs1933801-<b>?</b>,5 x 10-35,,NR,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,6:104917850,Anthropometric
2114,LIN28B,LIN28B,Paternal,rs9391253-<b>?</b>,4 x 10-8,,NR,'-,0.03476676 unit increase,[0.022-0.047],LIN28B-AS1,Height,body height,GCST008053,6:104919741,Anthropometric
2115,LIN28B,LIN28B,Paternal,rs1933801-<b>?</b>,2 x 10-14,,NR,'-,'-,'-,LIN28B-AS1,Heel bone mineral density,heel bone mineral density,GCST007066,6:104917850,Anthropometric
2116,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,3 x 10-11,,0.321912,'-,0.00997693 unit decrease,[0.007-0.0129],LIN28B-AS1,Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,6:104931079,Anthropometric
2117,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,1 x 10-8,,0.13,'-,0.41 cm increase,[0.26-0.59],LIN28B,Height,body height,GCST000176,6:104959787,Anthropometric
2118,LIN28B,LIN28B,Paternal,rs314268-<b>C</b>,8 x 10-7,,0.34,'-,4.6 % s.d. increase,[2.84-6.36],LIN28B,Height,body height,GCST000175,6:104970103,Anthropometric
2119,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,3 x 10-7,,0.318936,'-,0.01352 unit decrease,NR,LIN28B,Body fat distribution (arm fat ratio),body fat distribution,GCST007293,6:104944870,Anthropometric
2120,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,3 x 10-6,(females),0.318936,'-,0.01491 unit decrease,NR,LIN28B,Body fat distribution (arm fat ratio),body fat distribution,GCST007293,6:104944870,Anthropometric
2121,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,1 x 10-22,(females),0.318936,'-,0.03499 unit decrease,NR,LIN28B,Body fat distribution (leg fat ratio),body fat distribution,GCST007295,6:104944870,Anthropometric
2122,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,1 x 10-14,(males),0.318936,'-,0.03054 unit decrease,NR,LIN28B,Body fat distribution (leg fat ratio),body fat distribution,GCST007295,6:104944870,Anthropometric
2123,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,2 x 10-35,,0.318936,'-,0.03303 unit decrease,NR,LIN28B,Body fat distribution (leg fat ratio),body fat distribution,GCST007295,6:104944870,Anthropometric
2124,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,1 x 10-16,(males),0.318936,'-,0.03328 unit increase,NR,LIN28B,Body fat distribution (trunk fat ratio),body fat distribution,GCST007294,6:104944870,Anthropometric
2125,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,8 x 10-44,,0.318936,'-,0.03644 unit increase,NR,LIN28B,Body fat distribution (trunk fat ratio),body fat distribution,GCST007294,6:104944870,Anthropometric
2126,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,3 x 10-29,(females),0.318936,'-,0.03898 unit increase,NR,LIN28B,Body fat distribution (trunk fat ratio),body fat distribution,GCST007294,6:104944870,Anthropometric
2127,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,2 x 10-10,,0.3169,'-,0.0257 unit increase,[0.018-0.034],LIN28B,Waist circumference adjusted for BMI in non-smokers,BMI-adjusted waist circumference,GCST004504,6:104949543,Anthropometric
2128,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,3 x 10-8,(men),0.3169,'-,0.0344 unit increase,[0.022-0.047],LIN28B,Waist circumference adjusted for BMI in non-smokers,BMI-adjusted waist circumference,GCST004504,6:104949543,Anthropometric
2129,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,6 x 10-14,(men),0.3169,'-,0.0398 unit increase,[0.029-0.05],LIN28B,Waist circumference adjusted for BMI (adjusted for smoking behaviour),"smoking behavior, BMI-adjusted waist circumference",GCST004500,6:104949543,Anthropometric
2130,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,5 x 10-14,,0.3169,'-,'-,'-,LIN28B,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),"smoking behavior, BMI-adjusted waist circumference",GCST004501,6:104949543,Anthropometric
2131,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,1 x 10-12,(men),0.3169,'-,'-,'-,LIN28B,Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),"smoking behavior, BMI-adjusted waist circumference",GCST004501,6:104949543,Anthropometric
2132,LIN28B,LIN28B,Paternal,rs221616-<b>?</b>,1 x 10-12,,NR,'-,'-,'-,LIN28B,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,6:105032819,Anthropometric
2133,LIN28B,LIN28B,Paternal,rs314263-<b>?</b>,6 x 10-10,,NR,'-,0.03827385 unit decrease,[0.026-0.05],LIN28B,Height,body height,GCST008053,6:104944870,Anthropometric
2134,LIN28B,LIN28B,Paternal,rs314268-<b>?</b>,2 x 10-6,,NR,'-,0.02793575 unit decrease,[0.016-0.039],LIN28B,Height,body height,GCST008053,6:104970103,Anthropometric
2135,LIN28B,LIN28B,Paternal,rs314261-<b>?</b>,3 x 10-10,,NR,'-,0.0133438 unit decrease,[0.0093-0.0174],LIN28B,Heel bone mineral density,heel bone mineral density,GCST006433,6:105005542,Anthropometric
2136,LIN28B,LIN28B,Paternal,rs7766336-<b>G</b>,1 x 10-10,,0.67998,'-,0.0477899 unit increase,[0.033-0.062],"LIN28B-AS1, LIN28B",Appendicular lean mass,appendicular lean mass,GCST009577,6:104940530,Anthropometric
2137,LIN28B,LIN28B,Paternal,rs9391253-<b>T</b>,5 x 10-12,,0.32,1.16,'-,[NR],LIN28B-AS1,Height,body height,GCST001956,6:104919741,Anthropometric
2138,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,4 x 10-7,(EA),0.4571,'-,0.0387 cm increase,[0.024-0.054],LIN28B-AS1,Waist circumference adjusted for BMI in inactive individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004565,6:104916546,Anthropometric
2139,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,7 x 10-7,,0.3294,'-,0.0372 cm increase,[0.023-0.052],LIN28B-AS1,Waist circumference adjusted for BMI in inactive individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004565,6:104931079,Anthropometric
2140,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,4 x 10-11,(men),0.3219,'-,0.0431 cm increase,[0.03-0.056],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2141,LIN28B,LIN28B,Paternal,rs7759938-<b>?</b>,3 x 10-13,(men),0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2142,LIN28B,LIN28B,Paternal,rs7759938-<b>?</b>,6 x 10-15,(women),0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2143,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,8 x 10-31,,0.68,'-,0.045 unit decrease,[NR],LIN28B-AS1,Height,body height,GCST000817,6:104931079,Anthropometric
2144,LIN28B,LIN28B,Paternal,rs7759938-<b>?</b>,6 x 10-8,,NR,'-,0.03224117 unit decrease,[0.021-0.044],LIN28B-AS1,Height,body height,GCST008053,6:104931079,Anthropometric
2180,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,2 x 10-6,,0.15,'-,0.63 mean 2D:4D increase,[0.41-0.85],LIN28B,Digit length ratio,digit length ratio,GCST000630,6:104959787,Anthropometric
2181,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,2 x 10-19,,0.155,'-,0.498 unit increase,[0.39-0.61],LIN28B,Digit length ratio (right hand),digit length ratio,GCST005748,6:104959787,Anthropometric
2182,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,1 x 10-21,,0.155,'-,0.476 unit increase,[0.38-0.57],LIN28B,Digit length ratio,digit length ratio,GCST005750,6:104959787,Anthropometric
2183,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,1 x 10-18,,0.16,'-,0.404 unit increase,[0.31-0.49],LIN28B,Digit length ratio (left hand),digit length ratio,GCST005749,6:104959787,Anthropometric
2184,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,6 x 10-18,(EA),0.155,'-,0.428 unit increase,[0.33-0.53],LIN28B,Digit length ratio (left hand),digit length ratio,GCST005749,6:104959787,Anthropometric
2206,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>?</b>,3 x 10-15,(EA),0.4566,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104916546,Anthropometric
2207,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,5 x 10-12,(women),0.3414,'-,0.0435 cm increase,[0.031-0.056],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2208,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,4 x 10-11,,0.3303,'-,0.0286 cm increase,[0.02-0.037],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2209,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>?</b>,1 x 10-15,,0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2210,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>?</b>,1 x 10-13,"(EA, men)",0.3209,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2211,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>?</b>,9 x 10-7,"(EA, women)",0.4566,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104916546,Anthropometric
2212,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,5 x 10-8,,0.56,'-,0.031 unit decrease,[0.017-0.045],LIN28B-AS1,Height,body height,GCST002702,6:104931079,Anthropometric
2213,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,2 x 10-6,"(EA, women)",0.6803,'-,0.0231 unit decrease,[0.013-0.033],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2214,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,2 x 10-13,(EA),0.6803,'-,0.0279 unit decrease,[0.02-0.035],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2215,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,1 x 10-9,"(EA,men)",0.6803,'-,0.0331 unit decrease,[0.023-0.044],LIN28B-AS1,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,6:104931079,Anthropometric
2216,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,2 x 10-15,(EA),0.4566,'-,0.0297 cm increase,[0.022-0.037],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104916546,Anthropometric
2217,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,3 x 10-13,(men),0.3303,'-,0.0416 cm increase,[0.03-0.053],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2218,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,2 x 10-6,"(EA, women)",0.4566,'-,0.0232 cm increase,[0.014-0.033],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104916546,Anthropometric
2219,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,2 x 10-13,"(EA, men)",0.3209,'-,0.0436 cm increase,[0.032-0.055],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2220,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,6 x 10-15,(women),0.3303,'-,0.043 cm increase,[0.032-0.054],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2221,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,3 x 10-15,,0.3303,'-,0.0302 cm increase,[0.023-0.038],LIN28B-AS1,Waist circumference adjusted for body mass index,"BMI-adjusted waist circumference, physical activity measurement",GCST004562,6:104931079,Anthropometric
2222,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,1 x 10-10,(EA),0.4566,'-,0.0275 cm increase,[0.019-0.036],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104916546,Anthropometric
2223,LIN28B,LIN28B-AS1,Paternal,rs1933801-<b>?</b>,5 x 10-35,,NR,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for body mass index,BMI-adjusted waist circumference,GCST009867,6:104917850,Anthropometric
2224,LIN28B,LIN28B-AS1,Paternal,rs9391253-<b>?</b>,4 x 10-8,,NR,'-,0.03476676 unit increase,[0.022-0.047],LIN28B-AS1,Height,body height,GCST008053,6:104919741,Anthropometric
2225,LIN28B,LIN28B-AS1,Paternal,rs1933801-<b>?</b>,2 x 10-14,,NR,'-,'-,'-,LIN28B-AS1,Heel bone mineral density,heel bone mineral density,GCST007066,6:104917850,Anthropometric
2226,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,3 x 10-11,,0.321912,'-,0.00997693 unit decrease,[0.007-0.0129],LIN28B-AS1,Body size at age 10,"comparative body size at age 10, self-reported",GCST010989,6:104931079,Anthropometric
2227,LIN28B,LIN28B-AS1,Paternal,rs12207399-<b>?</b>,1 x 10-33,,NR,'-,0.037892476 unit decrease,[0.032-0.044],"LIN28B, LIN28B-AS1",Height,body height,GCST008839,6:104937737,Anthropometric
2228,LIN28B,LIN28B-AS1,Paternal,rs9391253-<b>T</b>,5 x 10-12,,0.32,1.16,'-,[NR],LIN28B-AS1,Height,body height,GCST001956,6:104919741,Anthropometric
2229,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,4 x 10-7,(EA),0.4571,'-,0.0387 cm increase,[0.024-0.054],LIN28B-AS1,Waist circumference adjusted for BMI in inactive individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004565,6:104916546,Anthropometric
2230,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,7 x 10-7,,0.3294,'-,0.0372 cm increase,[0.023-0.052],LIN28B-AS1,Waist circumference adjusted for BMI in inactive individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004565,6:104931079,Anthropometric
2231,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,4 x 10-11,(men),0.3219,'-,0.0431 cm increase,[0.03-0.056],LIN28B-AS1,Waist circumference adjusted for BMI in active individuals,"BMI-adjusted waist circumference, physical activity measurement",GCST004564,6:104931079,Anthropometric
2232,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>?</b>,3 x 10-13,(men),0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2233,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>?</b>,6 x 10-15,(women),0.3303,'-,'-,'-,LIN28B-AS1,Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),"BMI-adjusted waist circumference, physical activity measurement",GCST004563,6:104931079,Anthropometric
2234,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,8 x 10-31,,0.68,'-,0.045 unit decrease,[NR],LIN28B-AS1,Height,body height,GCST000817,6:104931079,Anthropometric
2235,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>?</b>,6 x 10-8,,NR,'-,0.03224117 unit decrease,[0.021-0.044],LIN28B-AS1,Height,body height,GCST008053,6:104931079,Anthropometric
2236,LIN28B,LIN28B-AS1,Paternal,rs7766336-<b>G</b>,1 x 10-10,,0.67998,'-,0.0477899 unit increase,[0.033-0.062],"LIN28B-AS1, LIN28B",Appendicular lean mass,appendicular lean mass,GCST009577,6:104940530,Anthropometric
2367,MKRN3,MKRN3,Paternal,rs117686021-<b>?</b>,6 x 10-16,,NR,'-,0.06609337 unit decrease,[0.05-0.082],"MIR4508, MKRN3",Height,body height,GCST008839,15:23565505,Anthropometric
2542,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,1 x 10-6,,NR,'-,'-,'-,PLAGL1,Body mass index,body mass index,GCST009871,6:143977063,Anthropometric
2564,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,5 x 10-10,,NR,'-,'-,'-,PLAGL1,Adult onset asthma and/or BMI,"adult onset asthma, body mass index",GCST009868,6:143977063,Anthropometric
2587,RASGRF1,RASGRF1,Paternal,rs57488047-<b>T</b>,1 x 10-12,,0.5316,'-,0.00986083 unit increase,[0.0071-0.0126],"ANKRD34C-AS1, RASGRF1",Adult body size,body height,GCST010988,15:79110660,Anthropometric
2588,RASGRF1,RASGRF1,Paternal,rs1521624-<b>?</b>,6 x 10-16,,NR,'-,'-,'-,"RASGRF1, ANKRD34C-AS1",Body mass index,body mass index,GCST007039,15:79120057,Anthropometric
2593,RASGRF1,RASGRF1,Paternal,rs1521624-<b>A</b>,4 x 10-8,,0.4716,'-,0.002 unit increase,[0.0014-0.0026],"RASGRF1, ANKRD34C-AS1",Hand grip strength,grip strength measurement,GCST005830,15:79120057,Anthropometric
2670,RTL1,RTL1,Paternal,rs67585357-<b>?</b>,4 x 10-13,,NR,'-,'-,'-,"AL117190.1, RTL1",Height,body height,GCST007841,14:100879977,Anthropometric
2871,SNRPN,SNRPN,Paternal,rs2030062-<b>G</b>,2 x 10-6,(Amylin ),0.105,'-,0.03 pM increase,[NR],"AC090983.2, SNRPN",Obesity-related traits,hormone measurement,GCST001762,15:24888839,Anthropometric
2879,ST8SIA1,ST8SIA1,Paternal,rs17646466-<b>?</b>,2 x 10-12,,NR,'-,'-,'-,ST8SIA1,Height,body height,GCST007841,12:22251427,Anthropometric
3022,VTRNA2-1,VTRNA2-1,Paternal,rs6882422-<b>G</b>,1 x 10-23,,0.88536,'-,0.0290008 unit increase,[0.023-0.035],"SMAD5-AS1, VTRNA2-1",Heel bone mineral density,heel bone mineral density,GCST006979,5:136094979,Anthropometric
3023,VTRNA2-1,VTRNA2-1,Paternal,rs6882422-<b>G</b>,2 x 10-7,(women),0.883658,'-,0.0374544 unit increase,[0.023-0.052],"SMAD5-AS1, VTRNA2-1",Heel bone mineral density,heel bone mineral density,GCST006288,5:136094979,Anthropometric
3024,VTRNA2-1,VTRNA2-1,Paternal,rs6882422-<b>G</b>,3 x 10-10,,0.883986,'-,0.0328092 unit increase,[0.022-0.043],"SMAD5-AS1, VTRNA2-1",Heel bone mineral density,heel bone mineral density,GCST006288,5:136094979,Anthropometric
3025,VTRNA2-1,VTRNA2-1,Paternal,rs6882422-<b>?</b>,8 x 10-25,,NR,'-,'-,'-,"SMAD5-AS1, VTRNA2-1",Heel bone mineral density,heel bone mineral density,GCST007066,5:136094979,Anthropometric
3026,VTRNA2-1,VTRNA2-1,Paternal,rs6882422-<b>?</b>,5 x 10-22,,NR,'-,0.0301471 unit increase,[0.024-0.037],"SMAD5-AS1, VTRNA2-1",Heel bone mineral density,heel bone mineral density,GCST006433,5:136094979,Anthropometric
3030,WT1,WT1,Paternal,rs7110547-<b>?</b>,2 x 10-12,,NR,'-,'-,'-,WT1,Waist-hip ratio,waist-hip ratio,GCST007067,11:32425801,Anthropometric
3101,ZC3H12C,ZC3H12C,Paternal,rs754621889-<b>T</b>,4 x 10-6,,0.0026,'-,0.4841 unit increase,[0.28-0.69],"RDX, ZC3H12C",Body mass index,body mass index,GCST008158,11:110153577,Anthropometric
3109,ZDBF2,ZDBF2,Paternal,rs55677225-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,ZDBF2,Body mass index,body mass index,GCST007039,2:206295628,Anthropometric
3110,ZDBF2,ZDBF2,Paternal,rs55677225-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,ZDBF2,Body mass index,body mass index,GCST009871,2:206295628,Anthropometric
3111,ZDBF2,ZDBF2,Paternal,rs10497882-<b>T</b>,2 x 10-12,,0.7234,'-,0.0127 unit decrease,[0.0092-0.0162],"ZDBF2, ACER2P1",Body mass index,body mass index,GCST009001,2:206368391,Anthropometric
3112,ZDBF2,ZDBF2,Paternal,rs972540-<b>A</b>,4 x 10-13,,0.7224,'-,0.0131 unit decrease,[0.0096-0.0166],"ACER2P1, ZDBF2",Body mass index,body mass index,GCST009004,2:206380059,Anthropometric
3113,ZDBF2,ZDBF2,Paternal,rs972540-<b>G</b>,4 x 10-7,,0.266,'-,0.017 kg/m2 increase,[0.01-0.023],"ACER2P1, ZDBF2",Body mass index,body mass index,GCST002783,2:206380059,Anthropometric
3114,ZDBF2,ZDBF2,Paternal,rs972540-<b>G</b>,2 x 10-7,(EA),0.269,'-,0.018 kg/m2 increase,[0.011-0.024],"ACER2P1, ZDBF2",Body mass index,body mass index,GCST002783,2:206380059,Anthropometric
3115,ZDBF2,ZDBF2,Paternal,rs972540-<b>A</b>,1 x 10-9,,0.731068162,'-,0.018581709 unit decrease,'-,"ACER2P1, ZDBF2",Body mass index,body mass index,GCST005951,2:206380059,Anthropometric
3116,ZDBF2,ZDBF2,Paternal,rs972540-<b>G</b>,6 x 10-9,,0.24,'-,0.016 unit increase,[0.01-0.022],"ACER2P1, ZDBF2",Body mass index,body mass index,GCST004904,2:206380059,Anthropometric
3117,ZDBF2,ZDBF2,Paternal,rs972540-<b>A</b>,2 x 10-10,,NR,'-,0.018 unit decrease,[NR],"ACER2P1, ZDBF2",Body mass index,body mass index,GCST006368,2:206380059,Anthropometric
3118,ZDBF2,ZDBF2,Paternal,rs181263645-<b>A</b>,1 x 10-6,(EA),NR,'-,0.2379 unit increase,[0.14-0.33],"ACER2P1, ZDBF2",Childhood obesity,obesity,GCST009382,2:206401557,Anthropometric
3121,ZFAT,ZFAT,Paternal,rs558657497-<b>?</b>,2 x 10-9,,NR,'-,0.0126142 unit decrease,[0.0085-0.0167],ZFAT,Heel bone mineral density,heel bone mineral density,GCST006433,8:134566394,Anthropometric
3122,ZFAT,ZFAT,Paternal,rs6577655-<b>T</b>,5 x 10-6,(overall),0.33,'-,'-,'-,ZFAT,Visceral adipose tissue/subcutaneous adipose tissue ratio,visceral:subcutaneous adipose tissue ratio,GCST001524,8:134581482,Anthropometric
3123,ZFAT,ZFAT,Paternal,rs16905190-<b>?</b>,4 x 10-104,,NR,'-,'-,'-,ZFAT,Height,body height,GCST007841,8:134586022,Anthropometric
3124,ZFAT,ZFAT,Paternal,rs112892337-<b>C</b>,1 x 10-23,,0.004,'-,0.14 unit increase,[0.11-0.17],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000025,8:134602310,Anthropometric
3125,ZFAT,ZFAT,Paternal,rs112892337-<b>C</b>,2 x 10-11,,0.004,'-,0.13 unit increase,[0.093-0.167],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000027,8:134602310,Anthropometric
3126,ZFAT,ZFAT,Paternal,rs112892337-<b>C</b>,5 x 10-14,,0.004,'-,0.16 unit increase,[0.12-0.2],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000026,8:134602310,Anthropometric
3127,ZFAT,ZFAT,Paternal,rs7007820-<b>A</b>,4 x 10-7,"(EA, women)",0.592,'-,0.0231 unit increase,[0.014-0.032],ZFAT,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,8:134604494,Anthropometric
3128,ZFAT,ZFAT,Paternal,rs7007820-<b>A</b>,1 x 10-8,(EA),0.592,'-,0.0205 unit increase,[0.013-0.028],ZFAT,Hip circumference adjusted for BMI,BMI-adjusted hip circumference,GCST004067,8:134604494,Anthropometric
3129,ZFAT,ZFAT,Paternal,rs12550577-<b>?</b>,5 x 10-15,,NR,'-,'-,'-,ZFAT,Heel bone mineral density,heel bone mineral density,GCST007066,8:134606579,Anthropometric
3130,ZFAT,ZFAT,Paternal,rs12680655-<b>C</b>,2 x 10-7,,0.52,'-,0.023 unit increase,[0.011-0.035],ZFAT,Height,body height,GCST002702,8:134625094,Anthropometric
3131,ZFAT,ZFAT,Paternal,rs12680655-<b>C</b>,2 x 10-14,,0.6,'-,0.028 unit increase,[NR],ZFAT,Height,body height,GCST000817,8:134625094,Anthropometric
3132,ZFAT,ZFAT,Paternal,rs4909323-<b>G</b>,2 x 10-9,,0.60695,'-,0.0113191 unit decrease,[0.0076-0.015],ZFAT,Heel bone mineral density,heel bone mineral density,GCST006979,8:134625449,Anthropometric
3133,ZFAT,ZFAT,Paternal,rs733254-<b>A</b>,2 x 10-6,,0.27,'-,0.041 unit decrease,[0.023-0.059],ZFAT,Height,body height,GCST001263,8:134626389,Anthropometric
3134,ZFAT,ZFAT,Paternal,rs12541381-<b>A</b>,3 x 10-49,,0.258,'-,0.03 unit decrease,[0.026-0.034],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000025,8:134637605,Anthropometric
3135,ZFAT,ZFAT,Paternal,rs12541381-<b>A</b>,3 x 10-19,,0.258,'-,0.03 unit decrease,[0.024-0.036],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000026,8:134637605,Anthropometric
3136,ZFAT,ZFAT,Paternal,rs12541381-<b>A</b>,3 x 10-32,,0.258,'-,0.03 unit decrease,[0.024-0.036],ZFAT,Appendicular lean mass,appendicular lean mass,GCST90000027,8:134637605,Anthropometric
3137,ZFAT,ZFAT,Paternal,rs1036821-<b>A</b>,1 x 10-30,,0.3,'-,0.037 unit decrease,[0.031-0.043],ZFAT,Height,body height,GCST002647,8:134638240,Anthropometric
3138,ZFAT,ZFAT,Paternal,rs6995599-<b>?</b>,2 x 10-14,,NR,'-,0.18309 unit decrease,[0.14-0.23],ZFAT,Fat-free mass,lean body mass,GCST007063,8:134641292,Anthropometric
3139,ZFAT,ZFAT,Paternal,rs6995599-<b>?</b>,1 x 10-9,(female),NR,'-,0.15921 unit decrease,[0.11-0.21],ZFAT,Fat-free mass,lean body mass,GCST007063,8:134641292,Anthropometric
3140,ZFAT,ZFAT,Paternal,rs6995599-<b>?</b>,6 x 10-8,(male),NR,'-,0.20463 unit decrease,[0.13-0.28],ZFAT,Fat-free mass,lean body mass,GCST007063,8:134641292,Anthropometric
3141,ZFAT,ZFAT,Paternal,rs7000796-<b>?</b>,7 x 10-16,,NR,'-,0.022957034 unit decrease,[0.017-0.029],ZFAT,Height,body height,GCST008839,8:134652430,Anthropometric
3142,ZFAT,ZFAT,Paternal,rs16905212-<b>T</b>,5 x 10-6,"(EA,women)",0.6915,'-,0.0224 unit increase,[0.013-0.032],ZFAT,Hip circumference,hip circumference,GCST004066,8:134656979,Anthropometric
3143,ZFAT,ZFAT,Paternal,rs16905212-<b>T</b>,2 x 10-8,(EA),0.6915,'-,0.0212 unit increase,[0.014-0.029],ZFAT,Hip circumference,hip circumference,GCST004066,8:134656979,Anthropometric
3144,ZFAT,ZFAT,Paternal,rs6997600-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,ZFAT,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,8:134661677,Anthropometric
3145,ZFAT,ZFAT,Paternal,rs7834111-<b>T</b>,1 x 10-13,,0.5755,'-,0.0135 unit increase,[0.01-0.017],ZFAT,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST008994,8:134686031,Anthropometric
3146,ZFAT,ZFAT,Paternal,rs7834111-<b>?</b>,4 x 10-11,,NR,'-,'-,'-,ZFAT,Waist-to-hip ratio adjusted for BMI,BMI-adjusted waist-hip ratio,GCST009858,8:134686031,Anthropometric
3147,ZFAT,ZFAT,Paternal,rs10505629-<b>?</b>,1 x 10-21,,NR,'-,'-,'-,ZFAT,Height,body height,GCST007841,8:134696371,Anthropometric
3148,ZFAT,ZFAT,Paternal,rs7821292-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,ZFAT,Waist-hip ratio,waist-hip ratio,GCST007067,8:134698105,Anthropometric
3208,ZIM2,ZIM2,Paternal,rs7259811-<b>?</b>,5 x 10-6,,NR,'-,'-,'-,"AC006115.2, ZIM2-AS1",Western dietary pattern,diet measurement,GCST004640,19:56713651,Anthropometric
3223,ZIM2,ZIM2-AS1,Paternal,rs7259811-<b>?</b>,5 x 10-6,,NR,'-,'-,'-,"AC006115.2, ZIM2-AS1",Western dietary pattern,diet measurement,GCST004640,19:56713651,Anthropometric
3835,FAM50B,FAM50B,Paternal,rs146144484-<b>T</b>,7 x 10-7,,0.0106,'-,0.1864 unit increase,[0.11-0.26],"FAM50B, TDGF1P4",Weight,body weight,GCST008152,6:3865792,Anthropometric
3839,FAM50B,FAM50B,Paternal,rs146144484-<b>T</b>,1 x 10-7,,0.0108,'-,0.2389 unit increase,[0.15-0.33],"FAM50B, TDGF1P4",Hip circumference,hip circumference,GCST008162,6:3865792,Anthropometric
1912,KCNQ1OT1,KCNQ1OT1,Paternal,rs7128926-<b>?</b>,9 x 10-10,,NR,'-,'-,'-,"KCNQ1OT1, KCNQ1",Height,body height,GCST007841,11:2675514,Anthropometric
311,DNMT1,DNMT1,Paternal,rs11085720-<b>A</b>,7 x 10-9,,0.438291,'-,0.014546 unit increase,[0.0096-0.0195],DNMT1,Birth weight,birth weight,GCST008362,19:10207087,Birth
312,DNMT1,DNMT1,Paternal,rs11085720-<b>A</b>,5 x 10-7,,0.435179,'-,0.014967 unit increase,[0.0091-0.0208],DNMT1,Offspring birth weight,"birth weight, parental genotype effect measurement",GCST008363,19:10207087,Birth
341,DSCAM,DSCAM,Paternal,rs9974083-<b>?</b>,4 x 10-6,,NR,1.73,'-,[1.34-2.24],DSCAM,Spontaneous preterm birth (preterm birth),spontaneous preterm birth,GCST008177,21:40072591,Birth
342,DSCAM,DSCAM,Paternal,rs2410212-<b>?</b>,2 x 10-6,,NR,3.17,'-,'-,DSCAM,Spontaneous preterm birth without premature rupture of membranes,spontaneous preterm birth,GCST008181,21:40092354,Birth
610,GLIS3,GLIS3,Paternal,rs501631-<b>T</b>,7 x 10-6,,0.48,1.33,'-,[NR],GLIS3,Spontaneous preterm birth (preterm delivery),"delivery measurement, spontaneous preterm birth",GCST002752,9:3943125,Birth
611,GLIS3,GLIS3,Paternal,rs10814916-<b>C</b>,4 x 10-8,,0.512983,'-,0.016154 unit increase,[0.01-0.022],GLIS3,Offspring birth weight,"birth weight, parental genotype effect measurement",GCST008363,9:4293150,Birth
1226,IGF2,IGF2,Paternal,rs72851023-<b>T</b>,7 x 10-10,,0.07,'-,0.0463 unit increase,[0.032-0.061],IGF2,Birth weight,birth weight,GCST005146,11:2109390,Birth
1278,IGF2,IGF2,Paternal,rs2585-<b>T</b>,1 x 10-8,,0.28,'-,0.024330052 unit increase,[0.016-0.033],IGF2,Birth weight (MTAG),birth weight,GCST009498,11:2129214,Birth
1291,IGF2,IGF2,Paternal,rs3213225-<b>A</b>,3 x 10-13,,0.39,'-,0.026 z score decrease,[0.018-0.034],"INS-IGF2, IGF2",Birth weight,birth weight,GCST009437,11:2135306,Birth
1308,IGF2,IGF2,Paternal,rs11042596-<b>T</b>,4 x 10-22,,0.336254,'-,0.026856 unit increase,[0.021-0.032],"H19, IGF2",Birth weight,birth weight,GCST008362,11:2097630,Birth
1383,IGF2,INS-IGF2,Paternal,rs3213225-<b>A</b>,3 x 10-13,,0.39,'-,0.026 z score decrease,[0.018-0.034],"INS-IGF2, IGF2",Birth weight,birth weight,GCST009437,11:2135306,Birth
1455,INS,INS,Paternal,rs3213225-<b>A</b>,3 x 10-13,,0.39,'-,0.026 z score decrease,[0.018-0.034],"INS-IGF2, IGF2",Birth weight,birth weight,GCST009437,11:2135306,Birth
1514,INS,INS-IGF2,Paternal,rs3213225-<b>A</b>,3 x 10-13,,0.39,'-,0.026 z score decrease,[0.018-0.034],"INS-IGF2, IGF2",Birth weight,birth weight,GCST009437,11:2135306,Birth
1532,IRAIN,IRAIN,Paternal,rs4965425-<b>T</b>,4 x 10-9,,0.47,'-,0.019 z score decrease,[0.013-0.025],"FAM169B, IRAIN",Birth weight,birth weight,GCST009437,15:98638434,Birth
3055,WT1,WT1,Paternal,rs12574749-<b>C</b>,1 x 10-9,,0.719504,'-,0.020571 unit increase,[0.014-0.027],"WT1, THEM7P",Offspring birth weight,"birth weight, parental genotype effect measurement",GCST008363,11:32383809,Birth
3056,WT1,WT1,Paternal,rs5030317-<b>C</b>,5 x 10-8,,0.29,'-,0.02 z score increase,[0.012-0.028],WT1,Birth weight,birth weight,GCST009437,11:32388791,Birth
3057,WT1,WT1,Paternal,rs5030317-<b>C</b>,3 x 10-9,,0.732755,'-,0.017273 unit increase,[0.012-0.023],WT1,Birth weight,birth weight,GCST008362,11:32388791,Birth
1940,KCNQ1OT1,KCNQ1OT1,Paternal,rs151216-<b>C</b>,6 x 10-9,,0.898719,'-,0.024751 unit increase,[0.016-0.033],"KCNQ1OT1, KCNQ1",Birth weight,birth weight,GCST008362,11:2659585,Birth
1941,KCNQ1OT1,KCNQ1OT1,Paternal,rs231350-<b>C</b>,3 x 10-6,,0.644553,'-,0.012585 unit increase,[0.0073-0.0178],"KCNQ1OT1, KCNQ1",Birth weight,birth weight,GCST008362,11:2692419,Birth
1942,KCNQ1OT1,KCNQ1OT1,Paternal,rs231350-<b>C</b>,5 x 10-8,,0.645376,'-,0.017947 unit increase,[0.012-0.024],"KCNQ1OT1, KCNQ1",Offspring birth weight,"birth weight, parental genotype effect measurement",GCST008363,11:2692419,Birth
137,DIO3,DIO3OS,Paternal,"rs10142332-<b>G</b>, rs12435279-<b>C</b>, rs12586651-<b>T</b>",3 x 10-7,,0.155,'-,'-,'-,AL049836.2 - DIO3OS; AL049836.2 - DIO3OS; AL049836.2 - DIO3OS,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,14:101519289|14:101522626|14:101519591,Blood
172,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>T</b>",1 x 10-7,,0.185,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Blood
173,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>C</b>",4 x 10-7,,0.355,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Blood
212,DLK1,DLK1,Paternal,rs4905994-<b>T</b>,4 x 10-6,,NR,'-,0.0234 mg/dl decrease,[NR],"AL132711.1, DLK1",Magnesium levels,magnesium measurement,GCST002860,14:100687735,Blood
213,DLK1,DLK1,Paternal,rs4905994-<b>T</b>,7 x 10-6,(EA),NR,'-,0.02871 mg/dl decrease,(-0.04119--0.01623),"AL132711.1, DLK1",Magnesium levels,magnesium measurement,GCST002860,14:100687735,Blood
214,DLK1,DLK1,Paternal,rs7149242-<b>G</b>,3 x 10-8,,NR,'-,2.142 10^9/l increase,[1.39-2.9],"DLK1, AL132711.1",Platelet count,platelet count,GCST001337,14:100693079,Blood
215,DLK1,DLK1,Paternal,rs10146962-<b>C</b>,5 x 10-13,,0.337467,'-,0.01479 SD unit decrease,[0.011-0.019],"DLK1, AL132711.1",Neutrophil count,neutrophil count,GCST90002351,14:100704203,Blood
216,DLK1,DLK1,Paternal,rs10146962-<b>C</b>,1 x 10-10,,0.402639,'-,'-,'-,"DLK1, AL132711.1",Neutrophil count,neutrophil count,GCST90002355,14:100704203,Blood
217,DLK1,DLK1,Paternal,rs10146962-<b>C</b>,3 x 10-12,,0.436149,'-,'-,'-,"DLK1, AL132711.1",White blood cell count,myeloid white cell count,GCST90002378,14:100704203,Blood
218,DLK1,DLK1,Paternal,rs10146962-<b>C</b>,6 x 10-15,,0.338281,'-,0.015367 SD unit decrease,[0.012-0.019],"DLK1, AL132711.1",White blood cell count,myeloid white cell count,GCST90002374,14:100704203,Blood
219,DLK1,DLK1,Paternal,rs10146962-<b>C</b>,4 x 10-11,,0.335362,'-,0.0154882325 unit decrease,[0.011-0.02],"DLK1, AL132711.1",Neutrophil count,neutrophil count,GCST90002398,14:100704203,Blood
220,DLK1,DLK1,Paternal,rs9324022-<b>C</b>,3 x 10-38,,0.2105,'-,0.05957088 unit decrease,[0.051-0.069],"AL132711.1, DLK1",Plateletcrit,platelet crit,GCST004607,14:100706106,Blood
221,DLK1,DLK1,Paternal,rs9324022-<b>C</b>,2 x 10-17,,0.210086,'-,0.027883587 unit decrease,[0.021-0.034],"AL132711.1, DLK1",Platelet count,platelet count,GCST90002402,14:100706106,Blood
222,DLK1,DLK1,Paternal,rs9635298-<b>?</b>,2 x 10-10,,NR,'-,0.02927 unit decrease,[0.02-0.038],"DLK1, AL132711.1",Platelet count,platelet count,GCST005991,14:100706205,Blood
223,DLK1,DLK1,Paternal,rs17099623-<b>C</b>,4 x 10-28,,0.207647,'-,0.034536447 unit decrease,[0.028-0.041],"DLK1, AL132711.1",Plateletcrit,platelet crit,GCST90002400,14:100706787,Blood
224,DLK1,DLK1,Paternal,rs10144381-<b>T</b>,6 x 10-58,"(DLK1, 6496_60_3)",0.37265625,'-,0.39199004 unit decrease,[0.35-0.44],"AL132711.1, DLK1",Blood protein levels,blood protein measurement,GCST006585,14:100706960,Blood
225,DLK1,DLK1,Paternal,rs10144381-<b>T</b>,6 x 10-62,"(SEMG2, 6373_54_3)",0.37265625,'-,0.40629548 unit decrease,[0.36-0.45],"AL132711.1, DLK1",Blood protein levels,blood protein measurement,GCST006585,14:100706960,Blood
226,DLK1,DLK1,Paternal,rs147352336-<b>C</b>,6 x 10-11,,0.191182,'-,0.018749962 unit decrease,[0.013-0.024],"AL132711.1, DLK1",Reticulocyte count,reticulocyte count,GCST90002405,14:100709419,Blood
227,DLK1,DLK1,Paternal,rs12881760-<b>C</b>,4 x 10-101,"(Protein delta homolog 1, DLK1.6496.60.3)",0.676,'-,0.54 unit increase,[0.48-0.6],"AL132711.1, DLK1",Blood protein levels,blood protein measurement,GCST005806,14:100709998,Blood
228,DLK1,DLK1,Paternal,rs12881760-<b>C</b>,2 x 10-106,"(Semenogelin-2, SEMG2.6373.54.3)",0.676,'-,0.55 unit increase,[0.49-0.61],"AL132711.1, DLK1",Blood protein levels,blood protein measurement,GCST005806,14:100709998,Blood
229,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,9 x 10-33,,0.2489,'-,0.05046488 unit decrease,[0.042-0.059],"DLK1, AL132711.1",Platelet count,platelet count,GCST004603,14:100710432,Blood
230,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,4 x 10-55,,0.2489,'-,0.06643256 unit decrease,[0.058-0.075],"DLK1, AL132711.1",Plateletcrit,platelet crit,GCST004607,14:100710432,Blood
231,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,2 x 10-18,,0.248777,'-,0.019622 SD unit increase,[0.015-0.024],"DLK1, AL132711.1",Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002322,14:100710432,Blood
232,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,2 x 10-29,,0.248775,'-,0.023978 SD unit increase,[0.02-0.028],"DLK1, AL132711.1",Mean corpuscular volume,mean corpuscular volume,GCST90002334,14:100710432,Blood
233,DLK1,DLK1,Paternal,rs1555405-<b>G</b>,4 x 10-12,,0.751668,'-,0.015514 SD unit increase,[0.011-0.02],"DLK1, AL132711.1",Mean platelet volume,mean platelet volume,GCST90002346,14:100710432,Blood
234,DLK1,DLK1,Paternal,rs1555405-<b>G</b>,3 x 10-11,,0.746094,'-,'-,'-,"DLK1, AL132711.1",Mean platelet volume,mean platelet volume,GCST90002349,14:100710432,Blood
235,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,5 x 10-128,,0.248867,'-,0.051785 SD unit decrease,[0.048-0.056],"DLK1, AL132711.1",Platelet count,platelet count,GCST90002357,14:100710432,Blood
236,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,2 x 10-27,,0.316777,'-,'-,'-,"DLK1, AL132711.1",Mean corpuscular volume,mean corpuscular volume,GCST90002338,14:100710432,Blood
237,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,6 x 10-10,,0.32917,'-,'-,'-,"DLK1, AL132711.1",Red blood cell count,red blood cell density measurement,GCST90002367,14:100710432,Blood
238,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,5 x 10-71,,0.248535,'-,0.052571632 unit decrease,[0.047-0.058],"DLK1, AL132711.1",Plateletcrit,platelet crit,GCST90002400,14:100710432,Blood
239,DLK1,DLK1,Paternal,rs1555405-<b>?</b>,1 x 10-18,,NR,'-,'-,'-,"DLK1, AL132711.1",Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST007068,14:100710432,Blood
240,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,5 x 10-36,,0.248535,'-,0.038010243 unit decrease,[0.032-0.044],"DLK1, AL132711.1",Platelet count,platelet count,GCST90002402,14:100710432,Blood
241,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,7 x 10-16,,0.248369,'-,0.020647107 unit increase,[0.016-0.026],"DLK1, AL132711.1",Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,14:100710432,Blood
242,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,2 x 10-23,,0.248356,'-,0.0261 unit increase,[0.021-0.031],"DLK1, AL132711.1",Mean corpuscular volume,mean corpuscular volume,GCST90002392,14:100710432,Blood
243,DLK1,DLK1,Paternal,rs1555405-<b>A</b>,8 x 10-11,,0.248732,'-,0.014108 SD unit decrease,[0.0099-0.0184],"DLK1, AL132711.1",Red blood cell count,red blood cell density measurement,GCST90002363,14:100710432,Blood
244,DLK1,DLK1,Paternal,rs72698718-<b>G</b>,5 x 10-12,,0.703717,'-,0.028203 SD units increase,[0.02-0.036],"AL132711.1, DLK1",Platelet count,platelet count,GCST90002358,14:100712218,Blood
245,DLK1,DLK1,Paternal,rs72698720-<b>G</b>,8 x 10-132,,0.167246,'-,'-,'-,"DLK1, AL132711.1",Platelet count,platelet count,GCST90002361,14:100712378,Blood
246,DLK1,DLK1,Paternal,rs72698722-<b>T</b>,3 x 10-16,,0.213643,'-,'-,'-,"AL132711.1, DLK1",Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002326,14:100715544,Blood
247,DLK1,DLK1,Paternal,rs72698722-<b>T</b>,2 x 10-30,,0.188578,'-,0.033054255 unit increase,[0.027-0.039],"AL132711.1, DLK1",Mean reticulocyte volume,mean reticulocyte volume,GCST90002396,14:100715544,Blood
248,DLK1,DLK1,Paternal,rs72698722-<b>T</b>,4 x 10-15,,0.188844,'-,0.022682102 unit decrease,[0.017-0.028],"AL132711.1, DLK1",Platelet distribution width,platelet component distribution width,GCST90002401,14:100715544,Blood
249,DLK1,DLK1,Paternal,rs72698722-<b>T</b>,4 x 10-34,,0.188557,'-,0.034860436 unit increase,[0.029-0.04],"AL132711.1, DLK1",Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,14:100715544,Blood
250,DLK1,DLK1,Paternal,rs7141210-<b>C</b>,3 x 10-11,,0.678543,'-,0.015980605 unit increase,[0.011-0.021],"DLK1, AL132711.1",Mean platelet volume,mean platelet volume,GCST90002395,14:100716133,Blood
251,DLK1,DLK1,Paternal,rs7141210-<b>C</b>,1 x 10-11,,0.678738,'-,0.015967809 unit increase,[0.011-0.021],"DLK1, AL132711.1",White blood cell count,leukocyte count,GCST90002407,14:100716133,Blood
252,DLK1,DLK1,Paternal,rs7141210-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,"DLK1, AL132711.1",White blood cell count,leukocyte count,GCST007070,14:100716133,Blood
286,DNMT1,DNMT1,Paternal,rs55818584-<b>A</b>,2 x 10-23,,0.23582,'-,0.026751902 unit decrease,[0.022-0.032],"S1PR2, DNMT1",Immature fraction of reticulocytes,reticulocyte measurement,GCST90002387,19:10221871,Blood
287,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,7 x 10-9,,0.6028,'-,0.02169456 unit decrease,[0.014-0.029],"S1PR2, DNMT1",Granulocyte count,granulocyte count,GCST004614,19:10222312,Blood
288,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,4 x 10-9,,0.6028,'-,0.02207318 unit decrease,[0.015-0.029],"S1PR2, DNMT1",Neutrophil count,neutrophil count,GCST004629,19:10222312,Blood
289,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,1 x 10-9,,0.6028,'-,0.02282543 unit decrease,[0.015-0.03],"S1PR2, DNMT1",Myeloid white cell count,myeloid white cell count,GCST004626,19:10222312,Blood
290,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,5 x 10-9,,0.6028,'-,0.02189254 unit decrease,[0.015-0.029],"S1PR2, DNMT1",Sum basophil neutrophil counts,"neutrophil count, basophil count",GCST004620,19:10222312,Blood
291,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,6 x 10-26,,0.601086,'-,0.021916 SD unit decrease,[0.018-0.026],"S1PR2, DNMT1",Neutrophil count,neutrophil count,GCST90002351,19:10222312,Blood
292,DNMT1,DNMT1,Paternal,rs10409243-<b>T</b>,5 x 10-9,,0.6029,'-,0.02187366 unit decrease,[0.015-0.029],"S1PR2, DNMT1",Sum neutrophil eosinophil counts,"neutrophil count, eosinophil count",GCST004613,19:10222312,Blood
293,DNMT1,DNMT1,Paternal,rs2116942-<b>G</b>,6 x 10-11,,0.603764,'-,0.016544709 unit decrease,[0.012-0.022],"S1PR2, DNMT1",High light scatter reticulocyte count,reticulocyte count,GCST90002385,19:10223987,Blood
294,DNMT1,DNMT1,Paternal,rs2116942-<b>G</b>,4 x 10-10,,0.603769,'-,0.015815193 unit decrease,[0.011-0.021],"S1PR2, DNMT1",High light scatter reticulocyte percentage of red cells,reticulocyte measurement,GCST90002386,19:10223987,Blood
295,DNMT1,DNMT1,Paternal,rs2116942-<b>G</b>,5 x 10-25,,0.564288,'-,'-,'-,"S1PR2, DNMT1",Neutrophil count,neutrophil count,GCST90002355,19:10223987,Blood
296,DNMT1,DNMT1,Paternal,rs2116942-<b>G</b>,3 x 10-10,,0.603804,'-,0.015971579 unit decrease,[0.011-0.021],"S1PR2, DNMT1",Reticulocyte count,reticulocyte count,GCST90002405,19:10223987,Blood
297,DNMT1,DNMT1,Paternal,rs2116942-<b>G</b>,5 x 10-9,,0.603813,'-,0.014899487 unit decrease,[0.0099-0.0199],"S1PR2, DNMT1",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,19:10223987,Blood
298,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,4 x 10-9,,0.0085,'-,0.1210407 unit decrease,[0.081-0.161],"DNMT1, S1PR2",High light scatter reticulocyte count,reticulocyte count,GCST004611,19:10224049,Blood
299,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,2 x 10-9,,0.0085,'-,0.1239822 unit decrease,[0.084-0.164],"DNMT1, S1PR2",High light scatter reticulocyte percentage of red cells,reticulocyte count,GCST004612,19:10224049,Blood
300,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,2 x 10-20,,0.009652,'-,0.10578037 unit decrease,[0.083-0.128],"DNMT1, S1PR2",High light scatter reticulocyte count,reticulocyte count,GCST90002385,19:10224049,Blood
301,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,9 x 10-21,,0.009651,'-,0.1066247 unit decrease,[0.084-0.129],"DNMT1, S1PR2",High light scatter reticulocyte percentage of red cells,reticulocyte measurement,GCST90002386,19:10224049,Blood
302,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,1 x 10-12,,0.009667,'-,0.08099172 unit decrease,[0.059-0.103],"DNMT1, S1PR2",Immature fraction of reticulocytes,reticulocyte measurement,GCST90002387,19:10224049,Blood
303,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,4 x 10-19,,0.009659,'-,0.089062 SD unit decrease,[0.07-0.109],"DNMT1, S1PR2",Monocyte count,monocyte count,GCST90002340,19:10224049,Blood
304,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,2 x 10-16,,0.00813241,'-,'-,'-,"DNMT1, S1PR2",Monocyte count,monocyte count,GCST90002344,19:10224049,Blood
305,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,5 x 10-9,,0.009672,'-,0.065826274 unit decrease,[0.044-0.088],"DNMT1, S1PR2",White blood cell count,leukocyte count,GCST90002407,19:10224049,Blood
306,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,1 x 10-18,,0.009664,'-,0.1011308 unit decrease,[0.079-0.124],"DNMT1, S1PR2",Reticulocyte count,reticulocyte count,GCST90002405,19:10224049,Blood
307,DNMT1,DNMT1,Paternal,rs117064827-<b>G</b>,4 x 10-20,,0.009665,'-,0.10543739 unit decrease,[0.083-0.128],"DNMT1, S1PR2",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,19:10224049,Blood
308,DNMT1,DNMT1,Paternal,rs140658666-<b>T</b>,1 x 10-15,,0.1718,'-,0.03780359 unit decrease,[0.029-0.047],"DNMT1, S1PR2",Immature fraction of reticulocytes,reticulocyte count,GCST004628,19:10228310,Blood
309,DNMT1,DNMT1,Paternal,rs2288937-<b>G</b>,3 x 10-23,,0.1724,'-,0.04712367 unit decrease,[0.038-0.056],"DNMT1, S1PR2",Reticulocyte fraction of red cells,reticulocyte count,GCST004619,19:10230236,Blood
329,DSCAM,DSCAM,Paternal,rs117342730-<b>T</b>,5 x 10-6,"(DSCAM, 9175_48_3)",0.971875,'-,0.33789855 unit decrease,[0.19-0.48],"DSCAM, AF064866.1",Blood protein levels,blood protein measurement,GCST006585,21:40748477,Blood
330,DSCAM,DSCAM,Paternal,rs2837828-<b>?</b>,1 x 10-6,,NR,'-,'-,'-,DSCAM,Neutrophil count,neutrophil count,GCST001059,21:40803034,Blood
367,ERAP2,ERAP2,Paternal,rs4869314-<b>?</b>,2 x 10-7,,NR,'-,'-,'-,"AC009126.1, ERAP2",White blood cell count,leukocyte count,GCST007070,5:96893521,Blood
368,ERAP2,ERAP2,Paternal,rs34261036-<b>G</b>,2 x 10-41,"(Endoplasmic reticulum aminopeptidase 2, ERAP2.8960.3.3)",0.005,'-,2.29 unit increase,[1.96-2.62],"AC009126.1, ERAP2",Blood protein levels,blood protein measurement,GCST005806,5:96895352,Blood
369,ERAP2,ERAP2,Paternal,rs17408150-<b>A</b>,4 x 10-230,"(Endoplasmic reticulum aminopeptidase 2, ERAP2.8960.3.3)",0.054,'-,1.56 unit decrease,[1.46-1.66],"ERAP2, AC009126.1",Blood protein levels,blood protein measurement,GCST005806,5:96903554,Blood
370,ERAP2,ERAP2,Paternal,rs11455840-<b>CA</b>,4 x 10-300,"(Endoplasmic reticulum aminopeptidase 2, ERAP2.8960.3.3)",0.381,'-,0.88 unit decrease,[0.84-0.92],"ERAP2, AC009126.1",Blood protein levels,blood protein measurement,GCST005806,5:96910265,Blood
371,ERAP2,ERAP2,Paternal,rs2927608-<b>A</b>,7 x 10-858,"(Endoplasmic reticulum aminopeptidase 2, ERAP2.8960.3.3)",0.437,'-,1.05 unit increase,[1.01-1.09],"ERAP2, AC009126.1",Blood protein levels,blood protein measurement,GCST005806,5:96916728,Blood
372,ERAP2,ERAP2,Paternal,rs2910686-<b>C</b>,4 x 10-14,,0.448579,'-,'-,'-,"AC009126.1, ERAP2",Neutrophil count,neutrophil count,GCST90002355,5:96916885,Blood
501,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>G</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",3 x 10-10,,0,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Blood
502,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>A</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",2 x 10-6,,0.123,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Blood
560,GLIS3,GLIS3,Paternal,rs10973267-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,"RFX3-AS1, GLIS3",Red blood cell count,erythrocyte count,GCST007069,9:3734162,Blood
561,GLIS3,GLIS3,Paternal,rs501461-<b>T</b>,2 x 10-17,,0.632393,'-,'-,'-,GLIS3,Lymphocyte counts,lymphocyte count,GCST90002320,9:4039727,Blood
562,GLIS3,GLIS3,Paternal,rs501461-<b>T</b>,5 x 10-11,,0.598654,'-,0.014883512 unit decrease,[0.01-0.019],GLIS3,White blood cell count,leukocyte count,GCST90002407,9:4039727,Blood
563,GLIS3,GLIS3,Paternal,rs501461-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,GLIS3,White blood cell count,leukocyte count,GCST007070,9:4039727,Blood
564,GLIS3,GLIS3,Paternal,rs501461-<b>T</b>,7 x 10-20,,0.599659,'-,0.017739 SD unit decrease,[0.014-0.022],GLIS3,Lymphocyte counts,lymphocyte count,GCST90002316,9:4039727,Blood
565,GLIS3,GLIS3,Paternal,rs501461-<b>T</b>,4 x 10-12,,0.59985,'-,0.013113 SD unit decrease,[0.0094-0.0168],GLIS3,White blood cell count,myeloid white cell count,GCST90002374,9:4039727,Blood
566,GLIS3,GLIS3,Paternal,rs501461-<b>T</b>,2 x 10-11,,0.645549,'-,'-,'-,GLIS3,White blood cell count,myeloid white cell count,GCST90002378,9:4039727,Blood
567,GLIS3,GLIS3,Paternal,rs7033677-<b>G</b>,7 x 10-17,,0.63997,'-,0.019664198 unit decrease,[0.015-0.024],GLIS3,Lymphocyte counts,lymphocyte count,GCST90002388,9:4049942,Blood
568,GLIS3,GLIS3,Paternal,rs7033677-<b>G</b>,7 x 10-17,,0.63997,'-,0.019664198 unit decrease,[0.015-0.024],GLIS3,Monocyte count,monocyte count,GCST90002393,9:4049942,Blood
569,GLIS3,GLIS3,Paternal,rs487732-<b>T</b>,5 x 10-9,,0.65438,'-,0.013705773 unit increase,[0.0091-0.0183],GLIS3,Lymphocyte percentage of white cells,lymphocyte percentage of leukocytes,GCST90002389,9:4099510,Blood
570,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,1 x 10-12,,0.6027,'-,0.02622343 unit decrease,[0.019-0.033],GLIS3,Hematocrit,hematocrit,GCST004604,9:4118111,Blood
571,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,9 x 10-12,,0.6026,'-,0.02539376 unit decrease,[0.018-0.033],GLIS3,Red blood cell count,erythrocyte count,GCST004601,9:4118111,Blood
572,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,9 x 10-26,,0.603457,'-,0.024032816 unit decrease,[0.02-0.029],GLIS3,Hemoglobin,hemoglobin measurement,GCST90002384,9:4118111,Blood
573,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,2 x 10-36,,0.60433,'-,0.024132 SD unit decrease,[0.02-0.028],GLIS3,Hemoglobin concentration,hemoglobin measurement,GCST90002310,9:4118111,Blood
574,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,4 x 10-36,,0.60432,'-,0.02406 SD unit decrease,[0.02-0.028],GLIS3,Hematocrit,hematocrit,GCST90002304,9:4118111,Blood
575,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,1 x 10-36,,0.657438,'-,'-,'-,GLIS3,Hematocrit,hematocrit,GCST90002308,9:4118111,Blood
576,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,6 x 10-36,,0.659297,'-,'-,'-,GLIS3,Hemoglobin concentration,hemoglobin measurement,GCST90002314,9:4118111,Blood
577,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,2 x 10-24,,0.603452,'-,0.023291219 unit decrease,[0.019-0.028],GLIS3,Hematocrit,hematocrit,GCST90002383,9:4118111,Blood
578,GLIS3,GLIS3,Paternal,rs6415788-<b>?</b>,4 x 10-26,,NR,'-,'-,'-,GLIS3,Red blood cell count,erythrocyte count,GCST007069,9:4118111,Blood
579,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,1 x 10-22,,0.603442,'-,0.022322582 unit decrease,[0.018-0.027],GLIS3,Red blood cell count,erythrocyte count,GCST90002403,9:4118111,Blood
580,GLIS3,GLIS3,Paternal,rs6415788-<b>G</b>,3 x 10-22,,'-,'-,0.022 unit increase,[NR],GLIS3,Hemoglobin levels,hemoglobin measurement,GCST010083,9:4118111,Blood
581,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,4 x 10-11,,0.6026,'-,0.0244589 unit decrease,[0.017-0.032],GLIS3,Hemoglobin concentration,hemoglobin measurement,GCST004615,9:4118111,Blood
582,GLIS3,GLIS3,Paternal,rs7043265-<b>C</b>,2 x 10-9,,0.231018,'-,0.015952703 unit increase,[0.011-0.021],GLIS3,Platelet count,platelet count,GCST90002402,9:4292012,Blood
632,GLIS3,GLIS3,Paternal,rs564816-<b>C</b>,3 x 10-7,,0.04,'-,'-,[NR],GLIS3,Methotrexate phramacokinetics (acute lymphoblastic leukemia),response to antineoplastic agent,GCST000523,9:4015370,Blood
782,GPR1,GPR1,Paternal,rs115067791-<b>A</b>,1 x 10-9,,0.057386,'-,0.029510975 unit decrease,[0.02-0.039],"EEF1B2, GPR1",Reticulocyte count,reticulocyte count,GCST90002405,2:206168582,Blood
783,GPR1,GPR1,Paternal,rs115067791-<b>A</b>,4 x 10-9,,0.057376,'-,0.028460527 unit decrease,[0.019-0.038],"EEF1B2, GPR1",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,2:206168582,Blood
784,GPR1,GPR1,Paternal,rs13028246-<b>T</b>,1 x 10-9,,0.5171,'-,0.013664011 unit increase,[0.0093-0.018],GPR1-AS,Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,2:206220097,Blood
787,GPR1,GPR1-AS,Paternal,rs13028246-<b>T</b>,1 x 10-9,,0.5171,'-,0.013664011 unit increase,[0.0093-0.018],GPR1-AS,Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,2:206220097,Blood
887,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>A</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",3 x 10-15,,0.011,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Blood
888,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>G</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",8 x 10-15,,0.23,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Blood
1228,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,6 x 10-11,,NR,'-,0.0188 unit increase,[0.013-0.024],IGF2,Glycated hemoglobin levels,HbA1c measurement,GCST90019509,11:2128634,Blood
1257,IGF2,IGF2,Paternal,rs11564722-<b>T</b>,2 x 10-15,,0.293296,'-,'-,'-,INS-IGF2,Hemoglobin concentration,hemoglobin measurement,GCST90002314,11:2157100,Blood
1270,IGF2,IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-13,,0.240949,'-,0.018659724 unit increase,[0.014-0.024],INS-IGF2,Red blood cell count,erythrocyte count,GCST90002403,11:2157100,Blood
1273,IGF2,IGF2,Paternal,rs11042596-<b>G</b>,5 x 10-10,,0.662929,'-,0.014945593 unit decrease,[0.01-0.02],"H19, IGF2",Reticulocyte count,reticulocyte count,GCST90002405,11:2097630,Blood
1274,IGF2,IGF2,Paternal,rs11564722-<b>?</b>,5 x 10-12,,NR,'-,'-,'-,INS-IGF2,Red blood cell count,erythrocyte count,GCST007069,11:2157100,Blood
1282,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-17,,NR,'-,0.025 unit increase,[0.019-0.031],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90019509,11:2159843,Blood
1287,IGF2,IGF2,Paternal,rs3842753-<b>T</b>,4 x 10-8,,0.284,'-,0.0075 unit increase,[0.0044-0.0106],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90002244,11:2159830,Blood
1293,IGF2,IGF2,Paternal,rs2239681-<b>A</b>,2 x 10-8,,'-,'-,0.014 unit increase,[NR],"IGF2-AS, INS-IGF2",Hemoglobin levels,hemoglobin measurement,GCST010083,11:2146751,Blood
1326,IGF2,IGF2-AS,Paternal,rs2239681-<b>A</b>,2 x 10-8,,'-,'-,0.014 unit increase,[NR],"IGF2-AS, INS-IGF2",Hemoglobin levels,hemoglobin measurement,GCST010083,11:2146751,Blood
1336,IGF2,INS-IGF2,Paternal,rs11564722-<b>T</b>,2 x 10-15,,0.293296,'-,'-,'-,INS-IGF2,Hemoglobin concentration,hemoglobin measurement,GCST90002314,11:2157100,Blood
1349,IGF2,INS-IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-13,,0.240949,'-,0.018659724 unit increase,[0.014-0.024],INS-IGF2,Red blood cell count,erythrocyte count,GCST90002403,11:2157100,Blood
1352,IGF2,INS-IGF2,Paternal,rs11564722-<b>?</b>,5 x 10-12,,NR,'-,'-,'-,INS-IGF2,Red blood cell count,erythrocyte count,GCST007069,11:2157100,Blood
1358,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-18,,NR,'-,0.0262 unit increase,[0.02-0.032],"INS-IGF2, INS",Blood glucose levels,glucose measurement,GCST90019508,11:2159843,Blood
1359,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-17,,NR,'-,0.025 unit increase,[0.019-0.031],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90019509,11:2159843,Blood
1366,IGF2,INS-IGF2,Paternal,rs3842753-<b>T</b>,4 x 10-8,,0.284,'-,0.0075 unit increase,[0.0044-0.0106],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90002244,11:2159830,Blood
1385,IGF2,INS-IGF2,Paternal,rs2239681-<b>A</b>,2 x 10-8,,'-,'-,0.014 unit increase,[NR],"IGF2-AS, INS-IGF2",Hemoglobin levels,hemoglobin measurement,GCST010083,11:2146751,Blood
1393,INS,INS,Paternal,rs3842752-<b>A</b>,1 x 10-17,,NR,'-,0.025 unit increase,[0.019-0.031],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90019509,11:2159843,Blood
1398,INS,INS,Paternal,rs3842753-<b>T</b>,4 x 10-8,,0.284,'-,0.0075 unit increase,[0.0044-0.0106],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90002244,11:2159830,Blood
1411,INS,INS,Paternal,rs11564722-<b>T</b>,2 x 10-15,,0.293296,'-,'-,'-,INS-IGF2,Hemoglobin concentration,hemoglobin measurement,GCST90002314,11:2157100,Blood
1423,INS,INS,Paternal,rs11564722-<b>T</b>,9 x 10-13,,0.240949,'-,0.018659724 unit increase,[0.014-0.024],INS-IGF2,Red blood cell count,erythrocyte count,GCST90002403,11:2157100,Blood
1426,INS,INS,Paternal,rs11564722-<b>?</b>,5 x 10-12,,NR,'-,'-,'-,INS-IGF2,Red blood cell count,erythrocyte count,GCST007069,11:2157100,Blood
1457,INS,INS,Paternal,rs2239681-<b>A</b>,2 x 10-8,,'-,'-,0.014 unit increase,[NR],"IGF2-AS, INS-IGF2",Hemoglobin levels,hemoglobin measurement,GCST010083,11:2146751,Blood
1467,INS,INS-IGF2,Paternal,rs11564722-<b>T</b>,2 x 10-15,,0.293296,'-,'-,'-,INS-IGF2,Hemoglobin concentration,hemoglobin measurement,GCST90002314,11:2157100,Blood
1480,INS,INS-IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-13,,0.240949,'-,0.018659724 unit increase,[0.014-0.024],INS-IGF2,Red blood cell count,erythrocyte count,GCST90002403,11:2157100,Blood
1483,INS,INS-IGF2,Paternal,rs11564722-<b>?</b>,5 x 10-12,,NR,'-,'-,'-,INS-IGF2,Red blood cell count,erythrocyte count,GCST007069,11:2157100,Blood
1490,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-17,,NR,'-,0.025 unit increase,[0.019-0.031],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90019509,11:2159843,Blood
1497,INS,INS-IGF2,Paternal,rs3842753-<b>T</b>,4 x 10-8,,0.284,'-,0.0075 unit increase,[0.0044-0.0106],"INS-IGF2, INS",Glycated hemoglobin levels,HbA1c measurement,GCST90002244,11:2159830,Blood
1516,INS,INS-IGF2,Paternal,rs2239681-<b>A</b>,2 x 10-8,,'-,'-,0.014 unit increase,[NR],"IGF2-AS, INS-IGF2",Hemoglobin levels,hemoglobin measurement,GCST010083,11:2146751,blood
1530,IRAIN,IRAIN,Paternal,rs1573891-<b>?</b>,6 x 10-8,,NR,'-,'-,'-,"IRAIN, FAM169B",Red cell distribution width,red blood cell distribution width,GCST007074,15:98643259,Blood
2163,LIN28B,LIN28B,Paternal,rs364663-<b>A</b>,2 x 10-9,,0.557338,'-,0.013224364 unit decrease,[0.0089-0.0176],LIN28B,White blood cell count,leukocyte count,GCST90002407,6:104995314,Blood
2365,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
2366,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
2531,WT1,PAWR,Paternal,rs4842316-<b>T</b>,1 x 10-13,,0.594967,'-,'-,'-,PAWR,White blood cell count,myeloid white cell count,GCST90002378,12:79580785,Blood
2533,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
2534,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
2545,PLAGL1,PLAGL1,Paternal,rs2064495-<b>?</b>,6 x 10-10,,NR,'-,'-,'-,PLAGL1,Eosinophil counts,eosinophil count,GCST007065,6:143948864,Blood
2546,PLAGL1,PLAGL1,Paternal,rs11373039-<b>AG</b>,1 x 10-12,,0.082789,'-,0.028627379 unit decrease,[0.021-0.037],PLAGL1,Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,6:144054680,Blood
2547,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,5 x 10-17,,0.0349,'-,0.08266498 unit decrease,[0.063-0.102],"SF3B5, PLAGL1",Neutrophil percentage of white cells,neutrophil percentage of leukocytes,GCST004633,6:144064640,Blood
2548,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,2 x 10-29,,0.0349,'-,0.110864 unit increase,[0.092-0.13],"SF3B5, PLAGL1",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST004609,6:144064640,Blood
2549,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,5 x 10-30,,0.0349,'-,0.1123782 unit decrease,[0.093-0.132],"SF3B5, PLAGL1",Granulocyte percentage of myeloid white cells,granulocyte percentage of myeloid white cells,GCST004608,6:144064640,Blood
2550,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,2 x 10-9,,0.0349,'-,0.05976161 unit increase,[0.04-0.079],"SF3B5, PLAGL1",Eosinophil percentage of granulocytes,eosinophil percentage of granulocytes,GCST004617,6:144064640,Blood
2551,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,3 x 10-16,,0.0349,'-,0.08070002 unit increase,[0.061-0.1],"SF3B5, PLAGL1",Monocyte count,monocyte count,GCST004625,6:144064640,Blood
2552,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,2 x 10-48,,0.036036,'-,0.074605 SD unit increase,[0.065-0.085],"SF3B5, PLAGL1",Monocyte count,monocyte count,GCST90002340,6:144064640,Blood
2553,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,4 x 10-13,,0.03569,'-,0.043554757 unit increase,[0.032-0.055],"SF3B5, PLAGL1",Lymphocyte percentage of white cells,lymphocyte percentage of leukocytes,GCST90002389,6:144064640,Blood
2554,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,7 x 10-46,,0.0345892,'-,'-,'-,"SF3B5, PLAGL1",Monocyte count,monocyte count,GCST90002344,6:144064640,Blood
2555,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,5 x 10-66,,0.035667,'-,0.10335902 unit increase,[0.092-0.115],"SF3B5, PLAGL1",Monocyte percentage of white cells,monocyte percentage of leukocytes,GCST90002394,6:144064640,Blood
2556,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,4 x 10-34,,0.03568,'-,0.07297152 unit decrease,[0.061-0.085],"SF3B5, PLAGL1",Neutrophil percentage of white cells,neutrophil percentage of leukocytes,GCST90002399,6:144064640,Blood
2557,PLAGL1,PLAGL1,Paternal,rs149110519-<b>T</b>,2 x 10-9,,0.0349,'-,0.05902827 unit decrease,[0.04-0.078],"SF3B5, PLAGL1",Neutrophil percentage of granulocytes,neutrophil percentage of granulocytes,GCST004623,6:144064640,Blood
2592,RASGRF1,RASGRF1,Paternal,rs7177831-<b>A</b>,4 x 10-212,"(CTSH, 8644_46_3)",0.819375,'-,0.9109655 unit decrease,[0.86-0.96],"RASGRF1, CTSH",Blood protein levels,blood protein measurement,GCST006585,15:78954000,Blood
2637,RHOBTB3,RHOBTB3,Paternal,rs57675369-<b>AG</b>,9 x 10-21,,0.1283,'-,0.04966919 unit decrease,[0.039-0.06],"GGCTP1, RHOBTB3",Immature fraction of reticulocytes,reticulocyte count,GCST004628,5:95826715,Blood
2638,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,1 x 10-44,,0.1283,'-,0.07505901 unit decrease,[0.065-0.086],"GGCTP1, RHOBTB3",High light scatter reticulocyte count,reticulocyte count,GCST004611,5:95826771,Blood
2639,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,6 x 10-44,,0.1283,'-,0.07450436 unit decrease,[0.064-0.085],"GGCTP1, RHOBTB3",High light scatter reticulocyte percentage of red cells,reticulocyte count,GCST004612,5:95826771,Blood
2640,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,1 x 10-49,,0.1283,'-,0.07948653 unit decrease,[0.069-0.09],"GGCTP1, RHOBTB3",Reticulocyte fraction of red cells,reticulocyte count,GCST004619,5:95826771,Blood
2641,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,5 x 10-49,,0.1282,'-,0.07895376 unit decrease,[0.068-0.089],"GGCTP1, RHOBTB3",Reticulocyte count,reticulocyte count,GCST004622,5:95826771,Blood
2642,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,9 x 10-119,,0.128442,'-,0.07749632 unit decrease,[0.071-0.084],"GGCTP1, RHOBTB3",High light scatter reticulocyte percentage of red cells,reticulocyte measurement,GCST90002386,5:95826771,Blood
2643,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,4 x 10-116,,0.128457,'-,0.076623626 unit decrease,[0.07-0.083],"GGCTP1, RHOBTB3",High light scatter reticulocyte count,reticulocyte count,GCST90002385,5:95826771,Blood
2644,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,2 x 10-70,,0.128408,'-,0.059802502 unit decrease,[0.053-0.066],"GGCTP1, RHOBTB3",Immature fraction of reticulocytes,reticulocyte measurement,GCST90002387,5:95826771,Blood
2645,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,4 x 10-96,,0.128393,'-,0.06998844 unit decrease,[0.063-0.077],"GGCTP1, RHOBTB3",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,5:95826771,Blood
2646,RHOBTB3,RHOBTB3,Paternal,rs10067881-<b>A</b>,9 x 10-91,,0.128408,'-,0.06798096 unit decrease,[0.061-0.075],"GGCTP1, RHOBTB3",Reticulocyte count,reticulocyte count,GCST90002405,5:95826771,Blood
2647,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,6 x 10-28,,0.1017,'-,0.06504534 unit increase,[0.053-0.077],"GGCTP1, RHOBTB3",High light scatter reticulocyte count,reticulocyte count,GCST004611,5:95827733,Blood
2648,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,3 x 10-27,,0.1017,'-,0.06416802 unit increase,[0.053-0.076],"GGCTP1, RHOBTB3",High light scatter reticulocyte percentage of red cells,reticulocyte count,GCST004612,5:95827733,Blood
2649,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,4 x 10-31,,0.1017,'-,0.06894116 unit increase,[0.057-0.081],"GGCTP1, RHOBTB3",Reticulocyte fraction of red cells,reticulocyte count,GCST004619,5:95827733,Blood
2650,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,9 x 10-31,,0.1017,'-,0.06854185 unit increase,[0.057-0.08],"GGCTP1, RHOBTB3",Reticulocyte count,reticulocyte count,GCST004622,5:95827733,Blood
2651,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,8 x 10-12,,0.1017,'-,0.04016075 unit increase,[0.029-0.052],"GGCTP1, RHOBTB3",Immature fraction of reticulocytes,reticulocyte count,GCST004628,5:95827733,Blood
2652,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,7 x 10-54,,0.101326,'-,0.057399277 unit increase,[0.05-0.065],"GGCTP1, RHOBTB3",High light scatter reticulocyte percentage of red cells,reticulocyte measurement,GCST90002386,5:95827733,Blood
2653,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,1 x 10-50,,0.101321,'-,0.055596527 unit increase,[0.048-0.063],"GGCTP1, RHOBTB3",High light scatter reticulocyte count,reticulocyte count,GCST90002385,5:95827733,Blood
2654,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,3 x 10-31,,0.101323,'-,0.04355093 unit increase,[0.036-0.051],"GGCTP1, RHOBTB3",Immature fraction of reticulocytes,reticulocyte measurement,GCST90002387,5:95827733,Blood
2655,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,2 x 10-43,,0.101359,'-,0.051599346 unit increase,[0.044-0.059],"GGCTP1, RHOBTB3",Reticulocyte fraction of red cells,reticulocyte measurement,GCST90002406,5:95827733,Blood
2656,RHOBTB3,RHOBTB3,Paternal,rs17462893-<b>G</b>,1 x 10-38,,0.101353,'-,0.04858195 unit increase,[0.041-0.056],"GGCTP1, RHOBTB3",Reticulocyte count,reticulocyte count,GCST90002405,5:95827733,Blood
2676,SGK2,SGK2,Paternal,rs3787271-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,SGK2,White blood cell count,leukocyte count,GCST007070,20:43573437,Blood
3049,WT1,WT1,Paternal,rs5030283-<b>C</b>,6 x 10-12,,0.210199,'-,0.018867975 unit decrease,[0.014-0.024],WT1,Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,11:32393565,Blood
3050,WT1,WT1,Paternal,rs5030241-<b>T</b>,1 x 10-10,,0.342555,'-,'-,'-,WT1,Hematocrit,hematocrit,GCST90002308,11:32402750,Blood
3051,WT1,WT1,Paternal,rs35317214-<b>AT</b>,2 x 10-10,,0.255148,'-,0.016297365 unit decrease,[0.011-0.021],WT1,Mean reticulocyte volume,mean reticulocyte volume,GCST90002396,11:32406629,Blood
3062,WT1,WT1,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Blood
3077,WT1,WT1-AS,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Blood
3091,WT1-AS,WT1-AS,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Blood
3161,ZFAT,ZFAT,Paternal,rs6471235-<b>?</b>,5 x 10-6,(TIMP1),'-,'-,0.0733 unit increase,[NR],"ZFAT, AC105180.2",Blood protein levels,blood protein measurement,GCST010104,8:134401610,Blood
3162,ZFAT,ZFAT,Paternal,rs2315834-<b>C</b>,4 x 10-7,,NR,'-,0.39 unit decrease,[0.24-0.54],ZFAT,Iron status biomarkers (iron levels),serum iron measurement,GCST004570,8:134507604,Blood
3163,ZFAT,ZFAT,Paternal,rs2315837-<b>C</b>,7 x 10-9,,0.499535,'-,0.012943483 unit decrease,[0.0086-0.0173],ZFAT,Mean reticulocyte volume,mean reticulocyte volume,GCST90002396,8:134610098,Blood
3164,ZFAT,ZFAT,Paternal,rs4909338-<b>T</b>,2 x 10-9,,0.509021,'-,0.01323606 unit decrease,[0.0089-0.0176],ZFAT,Mean spheric corpuscular volume,mean corpuscular volume,GCST90002397,8:134639373,Blood
3165,ZFAT,ZFAT,Paternal,rs34074875-<b>A</b>,7 x 10-17,,0.156831,'-,0.025431197 unit increase,[0.019-0.031],ZFAT,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST90002390,8:134640328,Blood
3166,ZFAT,ZFAT,Paternal,rs34074875-<b>A</b>,4 x 10-15,,0.156826,'-,0.0251213 unit increase,[0.02-0.031],ZFAT,Mean corpuscular volume,mean corpuscular volume,GCST90002392,8:134640328,Blood
3167,ZFAT,ZFAT,Paternal,rs34074875-<b>?</b>,4 x 10-22,,NR,'-,'-,'-,ZFAT,Mean corpuscular hemoglobin,mean corpuscular hemoglobin,GCST007068,8:134640328,Blood
3168,ZFAT,ZFAT,Paternal,rs72719796-<b>?</b>,2 x 10-13,,NR,'-,'-,'-,ZFAT,Red blood cell count,erythrocyte count,GCST007069,8:134646328,Blood
3169,ZFAT,ZFAT,Paternal,rs72719796-<b>G</b>,1 x 10-14,,0.15861,'-,0.023279663 unit decrease,[0.017-0.029],ZFAT,Red blood cell count,erythrocyte count,GCST90002403,8:134646328,Blood
3170,ZFAT,ZFAT,Paternal,rs13271002-<b>G</b>,7 x 10-21,,0.130007,'-,'-,'-,ZFAT,Mean corpuscular volume,mean corpuscular volume,GCST90002338,8:134662361,Blood
3171,ZFAT,ZFAT,Paternal,rs71528371-<b>T</b>,7 x 10-24,,0.146953,'-,0.027458 SD unit increase,[0.022-0.033],ZFAT,Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002322,8:134672395,Blood
3172,ZFAT,ZFAT,Paternal,rs71528371-<b>T</b>,2 x 10-21,,0.121487,'-,'-,'-,ZFAT,Mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,GCST90002326,8:134672395,Blood
3173,ZFAT,ZFAT,Paternal,rs71528371-<b>T</b>,3 x 10-22,,0.146831,'-,0.024898 SD unit increase,[0.02-0.03],ZFAT,Mean corpuscular volume,mean corpuscular volume,GCST90002334,8:134672395,Blood
3174,ZFAT,ZFAT,Paternal,rs71528371-<b>T</b>,8 x 10-15,,0.146819,'-,0.020325 SD unit decrease,[0.015-0.025],ZFAT,Red blood cell count,red blood cell density measurement,GCST90002363,8:134672395,Blood
3175,ZFAT,ZFAT,Paternal,rs67654984-<b>A</b>,6 x 10-9,,0.159008,'-,0.017579276 unit decrease,[0.012-0.024],ZFAT,Eosinophil percentage of white cells,eosinophil percentage of leukocytes,GCST90002382,8:134695739,Blood
3176,ZFAT,ZFAT,Paternal,rs9969668-<b>A</b>,2 x 10-10,,0.132914,'-,'-,'-,"ZFAT, AC087045.2",Eosinophil counts,eosinophil count,GCST90002302,8:134719335,Blood
3177,ZFAT,ZFAT,Paternal,rs9969668-<b>A</b>,2 x 10-11,,0.154615,'-,0.018537 SD unit decrease,[0.013-0.024],"ZFAT, AC087045.2",Eosinophil counts,eosinophil count,GCST90002298,8:134719335,Blood
3178,ZFAT,ZFAT,Paternal,rs7818560-<b>C</b>,3 x 10-11,,0.154434,'-,0.020340048 unit decrease,[0.014-0.026],"ZFAT, AC087045.2",Eosinophil counts,eosinophil count,GCST90002381,8:134719710,Blood
3192,ZFP90,ZFP90,Paternal,rs8050260-<b>A</b>,2 x 10-9,,0.2093,'-,0.02726745 unit increase,[0.018-0.036],"ZFP90, RPL35AP33",Plateletcrit,platelet crit,GCST004607,16:68517374,Blood
3193,ZFP90,ZFP90,Paternal,rs1170439-<b>C</b>,3 x 10-18,,0.77913,'-,0.023427002 unit increase,[0.018-0.029],"ZFP90, AC126773.3",Eosinophil percentage of white cells,eosinophil percentage of leukocytes,GCST90002382,16:68574608,Blood
3194,ZFP90,ZFP90,Paternal,rs1170439-<b>C</b>,9 x 10-21,,0.783079,'-,'-,'-,"ZFP90, AC126773.3",Eosinophil counts,eosinophil count,GCST90002302,16:68574608,Blood
3195,ZFP90,ZFP90,Paternal,rs1170439-<b>?</b>,3 x 10-25,,NR,'-,'-,'-,"ZFP90, AC126773.3",Eosinophil counts,eosinophil count,GCST007065,16:68574608,Blood
3196,ZFP90,ZFP90,Paternal,rs1170439-<b>C</b>,6 x 10-18,,0.779149,'-,0.02335192 unit increase,[0.018-0.029],"ZFP90, AC126773.3",Eosinophil counts,eosinophil count,GCST90002381,16:68574608,Blood
3210,ZIM2,ZIM2,Paternal,rs77926443-<b>T</b>,3 x 10-6,,0.011,3.692,'-,[2.128-6.407],"ZNF71, ZIM2-AS1",Venous thromboembolism adjusted for sickle cell variant rs77121243-T,venous thromboembolism,GCST004068,19:56595798,Blood
3220,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
3225,ZIM2,ZIM2-AS1,Paternal,rs77926443-<b>T</b>,3 x 10-6,,0.011,3.692,'-,[2.128-6.407],"ZNF71, ZIM2-AS1",Venous thromboembolism adjusted for sickle cell variant rs77121243-T,venous thromboembolism,GCST004068,19:56595798,Blood
3221,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Blood
3830,SNORD116,SNORD116,Paternal,rs7986114-<b>T</b>,2 x 10-9,,0.530269,'-,0.013508062 unit increase,[0.0091-0.0179],SNORD116,Eosinophil percentage of white cells,eosinophil percentage of leukocytes,GCST90002382,13:39940401,Blood
3831,SNORD116,SNORD116,Paternal,rs9548987-<b>G</b>,1 x 10-11,,0.47282,'-,0.015176305 unit increase,[0.011-0.02],SNORD116,Eosinophil counts,eosinophil count,GCST90002381,13:39929435,Blood
3832,SNORD116,SNORD116,Paternal,rs7986114-<b>?</b>,2 x 10-15,,NR,'-,'-,'-,SNORD116,Eosinophil counts,eosinophil count,GCST007065,13:39940401,Blood
1933,KCNQ1OT1,KCNQ1OT1,Paternal,rs231353-<b>G</b>,2 x 10-9,,0.3493,'-,0.02308014 unit decrease,[0.016-0.031],"KCNQ1OT1, KCNQ1",Plateletcrit,platelet crit,GCST004607,11:2687789,Blood
1934,KCNQ1OT1,KCNQ1OT1,Paternal,rs231353-<b>G</b>,4 x 10-14,,0.357997,'-,0.014844 SD unit decrease,[0.011-0.019],"KCNQ1OT1, KCNQ1",Platelet count,platelet count,GCST90002357,11:2687789,Blood
1935,KCNQ1OT1,KCNQ1OT1,Paternal,rs231353-<b>G</b>,2 x 10-14,,0.465753,'-,'-,'-,"KCNQ1OT1, KCNQ1",Platelet count,platelet count,GCST90002361,11:2687789,Blood
1936,KCNQ1OT1,KCNQ1OT1,Paternal,rs231353-<b>G</b>,3 x 10-26,,0.349972,'-,0.025168354 unit decrease,[0.021-0.03],"KCNQ1OT1, KCNQ1",Plateletcrit,platelet crit,GCST90002400,11:2687789,Blood
1937,KCNQ1OT1,KCNQ1OT1,Paternal,rs231353-<b>G</b>,3 x 10-10,,0.349952,'-,0.014821836 unit decrease,[0.01-0.019],"KCNQ1OT1, KCNQ1",Platelet count,platelet count,GCST90002402,11:2687789,Blood
1938,KCNQ1OT1,KCNQ1OT1,Paternal,rs35957135-<b>A</b>,8 x 10-9,,0.308944,'-,0.014082907 unit decrease,[0.0093-0.0189],"KCNQ1OT1, KCNQ1",Mean platelet volume,mean platelet volume,GCST90002395,11:2698445,Blood
1939,KCNQ1OT1,KCNQ1OT1,Paternal,rs368427206-<b>G</b>,3 x 10-10,,0.274311,'-,'-,'-,"KCNQ1, KCNQ1OT1",Mean platelet volume,mean platelet volume,GCST90002349,11:2699514,Blood
133,DIO3,DIO3,Paternal,rs11621975-<b>?</b>,5 x 10-6,,NR,2.31,'-,'-,"DIO3, LINC02320",Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,"overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,14:101565415,Cancer
137,DIO3,DIO3OS,Paternal,"rs10142332-<b>G</b>, rs12435279-<b>C</b>, rs12586651-<b>T</b>",3 x 10-7,,0.155,'-,'-,'-,AL049836.2 - DIO3OS; AL049836.2 - DIO3OS; AL049836.2 - DIO3OS,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,14:101519289|14:101522626|14:101519591,Cancer
154,DLGAP2,DLGAP2,Paternal,rs138808635-<b>C</b>,9 x 10-6,,'-,'-,0.6906 SD units decrease,[0.39-0.99],DLGAP2,Tumor necrosis factor alpha levels,tumor necrosis factor-alpha measurement,GCST004426,8:1135584,Cancer
155,DLGAP2,DLGAP2,Paternal,rs34582125-<b>G</b>,9 x 10-6,,'-,'-,0.1617 SD units increase,[0.09-0.233],DLGAP2,Tumor necrosis factor beta levels,tumor necrosis factor beta measurement,GCST004425,8:1188292,Cancer
172,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>T</b>",1 x 10-7,,0.185,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Cancer
173,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>C</b>",4 x 10-7,,0.355,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Cancer
174,DLGAP2,DLGAP2,Paternal,rs28367414-<b>?</b>,3 x 10-6,,'-,'-,'-,'-,DLGAP2,Clostridium difficile infection in multiple myeloma,"clostridium difficile infection, multiple myeloma",GCST005686,8:1470728,Cancer
175,DLGAP2,DLGAP2,Paternal,rs2404618-<b>T</b>,7 x 10-6,,0.465822007,1.0544931,'-,[1.030451547-1.07909551],DLGAP2,Lung cancer,lung carcinoma,GCST004748,8:1514102,Cancer
184,DLGAP2,DLGAP2,Paternal,rs192316701-<b>C</b>,5 x 10-6,(AA),0.997,'-,0.163 unit increase,'-,DLGAP2,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507902,Cancer
185,DLGAP2,DLGAP2,Paternal,rs139288166-<b>?</b>,7 x 10-8,,0.03,4.3,'-,[2.53-7.31],DLGAP2,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),"Hematochezia, response to radiation, prostate carcinoma",GCST008381,8:755922,Cancer
345,DSCAM,DSCAM,Paternal,rs9981861-<b>G</b>,4 x 10-6,,NR,1.33,'-,[0.82-2.15],DSCAM,Non-small cell lung cancer (survival),non-small cell lung carcinoma,GCST000871,21:40043117,Cancer
346,DSCAM,DSCAM,Paternal,rs727333-<b>?</b>,1 x 10-6,,0.081,'-,1.542 unit increase,[1.295-1.837],DSCAM,Estradiol plasma levels (breast cancer),estradiol measurement,GCST001914,21:40331020,Cancer
500,GLI3,GLI3,Paternal,rs9791676-<b>?</b>,8 x 10-6,(clearcell),NR,1.96,'-,'-,GLI3,Epithelial ovarian cancer,ovarian carcinoma,GCST007728,7:42053156,Cancer
501,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>G</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",3 x 10-10,,0,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Cancer
502,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>A</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",2 x 10-6,,0.123,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Cancer
607,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,2 x 10-8,,0.6,'-,0.0107 unit decrease,[0.0069-0.0145],GLIS3,Urate levels,urate measurement,GCST011119,9:4118111,Cancer
621,GLIS3,GLIS3,Paternal,rs199600662-<b>?</b>,5 x 10-6,,NR,0.8728601,'-,[0.82-0.93],"GLIS3, RFX3-AS1",Breast cancer specific mortality in breast cancer,"breast carcinoma, mortality",GCST007477,9:3708602,Cancer
622,GLIS3,GLIS3,Paternal,rs954980-<b>?</b>,5 x 10-6,,'-,1.3933399,'-,[NR],"GLIS3, RFX3-AS1",Colorectal cancer,colorectal cancer,GCST005152,9:3761909,Cancer
623,GLIS3,GLIS3,Paternal,rs10974465-<b>T</b>,6 x 10-6,,0.161054917,1.122095,'-,[1.067564608-1.179410829],GLIS3,Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,9:4326243,Cancer
632,GLIS3,GLIS3,Paternal,rs564816-<b>C</b>,3 x 10-7,,0.04,'-,'-,[NR],GLIS3,Methotrexate phramacokinetics (acute lymphoblastic leukemia),response to antineoplastic agent,GCST000523,9:4015370,Cancer
773,DIRAS3,GNG12-AS1,Paternal,rs1367448-<b>C</b>,5 x 10-6,(Dominant model),0.526,1.554,'-,[1.212-1.993],"GNG12-AS1, WLS",Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),"response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,1:68168241,Cancer
887,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>A</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",3 x 10-15,,0.011,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Cancer
888,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>G</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",8 x 10-15,,0.23,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Cancer
1235,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,8 x 10-17,,NR,'-,0.0234 unit increase,[0.018-0.029],IGF2,Urate levels,urate measurement,GCST90019524,11:2128634,Cancer
1243,IGF2,IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Cancer
1244,IGF2,IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Cancer
1251,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1252,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1253,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1254,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1271,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Cancer
1290,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Cancer
1310,IGF2,IGF2,Paternal,rs7482894-<b>T</b>,4 x 10-14,,0.65,'-,0.0147 unit increase,[0.011-0.019],"H19, IGF2",Urate levels,urate measurement,GCST011119,11:2100034,Cancer
1315,IGF2,IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Cancer
1322,IGF2,IGF2-AS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Cancer
1323,IGF2,IGF2-AS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Cancer
1330,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1331,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1332,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1333,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1350,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Cancer
1368,IGF2,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Cancer
1369,IGF2,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Cancer
1373,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Cancer
1390,IGF2,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Cancer
1401,INS,INS,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Cancer
1405,INS,INS,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1406,INS,INS,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1407,INS,INS,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1408,INS,INS,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1424,INS,INS,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Cancer
1434,INS,INS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Cancer
1435,INS,INS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Cancer
1442,INS,INS,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Cancer
1461,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1462,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Cancer
1463,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1464,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Cancer
1481,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Cancer
1499,INS,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Cancer
1500,INS,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Cancer
1504,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Cancer
1521,INS,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Cancer
2178,LIN28B,LIN28B,Paternal,rs17065417-<b>A</b>,1 x 10-8,,0.89,1.38,'-,[1.23-1.54],LIN28B,Neuroblastoma,neuroblastoma,GCST001660,6:104958399,Cancer
2179,LIN28B,LIN28B,Paternal,rs17065417-<b>C</b>,5 x 10-9,"(European American, conditioned on rs72990858)",0.9,1.4285715,'-,[1.25-1.67],LIN28B,Sporadic neuroblastoma,neuroblastoma,GCST004510,6:104958399,Cancer
2364,MIMT1,MIMT1,Paternal,rs7249211-<b>G</b>,6 x 10-6,(men),0.29,'-,0.104 kg/m2 increase,[0.059-0.149],"MIMT1, AC044792.1",Urate levels in lean individuals,"urate measurement, underweight body mass index status",GCST002830,19:56906546,Cancer
2365,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
2366,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
2533,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
2534,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
2674,SGCE,SGCE,Paternal,rs111307654-<b>GAAA</b>,1 x 10-12,(EA),0.7248,'-,0.0497 unit decrease,[0.036-0.063],SGCE,Breast cancer,breast carcinoma,GCST004988,7:94655778,Cancer
3059,WT1,WT1,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Cancer
3060,WT1,WT1,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Cancer
3075,WT1,WT1-AS,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Cancer
3076,WT1,WT1-AS,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Cancer
3089,WT1-AS,WT1-AS,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Cancer
3090,WT1-AS,WT1-AS,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Cancer
3094,WT1,WTAP,Paternal,rs11752345-<b>T</b>,1 x 10-7,,NR,1.0968521,'-,NR,"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST90011808,6:159727316,Cancer
3095,WT1,WTAP,Paternal,rs963800-<b>C</b>,3 x 10-16,,NR,1.064,'-,[1.05-1.08],"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST011049,6:159729247,Cancer
3096,WT1,WTAP,Paternal,rs963800-<b>C</b>,6 x 10-6,,0.599,1.087,'-,[1.05-1.13],"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST011046,6:159729247,Cancer
3205,ZFP90,ZFP90,Paternal,rs137866923-<b>?</b>,8 x 10-7,,'-,1.15,'-,[1.09-1.22],"RPL35AP33, ZFP90",Ovarian cancer (MTAG),ovarian carcinoma,GCST009829,16:68497433,Cancer
3206,ZFP90,ZFP90,Paternal,rs137866923-<b>?</b>,3 x 10-7,,'-,3.82,'-,[2.29-6.36],"RPL35AP33, ZFP90",Ovarian cancer,ovarian carcinoma,GCST009830,16:68497433,Cancer
3219,ZIM2,ZIM2,Paternal,rs7258285-<b>G</b>,3 x 10-6,,0.7,1.66,'-,[1.34-2.06],"AC006115.2, ZIM2-AS1",Prostate cancer,prostate carcinoma,GCST005786,19:56687205,Cancer
3220,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
3221,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Cancer
3234,ZIM2,ZIM2-AS1,Paternal,rs7258285-<b>G</b>,3 x 10-6,,0.7,1.66,'-,[1.34-2.06],"AC006115.2, ZIM2-AS1",Prostate cancer,prostate carcinoma,GCST005786,19:56687205,Cancer
3848,MIR371A,MIR371A,Paternal,rs4599029-<b>G</b>,1 x 10-8,,0.74,1.16,'-,[1.11–1.22],"SEPTIN7P8, MIR371A",Testicular germ cell tumor,Testicular Germ Cell Tumor,GCST004635,19:53781435,Cancer
134,DIO3,DIO3OS,Paternal,rs11626434-<b>G</b>,8 x 10-10,,0.6384,'-,0.1345 unit increase,[0.092-0.177],"AL049836.2, DIO3OS",Pulse pressure,pulse pressure measurement,GCST006626,14:101532106,Cardiovascular
142,DLGAP2,DLGAP2,Paternal,rs28680850-<b>A</b>,7 x 10-9,,NR,1.26,'-,[1.15–1.39],DLGAP2,Triglycerides,triglyceride measurement,GCST002468,8:1425554,Cardiovascular
143,DLGAP2,DLGAP2,Paternal,rs1451882-<b>?</b>,2 x 10-6,(AA),NR,14.73,'-,[12.97-16.49],DLGAP2,Peripheral arterial disease (traffic-related air pollution interaction),"peripheral arterial disease, traffic air pollution measurement",GCST004482,8:1133364,Cardiovascular
206,DLK1,DLK1,Paternal,rs59228823-<b>?</b>,5 x 10-8,,NR,'-,'-,'-,"DLK1, AL132711.1",Systolic blood pressure,systolic blood pressure,GCST007087,14:100718850,Cardiovascular
256,DLK1,DLK1,Paternal,rs2400940-<b>T</b>,4 x 10-8,(EA),NR,'-,2.5285 unit increase,NR,"MEG3, DLK1",Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension,"response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,14:100758585,Cardiovascular
282,DNMT1,DNMT1,Paternal,rs10409243-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,"S1PR2, DNMT1",Cardiovascular disease,cardiovascular disease,GCST007072,19:10222312,Cardiovascular
283,DNMT1,DNMT1,Paternal,rs10409243-<b>?</b>,1 x 10-17,,NR,'-,'-,'-,"S1PR2, DNMT1",Systolic blood pressure,systolic blood pressure,GCST007087,19:10222312,Cardiovascular
284,DNMT1,DNMT1,Paternal,rs2116941-<b>C</b>,3 x 10-8,,0.80902067,'-,0.2198 unit decrease,[0.14-0.3],"S1PR2, DNMT1",Pulse pressure,pulse pressure measurement,GCST004278,19:10223767,Cardiovascular
285,DNMT1,DNMT1,Paternal,rs2116942-<b>T</b>,7 x 10-10,,0.3977,'-,0.2156 mmHg increase,[0.15-0.28],"S1PR2, DNMT1",Systolic blood pressure,systolic blood pressure,GCST007267,19:10223987,Cardiovascular
315,DNMT1,DNMT1,Paternal,rs2116940-<b>G</b>,3 x 10-6,(AA-triglyceride response),0.19,'-,19.71 mg/dL decrease,[11.4-28.02],DNMT1,Thiazide-induced adverse metabolic effects in hypertensive patients,"response to hydrochlorothiazide, triglyceride measurement",GCST001859,19:10199716,Cardiovascular
327,DSCAM,DSCAM,Paternal,rs1882758-<b>C</b>,5 x 10-7,,0.3975,0.6509,'-,[0.5507-0.7694],DSCAM,Coronary artery disease in diabetes,"diabetes mellitus, coronary artery disease",GCST90014128,21:40238869,Cardiovascular
358,ERAP2,ERAP2,Paternal,rs1230361-<b>A</b>,9 x 10-6,,0.47,'-,2.1 percent increase,'-,"AC009126.1, ERAP2",Diastolic blood pressure night-to-day ratio in hypertension,"diastolic blood pressure change measurement, hypertension",GCST006273,5:96877467,Cardiovascular
478,GLI3,GLI3,Paternal,rs7791745-<b>T</b>,7 x 10-7,(drinks/week),0.8,'-,0.196 unit decrease,[0.12-0.27],"GLI3, LINC01448",Mean arterial pressure (alcohol consumption interaction),"mean arterial pressure, alcohol drinking",GCST002308,7:42345021,Cardiovascular
519,GLIS3,GLIS3,Paternal,rs28558845-<b>C</b>,1 x 10-10,,0.1551,'-,0.218 mmHg decrease,[0.15-0.28],GLIS3,Systolic blood pressure,systolic blood pressure,GCST006624,9:4334791,Cardiovascular
767,DIRAS3,GNG12-AS1,Paternal,rs112611436-<b>T</b>,2 x 10-6,,0.99,'-,12.42 ms increase,[7.3-17.54],"WLS, GNG12-AS1",QT interval,QT interval,GCST005171,1:68134564,Cardiovascular
768,DIRAS3,GNG12-AS1,Paternal,rs74081211-<b>?</b>,6 x 10-6,,NR,'-,'-,'-,"WLS, GNG12-AS1",Postoperative complication after cardiac surgery,"response to surgery, post-operative sign or symptom",GCST007981,1:68176557,Cardiovascular
781,GPR1,GPR1,Paternal,rs111520052-<b>G</b>,2 x 10-8,(men),0.988,'-,0.19 unit increase,[0.12-0.26],"ATP5POP1, GPR1-AS",TPE interval (resting),TPE interval measurement,GCST010346,2:206236506,Cardiovascular
786,GPR1,GPR1-AS,Paternal,rs111520052-<b>G</b>,2 x 10-8,(men),0.988,'-,0.19 unit increase,[0.12-0.26],"ATP5POP1, GPR1-AS",TPE interval (resting),TPE interval measurement,GCST010346,2:206236506,Cardiovascular
1246,IGF2,IGF2,Paternal,rs3741210-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"IGF2-AS, INS-IGF2",Systolic blood pressure,systolic blood pressure,GCST007087,11:2148310,Cardiovascular
1298,IGF2,IGF2,Paternal,rs117212336-<b>T</b>,2 x 10-7,,0.044348902,'-,0.707 unit increase,[0.44-0.97],"IGF2, H19",Systolic blood pressure,systolic blood pressure,GCST004279,11:2095084,Cardiovascular
1325,IGF2,IGF2-AS,Paternal,rs3741210-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"IGF2-AS, INS-IGF2",Systolic blood pressure,systolic blood pressure,GCST007087,11:2148310,Cardiovascular
1374,IGF2,INS-IGF2,Paternal,rs3741210-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"IGF2-AS, INS-IGF2",Systolic blood pressure,systolic blood pressure,GCST007087,11:2148310,Cardiovascular
1437,INS,INS,Paternal,rs3741210-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"IGF2-AS, INS-IGF2",Systolic blood pressure,systolic blood pressure,GCST007087,11:2148310,Cardiovascular
1505,INS,INS-IGF2,Paternal,rs3741210-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"IGF2-AS, INS-IGF2",Systolic blood pressure,systolic blood pressure,GCST007087,11:2148310,Cardiovascular
2589,RASGRF1,RASGRF1,Paternal,rs3743200-<b>A</b>,2 x 10-6,,0.27,'-,0.16 unit increase,[0.10-0.22],"AC011944.1, RASGRF1",RR interval (heart rate),RR interval,GCST000451,15:78981704,Cardiovascular
2590,RASGRF1,RASGRF1,Paternal,rs8030485-<b>A</b>,3 x 10-6,,0.6146,'-,0.0088 unit increase,[0.0051-0.0125],"RASGRF1, ANKRD34C-AS1",Left ventricle wall thickness,left ventricular structural measurement,GCST004646,15:79116590,Cardiovascular
2872,SNRPN,SNRPN,Paternal,rs34318108-<b>A</b>,5 x 10-6,,NR,'-,0.11261877 unit decrease,[0.064-0.161],"AC090983.2, SNRPN",Carotid plaque burden,carotid plaque build,GCST004162,15:24853480,Cardiovascular
2880,ST8SIA1,ST8SIA1,Paternal,rs11046430-<b>T</b>,4 x 10-6,(AA),0.12,'-,0.21 unit decrease,[0.13-0.29],"ST8SIA1, AC053513.1",Coronary artery calcification,coronary artery calcification,GCST002097,12:22413495,Cardiovascular
3031,WT1,WT1,Paternal,rs11031737-<b>G</b>,6 x 10-7,,0.5227,'-,0.331 ms increase,[0.2-0.46],"THEM7P, WT1",PR interval,PR interval,GCST010320,11:32351226,Cardiovascular
3032,WT1,WT1,Paternal,rs11031737-<b>G</b>,5 x 10-8,,0.52,'-,0.35 ms increase,[0.23-0.47],"THEM7P, WT1",PR interval,PR interval,GCST010321,11:32351226,Cardiovascular
3033,WT1,WT1,Paternal,rs4922591-<b>T</b>,1 x 10-12,,0.3867,'-,0.1513 unit decrease,[0.11-0.19],"THEM7P, WT1",Pulse pressure,pulse pressure measurement,GCST006626,11:32352653,Cardiovascular
3034,WT1,WT1,Paternal,rs7118294-<b>T</b>,3 x 10-13,(-26 ms),0.479124,'-,0.040106 unit decrease,[0.029-0.051],"THEM7P, WT1",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,11:32358975,Cardiovascular
3035,WT1,WT1,Paternal,rs7118294-<b>T</b>,2 x 10-9,(-30 ms),0.479124,'-,0.0331025 unit decrease,[0.022-0.044],"THEM7P, WT1",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,11:32358975,Cardiovascular
3036,WT1,WT1,Paternal,rs7118294-<b>T</b>,6 x 10-12,(-28 ms),0.479124,'-,0.0375267 unit decrease,[0.027-0.049],"THEM7P, WT1",Electrocardiogram morphology (amplitude at temporal datapoints),electrocardiography,GCST010796,11:32358975,Cardiovascular
3037,WT1,WT1,Paternal,rs7115190-<b>?</b>,2 x 10-9,,NR,'-,0.0315147 unit increase,[0.021-0.042],WT1,Coronary artery disease,coronary artery disease,GCST010866,11:32419831,Cardiovascular
3038,WT1,WT1,Paternal,rs5030179-<b>?</b>,6 x 10-9,,NR,'-,'-,'-,WT1,Systolic blood pressure,systolic blood pressure,GCST007087,11:32426709,Cardiovascular
3039,WT1,WT1,Paternal,rs3809060-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS,Cardiovascular disease,cardiovascular disease,GCST007072,11:32437261,Cardiovascular
3053,WT1,WT1,Paternal,rs12292135-<b>G</b>,2 x 10-9,,0.684313,'-,0.0126524 unit increase,[0.0085-0.0168],WT1-AS,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,11:32448758,Cardiovascular
3061,WT1,WT1,Paternal,rs7110547-<b>G</b>,5 x 10-10,,0.380033,'-,0.050580226 unit increase,[0.035-0.067],WT1,Medication use (diuretics),Diuretic use measurement,GCST007928,11:32425801,Cardiovascular
3066,WT1,WT1-AS,Paternal,rs3809060-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS,Cardiovascular disease,cardiovascular disease,GCST007072,11:32437261,Cardiovascular
3080,WT1-AS,WT1-AS,Paternal,rs3809060-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS,Cardiovascular disease,cardiovascular disease,GCST007072,11:32437261,Cardiovascular
3102,ZC3H12C,ZC3H12C,Paternal,rs746463-<b>?</b>,5 x 10-6,(P3MRSBP),NR,'-,'-,'-,"RDX, ZC3H12C",Exercise treadmill test traits,exercise test,GCST000089,11:110125219,Cardiovascular
3149,ZFAT,ZFAT,Paternal,rs7827545-<b>C</b> x rs1372662-<b>G</b>,2 x 10-44,,NR,'-,'-,'-,ZFAT x ZFAT,Hypertension (SNP x SNP interaction),hypertension,GCST001085,8:134554324|8:134554803,Cardiovascular
3150,ZFAT,ZFAT,Paternal,rs894344-<b>A</b>,3 x 10-8,,0.6,'-,0.258 unit decrease,[0.16-0.36],"ZFAT, ZFAT-AS1",Systolic blood pressure,systolic blood pressure,GCST004279,8:134600502,Cardiovascular
3151,ZFAT,ZFAT,Paternal,rs894348-<b>?</b>,1 x 10-13,,NR,'-,'-,'-,ZFAT,Systolic blood pressure,systolic blood pressure,GCST007087,8:134615506,Cardiovascular
3152,ZFAT,ZFAT,Paternal,rs1036821-<b>A</b>,4 x 10-9,,0.2954,'-,0.2143 mmHg increase,[0.14-0.29],ZFAT,Systolic blood pressure,systolic blood pressure,GCST007267,8:134638240,Cardiovascular
3153,ZFAT,ZFAT,Paternal,rs1036821-<b>A</b>,2 x 10-8,,0.2957,'-,0.1536 mmHg increase,[0.1-0.21],ZFAT,Pulse pressure,pulse pressure measurement,GCST007269,8:134638240,Cardiovascular
3185,ZFAT,ZFAT-AS1,Paternal,rs894344-<b>A</b>,3 x 10-8,,0.6,'-,0.258 unit decrease,[0.16-0.36],"ZFAT, ZFAT-AS1",Systolic blood pressure,systolic blood pressure,GCST004279,8:134600502,Cardiovascular
3825,ZFAT-AS1,ZFAT-AS1,Paternal,rs894344-<b>A</b>,3 x 10-8,,0.6,'-,0.258 unit decrease,[0.16-0.36],"ZFAT, ZFAT-AS1",Systolic blood pressure,systolic blood pressure,GCST004279,8:134600502,Cardiovascular
1913,KCNQ1OT1,KCNQ1OT1,Paternal,rs78695585-<b>A</b>,3 x 10-9,,0.04,'-,3.48 ms increase,[2.32-4.64],"KCNQ1, KCNQ1OT1",QT interval,QT interval,GCST005171,11:2623314,Cardiovascular
1914,KCNQ1OT1,KCNQ1OT1,Paternal,rs80127491-<b>?</b>,5 x 10-8,,NR,'-,'-,'-,"KCNQ1OT1, KCNQ1",Electrocardiographic traits (multivariate),electrocardiography,GCST011010,11:2624564,Cardiovascular
1915,KCNQ1OT1,KCNQ1OT1,Paternal,rs10832417-<b>T</b>,4 x 10-7,"(MAP, response to intervention)",0.31,'-,1.05 mmHg decrease,[0.64-1.46],"KCNQ1OT1, KCNQ1",Blood pressure measurement (high sodium intervention),"mean arterial pressure, response to high sodium diet",GCST002249,11:2631427,Cardiovascular
1916,KCNQ1OT1,KCNQ1OT1,Paternal,rs10832417-<b>T</b>,1 x 10-6,"(SBP, response to intervention)",0.31,'-,1.3 mmHg decrease,[0.77-1.83],"KCNQ1OT1, KCNQ1",Blood pressure measurement (high sodium intervention),"systolic blood pressure, response to high sodium diet",GCST002249,11:2631427,Cardiovascular
1917,KCNQ1OT1,KCNQ1OT1,Paternal,rs874031-<b>?</b>,6 x 10-9,,NR,'-,5.612 unit increase,[3.72-7.5],"KCNQ1OT1, KCNQ1",QT interval,QT interval,GCST008043,11:2691336,Cardiovascular
1918,KCNQ1OT1,KCNQ1OT1,Paternal,rs874031-<b>?</b>,4 x 10-9,(Hispanic/Latino),NR,'-,5.710829 unit increase,[3.81-7.61],"KCNQ1OT1, KCNQ1",QT interval,QT interval,GCST008043,11:2691336,Cardiovascular
520,GLIS3,GLIS3,Paternal,rs476155-<b>C</b>,7 x 10-6,,NR,1.0638298,'-,[0.88-1.28],GLIS3,Low high density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST003391,9:3940759,Cholesterol
2379,NDN,NDN,Paternal,rs1818917-<b>C</b>,2 x 10-9,,0.487558,'-,0.0114094 unit decrease,[0.0077-0.0152],"AC087490.1, NDN",HDL cholesterol levels,high density lipoprotein cholesterol measurement,GCST010242,15:23696531,Cholesterol
3103,ZC3H12C,ZC3H12C,Paternal,rs661171-<b>?</b>,3 x 10-8,,NR,'-,'-,'-,"ZC3H12C, RDX",Lipid traits (pleiotropy) (HIPO component 1),"total cholesterol measurement, triglyceride measurement, low density lipoprotein cholesterol measurement, high density lipoprotein cholesterol measurement",GCST006666,11:110145794,Cholesterol
3104,ZC3H12C,ZC3H12C,Paternal,rs10789752-<b>T</b>,3 x 10-9,,NR,'-,0.018 unit increase,'-,"RDX, ZC3H12C",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST007132,11:110109220,Cholesterol
3105,ZC3H12C,ZC3H12C,Paternal,rs746463-<b>T</b>,2 x 10-13,,NR,'-,0.015222964 unit decrease,[0.011-0.019],"RDX, ZC3H12C",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST009151,11:110125219,Cholesterol
3106,ZC3H12C,ZC3H12C,Paternal,rs746463-<b>T</b>,2 x 10-8,,0.68,'-,0.018 unit decrease,'-,"RDX, ZC3H12C",High density lipoprotein cholesterol levels,high density lipoprotein cholesterol measurement,GCST009148,11:110125219,Cholesterol
3107,ZC3H12C,ZC3H12C,Paternal,rs689183-<b>T</b>,4 x 10-9,,0.7461,'-,0.0182 mg dl-1 decrease,[0.012-0.024],"ZC3H12C, RDX",HDL cholesterol,high density lipoprotein cholesterol measurement,GCST006611,11:110141418,Cholesterol
3834,FAM50B,FAM50B,Paternal,rs146807753-<b>?</b>,7 x 10-7,(AA),NR,'-,0.06 unit increase,'-,"TDGF1P4, FAM50B",Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,"response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:3904005,Cholesterol
325,DSCAM,DSCAM,Paternal,rs62225548-<b>?</b>,6 x 10-7,,'-,'-,3.693 unit decrease,[2.32-5.07],DSCAM,"Dental caries (decayed, missing and filled teeth)",dental caries,GCST009267,21:40530804,Dental
2384,NPAP1,NPAP1,Paternal,rs12902137-<b>T</b>,6 x 10-6,(Age 20-60 years),0.72,'-,0.1809 unit decrease,[0.10-0.26],"PWRN1, AC090983.2, NPAP1",Periodontitis (DPAL),periodontitis,GCST002129,15:24679516,Dental
2873,SNRPN,SNRPN,Paternal,rs904310-<b>?</b>,4 x 10-8,,NR,'-,0.39 unit increase,[0.25-0.53],"AC090983.2, SNRPN",Periodontal disease related phenotype (PCT5),periodontal measurement,GCST008442,15:24857294,Dental
260,DLK1,DLK1,Paternal,rs200197449-<b>?</b>,2 x 10-6,"(AA, adjusted for duration of diabetes and glycemic control)",NR,1.44,'-,[NR],"AL132711.1, DLK1",Proliferative diabetic retinopathy (vs no DR),proliferative diabetic retinopathy,GCST007291,14:100689809,Diabetes
328,DSCAM,DSCAM,Paternal,rs455489-<b>C</b>,3 x 10-9,,0.023266667,'-,6.7566 unit increase,[4.53-8.99],DSCAM,Fasting plasma glucose,fasting blood glucose measurement,GCST008144,21:40567642,Diabetes
327,DSCAM,DSCAM,Paternal,rs1882758-<b>C</b>,5 x 10-7,,0.3975,0.6509,'-,[0.5507-0.7694],DSCAM,Coronary artery disease in diabetes,"diabetes mellitus, coronary artery disease",GCST90014128,21:40238869,Diabetes
417,GDAP1L1,GDAP1L1,Paternal,rs76811102-<b>T</b>,1 x 10-7,,0.0424,1.09,'-,[1.06-1.13],GDAP1L1,Type 2 diabetes,type II diabetes mellitus,GCST009379,20:44276775,Diabetes
517,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,7 x 10-7,,0.4938,'-,0.0008 unit increase,[-0.0005-0.0021],GLIS3,Fasting blood glucose (BMI interaction),"body mass index, fasting blood glucose measurement",GCST001527,9:4289050,Diabetes
534,GLIS3,GLIS3,Paternal,rs510807-<b>A</b>,1 x 10-6,,0.4906,1.03,'-,[1.02-1.04],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST009379,9:3965689,Diabetes
535,GLIS3,GLIS3,Paternal,rs79103584-<b>T</b>,4 x 10-6,,0.9862,1.14,'-,[1.08-1.21],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST009379,9:4243045,Diabetes
536,GLIS3,GLIS3,Paternal,rs34494309-<b>A</b>,1 x 10-15,,0.420826065,1.0707946,'-,[1.053007719-1.088881797],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST90013693,9:4284962,Diabetes
537,GLIS3,GLIS3,Paternal,rs57884925-<b>?</b>,2 x 10-8,,NR,'-,0.02688 unit increase,[0.018-0.036],GLIS3,Blood sugar levels,glucose measurement,GCST006002,9:4285119,Diabetes
538,GLIS3,GLIS3,Paternal,rs3934283-<b>G</b>,1 x 10-9,,0.46,'-,0.061 unit increase,[0.041-0.081],GLIS3,Fasting blood glucose,fasting blood glucose measurement,GCST011587,9:4285119,Diabetes
539,GLIS3,GLIS3,Paternal,rs7041847-<b>A</b>,5 x 10-6,,0.5,1.05,'-,[1.01-1.09],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST002352,9:4287466,Diabetes
540,GLIS3,GLIS3,Paternal,rs7041847-<b>G</b>,3 x 10-8,,0.4672,'-,0.043 unit decrease,[0.027-0.059],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST004894,9:4287466,Diabetes
541,GLIS3,GLIS3,Paternal,rs7041847-<b>A</b>,2 x 10-14,,0.41,1.1,'-,[1.07–1.13],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST001351,9:4287466,Diabetes
542,GLIS3,GLIS3,Paternal,rs7034200-<b>C</b>,3 x 10-12,,0.5866,'-,0.0608 unit decrease,[0.044-0.078],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST010553,9:4289050,Diabetes
543,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,1 x 10-12,,0.49,'-,0.018 mmol/L increase,[0.012-0.024],GLIS3,Fasting blood glucose,fasting blood glucose measurement,GCST000568,9:4289050,Diabetes
544,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,1 x 10-13,,0.49,'-,0.02 unit decrease,[0.012-0.028],GLIS3,Homeostasis model assessment of beta-cell function,HOMA-B,GCST005180,9:4289050,Diabetes
545,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,2 x 10-6,,0.4942,'-,0.0148 unit increase,[0.0087-0.0209],GLIS3,Fasting blood glucose,fasting blood glucose measurement,GCST005186,9:4289050,Diabetes
546,GLIS3,GLIS3,Paternal,rs7034200-<b>A</b>,8 x 10-12,,0.41,1.06,'-,1.04-1.08,GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST007847,9:4289050,Diabetes
547,GLIS3,GLIS3,Paternal,rs7034200-<b>C</b>,3 x 10-8,,0.496543973,'-,0.017206302 unit decrease,[0.011-0.023],GLIS3,Fasting blood glucose,fasting blood glucose measurement,GCST007899,9:4289050,Diabetes
548,GLIS3,GLIS3,Paternal,rs4237150-<b>C</b>,4 x 10-27,,0.426,1.07,'-,[1.06-1.09],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST010118,9:4290085,Diabetes
549,GLIS3,GLIS3,Paternal,rs4237150-<b>G</b>,7 x 10-31,,0.5708,'-,0.0433 unit decrease,[0.036-0.051],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST010557,9:4290085,Diabetes
550,GLIS3,GLIS3,Paternal,rs4237150-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,GLIS3,Circulating leptin levels or type 2 diabetes,"leptin measurement, type II diabetes mellitus",GCST010272,9:4290085,Diabetes
551,GLIS3,GLIS3,Paternal,rs4237150-<b>?</b>,4 x 10-9,,NR,'-,0.053 unit increase,[0.035-0.071],GLIS3,Fasting plasma glucose,fasting blood glucose measurement,GCST002586,9:4290085,Diabetes
552,GLIS3,GLIS3,Paternal,rs10974438-<b>C</b>,2 x 10-14,,0.3567,1.05,'-,[1.04-1.07],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST009379,9:4291928,Diabetes
553,GLIS3,GLIS3,Paternal,rs10974438-<b>C</b>,9 x 10-23,,0.3556,'-,0.047 unit increase,[0.038-0.056],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST010555,9:4291928,Diabetes
554,GLIS3,GLIS3,Paternal,rs10974438-<b>C</b>,3 x 10-15,,0.351215241,'-,0.0591 unit increase,[0.044-0.074],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST006867,9:4291928,Diabetes
555,GLIS3,GLIS3,Paternal,rs10974438-<b>?</b>,5 x 10-9,,NR,'-,'-,'-,GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST007077,9:4291928,Diabetes
556,GLIS3,GLIS3,Paternal,rs10758593-<b>A</b>,6 x 10-7,(men),NR,1.08,'-,[1.05-1.11],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST005047,9:4292083,Diabetes
557,GLIS3,GLIS3,Paternal,rs10758593-<b>A</b>,3 x 10-7,,0.424978206,1.06,'-,[1.04-1.09],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST005047,9:4292083,Diabetes
558,GLIS3,GLIS3,Paternal,rs10814916-<b>C</b>,6 x 10-12,,0.439,1.11,'-,[1.08-1.15],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST001666,9:4293150,Diabetes
559,GLIS3,GLIS3,Paternal,rs4258054-<b>T</b>,6 x 10-8,(Japanese),NR,1.10466,'-,[1.06565-1.1451],GLIS3,Type 2 diabetes,type II diabetes mellitus,GCST003400,9:4297892,Diabetes
598,GLIS3,GLIS3,Paternal,rs6476839-<b>T</b>,1 x 10-9,,0.4,1.12,'-,'-,GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST005536,9:4290823,Diabetes
599,GLIS3,GLIS3,Paternal,rs7020673-<b>?</b>,5 x 10-12,,0.5,1.14,'-,[1.08-1.20],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST000392,9:4291747,Diabetes
600,GLIS3,GLIS3,Paternal,rs10974438-<b>C</b>,1 x 10-6,,'-,'-,0.12805976 unit increase,[0.076-0.18],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST90000529,9:4291928,Diabetes
601,GLIS3,GLIS3,Paternal,rs10758593-<b>A</b>,3 x 10-6,,NR,1.13,'-,[1.07-1.19],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST000244,9:4292083,Diabetes
631,GLIS3,GLIS3,Paternal,rs1017568-<b>?</b>,3 x 10-7,(AA),NR,'-,0.265 unit increase,'-,GLIS3,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,"triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,9:3948365,Diabetes
880,HECW1,HECW1,Paternal,rs10231619-<b>T</b>,4 x 10-6,(AA),0.74,1.13,'-,[1.07-1.18],HECW1,Type 2 diabetes,type II diabetes mellitus,GCST002560,7:43280995,Diabetes
1238,IGF2,IGF2,Paternal,rs149483638-<b>C</b>,6 x 10-14,,0.86,1.28,'-,[1.20-1.37],"IGF2, INS-IGF2",Type 2 diabetes,type II diabetes mellitus,GCST006145,11:2140300,Diabetes
1241,IGF2,IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Diabetes
1245,IGF2,IGF2,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Diabetes
1267,IGF2,IGF2,Paternal,rs78896587-<b>T</b>,1 x 10-9,,'-,'-,0.20937194 unit decrease,[0.14-0.28],"IGF2, H19",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2055620,Diabetes
1276,IGF2,IGF2,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Diabetes
1277,IGF2,IGF2,Paternal,rs555759341-<b>C</b>,4 x 10-8,,0.0049,1.38,'-,[1.23-1.55],IGF2,Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2130531,Diabetes
1281,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-18,,NR,'-,0.0262 unit increase,[0.02-0.032],"INS-IGF2, INS",Blood glucose levels,glucose measurement,GCST90019508,11:2159843,Diabetes
1286,IGF2,IGF2,Paternal,rs3842753-<b>T</b>,3 x 10-9,,0.2806,'-,0.0134 unit increase,[0.0091-0.0177],"INS-IGF2, INS",Fasting glucose,glucose measurement,GCST90002232,11:2159830,Diabetes
1294,IGF2,IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Diabetes
1297,IGF2,IGF2,Paternal,rs11042596-<b>G</b>,2 x 10-8,,0.6649,1.04,'-,[1.03-1.05],"H19, IGF2",Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2097630,Diabetes
1302,IGF2,IGF2,Paternal,rs3842770-<b>A</b>,3 x 10-8,(AA),0.23,1.14,'-,[1.09-1.19],INS-IGF2,Type 2 diabetes,type II diabetes mellitus,GCST002560,11:2157440,Diabetes
1303,IGF2,IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Diabetes
1304,IGF2,IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Diabetes
1311,IGF2,IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Diabetes
1312,IGF2,IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Diabetes
1314,IGF2,IGF2,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Diabetes
1313,IGF2,IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Diabetes
1320,IGF2,IGF2-AS,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Diabetes
1324,IGF2,IGF2-AS,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Diabetes
1354,IGF2,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Diabetes
1356,IGF2,INS-IGF2,Paternal,rs149483638-<b>C</b>,6 x 10-14,,0.86,1.28,'-,[1.20-1.37],"IGF2, INS-IGF2",Type 2 diabetes,type II diabetes mellitus,GCST006145,11:2140300,Diabetes
1364,IGF2,INS-IGF2,Paternal,rs3842753-<b>T</b>,3 x 10-9,,0.2806,'-,0.0134 unit increase,[0.0091-0.0177],"INS-IGF2, INS",Fasting glucose,glucose measurement,GCST90002232,11:2159830,Diabetes
1365,IGF2,INS-IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Diabetes
1370,IGF2,INS-IGF2,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Diabetes
1377,IGF2,INS-IGF2,Paternal,rs3842770-<b>A</b>,3 x 10-8,(AA),0.23,1.14,'-,[1.09-1.19],INS-IGF2,Type 2 diabetes,type II diabetes mellitus,GCST002560,11:2157440,Diabetes
1378,IGF2,INS-IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Diabetes
1379,IGF2,INS-IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Diabetes
1382,IGF2,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Diabetes
1386,IGF2,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Diabetes
1387,IGF2,INS-IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Diabetes
1388,IGF2,INS-IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Diabetes
1389,IGF2,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Diabetes
1391,INS,INS,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Diabetes
1392,INS,INS,Paternal,rs3842752-<b>A</b>,2 x 10-18,,NR,'-,0.0262 unit increase,[0.02-0.032],"INS-IGF2, INS",Blood glucose levels,glucose measurement,GCST90019508,11:2159843,Diabetes
1397,INS,INS,Paternal,rs3842753-<b>T</b>,3 x 10-9,,0.2806,'-,0.0134 unit increase,[0.0091-0.0177],"INS-IGF2, INS",Fasting glucose,glucose measurement,GCST90002232,11:2159830,Diabetes
1404,INS,INS,Paternal,rs571342427-<b>C</b>,1 x 10-6,,0.0015,1.68,'-,[1.36-2.07],"INS, TH",Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2161289,Diabetes
1429,INS,INS,Paternal,rs149483638-<b>C</b>,6 x 10-14,,0.86,1.28,'-,[1.20-1.37],"IGF2, INS-IGF2",Type 2 diabetes,type II diabetes mellitus,GCST006145,11:2140300,Diabetes
1432,INS,INS,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Diabetes
1436,INS,INS,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Diabetes
1438,INS,INS,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Diabetes
1439,INS,INS,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Diabetes
1440,INS,INS,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Diabetes
1441,INS,INS,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Diabetes
1443,INS,INS,Paternal,rs3842727-<b>A</b>,3 x 10-7,,0.716,1.9841269,'-,'-,"TH, INS",Type 1 diabetes in high risk HLA genotype individuals (time to event),"disease free survival, type I diabetes mellitus, carrier status",GCST006196,11:2163618,Diabetes
1444,INS,INS,Paternal,rs3842727-<b>A</b>,1 x 10-7,(multiple-IA),0.716,1.6638935,'-,'-,"TH, INS",Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),"event free survival time, type I diabetes mellitus, carrier status, autoantibody measurement",GCST006197,11:2163618,Diabetes
1445,INS,INS,Paternal,rs3842727-<b>A</b>,6 x 10-6,(IAA-first),0.716,1.7513134,'-,'-,"TH, INS",Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),"event free survival time, type I diabetes mellitus, carrier status, autoantibody measurement",GCST006197,11:2163618,Diabetes
1448,INS,INS,Paternal,rs3842770-<b>A</b>,3 x 10-8,(AA),0.23,1.14,'-,[1.09-1.19],INS-IGF2,Type 2 diabetes,type II diabetes mellitus,GCST002560,11:2157440,Diabetes
1449,INS,INS,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Diabetes
1450,INS,INS,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Diabetes
1452,INS,INS,Paternal,rs3842727-<b>T</b>,1 x 10-13,,0.26,1.53,'-,[1.37–1.72],"TH, INS",Type 1 diabetes,type I diabetes mellitus,GCST009916,11:2163618,Diabetes
1458,INS,INS,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Diabetes
1485,INS,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Diabetes
1487,INS,INS-IGF2,Paternal,rs149483638-<b>C</b>,6 x 10-14,,0.86,1.28,'-,[1.20-1.37],"IGF2, INS-IGF2",Type 2 diabetes,type II diabetes mellitus,GCST006145,11:2140300,Diabetes
1489,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-18,,NR,'-,0.0262 unit increase,[0.02-0.032],"INS-IGF2, INS",Blood glucose levels,glucose measurement,GCST90019508,11:2159843,Diabetes
1495,INS,INS-IGF2,Paternal,rs3842753-<b>T</b>,3 x 10-9,,0.2806,'-,0.0134 unit increase,[0.0091-0.0177],"INS-IGF2, INS",Fasting glucose,glucose measurement,GCST90002232,11:2159830,Diabetes
1496,INS,INS-IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Diabetes
1501,INS,INS-IGF2,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Diabetes
1508,INS,INS-IGF2,Paternal,rs3842770-<b>A</b>,3 x 10-8,(AA),0.23,1.14,'-,[1.09-1.19],INS-IGF2,Type 2 diabetes,type II diabetes mellitus,GCST002560,11:2157440,Diabetes
1509,INS,INS-IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Diabetes
1510,INS,INS-IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Diabetes
1513,INS,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Diabetes
1517,INS,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Diabetes
1518,INS,INS-IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Diabetes
1520,INS,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Diabetes
1519,INS,INS-IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Diabetes
2543,PLAGL1,PLAGL1,Paternal,rs77691416-<b>A</b>,8 x 10-17,,0.91,'-,0.1151 unit increase,'-,PLAGL1,Resistin levels,resistin measurement,GCST90012034,6:144032982,Diabetes
2544,PLAGL1,PLAGL1,Paternal,rs73008259-<b>A</b>,1 x 10-35,,0.053,'-,0.2214 unit increase,'-,"SF3B5, PLAGL1",Resistin levels,resistin measurement,GCST90012034,6:144090201,Diabetes
2591,RASGRF1,RASGRF1,Paternal,rs28582793-<b>A</b>,6 x 10-7,,NR,'-,4.977 z score decrease,NR,RASGRF1,Pancreatic beta-cell glucose sensitivity,diabetes mellitus biomarker,GCST011569,15:78968601,Diabetes
3048,WT1,WT1,Paternal,rs7943101-<b>T</b>,9 x 10-6,,0.1614,1.04,'-,[1.02-1.06],WT1-AS,Type 2 diabetes,type II diabetes mellitus,GCST009379,11:32439327,Diabetes
3071,WT1,WT1-AS,Paternal,rs7943101-<b>T</b>,9 x 10-6,,0.1614,1.04,'-,[1.02-1.06],WT1-AS,Type 2 diabetes,type II diabetes mellitus,GCST009379,11:32439327,Diabetes
3085,WT1-AS,WT1-AS,Paternal,rs7943101-<b>T</b>,9 x 10-6,,0.1614,1.04,'-,[1.02-1.06],WT1-AS,Type 2 diabetes,type II diabetes mellitus,GCST009379,11:32439327,Diabetes
3834,FAM50B,FAM50B,Paternal,rs146807753-<b>?</b>,7 x 10-7,(AA),NR,'-,0.06 unit increase,'-,"TDGF1P4, FAM50B",Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,"response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:3904005,Diabetes
3849,MIR296,MIR296,Paternal,rs911300-<b>G</b>,5 x 10-14,,0.5422,'-,0.0348 unit increase,[0.026-0.044],"PIEZO1P2, MIR296",Type 2 diabetes,type II diabetes mellitus,GCST010555,20:58812207,Diabetes
1919,KCNQ1OT1,KCNQ1OT1,Paternal,rs80102379-<b>G</b>,9 x 10-8,,0.9822,1.15,'-,[1.09-1.21],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2612947,Diabetes
1920,KCNQ1OT1,KCNQ1OT1,Paternal,rs2106463-<b>A</b>,3 x 10-24,,NR,0.8716614,'-,[0.848891758178977-0.895041827744204],"KCNQ1OT1, KCNQ1",Type 2 diabetes,type II diabetes mellitus,GCST90013693,11:2618062,Diabetes
1921,KCNQ1OT1,KCNQ1OT1,Paternal,rs77402029-<b>G</b>,3 x 10-24,,0.9,1.17,'-,1.13-1.20,"KCNQ1OT1, KCNQ1",Type 2 diabetes,type II diabetes mellitus,GCST007847,11:2619190,Diabetes
1922,KCNQ1OT1,KCNQ1OT1,Paternal,rs117601636-<b>A</b>,1 x 10-7,(Japanese),NR,1.15959,'-,[1.09783-1.22483],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST003400,11:2620807,Diabetes
1923,KCNQ1OT1,KCNQ1OT1,Paternal,rs231349-<b>T</b>,2 x 10-11,,0.1024,1.07,'-,[1.05-1.10],"KCNQ1OT1, KCNQ1",Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2651591,Diabetes
1924,KCNQ1OT1,KCNQ1OT1,Paternal,rs231362-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST007077,11:2670241,Diabetes
1925,KCNQ1OT1,KCNQ1OT1,Paternal,rs231362-<b>G</b>,3 x 10-13,,'-,1.08,'-,[1.06-1.10],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST000712,11:2670241,Diabetes
1926,KCNQ1OT1,KCNQ1OT1,Paternal,rs231362-<b>G</b>,2 x 10-11,,0.498,'-,0.064 unit increase,[0.044-0.084],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST004894,11:2670241,Diabetes
1927,KCNQ1OT1,KCNQ1OT1,Paternal,rs231362-<b>G</b>,4 x 10-9,(EA),0.498,'-,0.0679 unit increase,[0.045-0.09],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST004894,11:2670241,Diabetes
1928,KCNQ1OT1,KCNQ1OT1,Paternal,rs231361-<b>A</b>,5 x 10-25,,0.2564,1.08,'-,[1.07-1.10],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST009379,11:2670270,Diabetes
1929,KCNQ1OT1,KCNQ1OT1,Paternal,rs231361-<b>A</b>,1 x 10-9,,0.285885252,1.09,'-,[1.06-1.12],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST005047,11:2670270,Diabetes
1930,KCNQ1OT1,KCNQ1OT1,Paternal,rs231361-<b>G</b>,2 x 10-9,,0.656,'-,0.08 unit decrease,[0.055-0.105],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST010556,11:2670270,Diabetes
1931,KCNQ1OT1,KCNQ1OT1,Paternal,rs231356-<b>T</b>,4 x 10-8,,0.27,1.09,'-,[1.06-1.13],"KCNQ1, KCNQ1OT1",Type 2 diabetes,type II diabetes mellitus,GCST002560,11:2684113,Diabetes
1932,KCNQ1OT1,KCNQ1OT1,Paternal,rs463924-<b>T</b>,4 x 10-15,,NR,1.0952718,'-,[1.07072996268252-1.12037619350107],"KCNQ1OT1, KCNQ1",Type 2 diabetes,type II diabetes mellitus,GCST90013693,11:2696450,Diabetes
1943,KCNQ1OT1,KCNQ1OT1,Paternal,rs231361-<b>A</b>,4 x 10-8,,0.250479,'-,0.073669426 unit increase,[0.047-0.1],"KCNQ1, KCNQ1OT1",Medication use (drugs used in diabetes),Drugs used in diabetes use measurement,GCST007923,11:2670270,Diabetes
152,DLGAP2,DLGAP2,Paternal,rs28719689-<b>?</b>,4 x 10-6,,NR,1.584,'-,[NR],DLGAP2,Colonoscopy-negative controls vs population controls,colorectal health,GCST005147,8:1322504,Digestive System
326,DSCAM,DSCAM,Paternal,rs2837588-<b>C</b>,7 x 10-6,(female),0.26,'-,1.45 unit increase,[0.82-2.08],DSCAM,Gut microbiota relative abundance (Prevotella),gut microbiome measurement,GCST90006990,21:40376132,Digestive System
360,ERAP2,ERAP2,Paternal,rs2549794-<b>C</b>,1 x 10-10,,0.409,1.05,'-,[1.02-1.09],"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST000879,5:96908845,Digestive System
361,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,6 x 10-13,,0.411,1.068,'-,[1.037-1.099],"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST001725,5:96917099,Digestive System
362,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,4 x 10-16,(EA),0.4212,1.10802,'-,[1.08-1.13],"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST003044,5:96917099,Digestive System
363,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,5 x 10-15,(EA),0.4212,1.084916,'-,[1.06-1.11],"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST003043,5:96917099,Digestive System
364,ERAP2,ERAP2,Paternal,rs1363907-<b>?</b>,1 x 10-14,,'-,'-,'-,'-,"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST004132,5:96917099,Digestive System
365,ERAP2,ERAP2,Paternal,rs1363907-<b>?</b>,1 x 10-10,,'-,'-,'-,'-,"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST004131,5:96917099,Digestive System
366,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,4 x 10-6,(EA),0.4212,1.0618593,'-,[1.04-1.09],"ERAP2, AC009126.1",Ulcerative colitis,ulcerative colitis,GCST003045,5:96917099,Digestive System
374,ERAP2,ERAP2,Paternal,rs2910686-<b>?</b>,2 x 10-21,(subset analysis),NR,'-,'-,'-,"AC009126.1, ERAP2","Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:96916885,Digestive System
492,GLI3,GLI3,Paternal,rs2299148-<b>?</b>,7 x 10-6,(genus_Desulfovibrio),NR,'-,0.5819566 unit decrease,[0.28-0.88],GLI3,Gut microbiome composition (summer),seasonal gut microbiome measurement,GCST003221,7:41983801,Digestive System
493,GLI3,GLI3,Paternal,rs6463094-<b>?</b>,4 x 10-6,(genus_Desulfovibrio),NR,'-,0.4885327 unit decrease,[0.24-0.74],"LINC01448, GLI3",Gut microbiome composition (summer),seasonal gut microbiome measurement,GCST003221,7:42241882,Digestive System
494,GLI3,GLI3,Paternal,rs2108370-<b>?</b>,2 x 10-6,(genus_Anaerotruncus),NR,'-,0.9657791 unit decrease,[0.54-1.39],"GLI3, LINC01448",Gut microbiome composition (summer),seasonal gut microbiome measurement,GCST003221,7:42334803,Digestive System
533,GLIS3,GLIS3,Paternal,rs10814901-<b>?</b>,3 x 10-6,,NR,'-,0.0505 unit decrease,[0.029-0.072],GLIS3,Tonsillectomy,tonsillectomy risk measurement,GCST005014,9:4257627,Digestive System
622,GLIS3,GLIS3,Paternal,rs954980-<b>?</b>,5 x 10-6,,'-,1.3933399,'-,[NR],"GLIS3, RFX3-AS1",Colorectal cancer,colorectal cancer,GCST005152,9:3761909,Digestive System
878,HECW1,HECW1,Paternal,rs17172185-<b>T</b>,5 x 10-6,,0.946,1.4706,'-,[1.25-1.75],"AC004692.2, HECW1",Esophageal adenocarcinoma,esophageal adenocarcinoma,GCST002232,7:43247240,Digestive System
879,HECW1,HECW1,Paternal,rs61756577-<b>C</b>,1 x 10-6,,0.0064,1.74,'-,[1.40-2.18],HECW1,Diverticular disease,diverticular disease,GCST008257,7:43492135,Digestive System
3047,WT1,WT1,Paternal,rs3809060-<b>G</b>,4 x 10-14,,0.63,1.11,'-,[1.08-1.14],WT1-AS,Inguinal hernia,Inguinal hernia,GCST003198,11:32437261,Digestive System
3063,WT1,WT1,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Digestive System
3070,WT1,WT1-AS,Paternal,rs3809060-<b>G</b>,4 x 10-14,,0.63,1.11,'-,[1.08-1.14],WT1-AS,Inguinal hernia,Inguinal hernia,GCST003198,11:32437261,Digestive System
3078,WT1,WT1-AS,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Digestive System
3084,WT1-AS,WT1-AS,Paternal,rs3809060-<b>G</b>,4 x 10-14,,0.63,1.11,'-,[1.08-1.14],WT1-AS,Inguinal hernia,Inguinal hernia,GCST003198,11:32437261,Digestive System
3092,WT1-AS,WT1-AS,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Digestive System
3159,ZFAT,ZFAT,Paternal,rs7463659-<b>?</b>,7 x 10-6,,NR,1.344086,'-,[NR],"AC105180.2, ZFAT",Colonoscopy-negative controls vs population controls,colorectal health,GCST005147,8:134419897,Digestive System
3187,ZFP90,ZFP90,Paternal,rs12149608-<b>?</b>,2 x 10-8,(EA),NR,'-,'-,'-,ZFP90,Ulcerative colitis,ulcerative colitis,GCST003045,16:68552601,Digestive System
3188,ZFP90,ZFP90,Paternal,rs1728785-<b>?</b>,4 x 10-8,,'-,'-,'-,'-,ZFP90,Ulcerative colitis,ulcerative colitis,GCST004133,16:68557327,Digestive System
3189,ZFP90,ZFP90,Paternal,rs1728785-<b>C</b>,4 x 10-8,,0.767,1.075,'-,[1.031-1.121],ZFP90,Ulcerative colitis,ulcerative colitis,GCST001728,16:68557327,Digestive System
3190,ZFP90,ZFP90,Paternal,rs1728785-<b>G</b>,3 x 10-8,,0.76,1.17,'-,[1.07-1.27],ZFP90,Ulcerative colitis,ulcerative colitis,GCST000527,16:68557327,Digestive System
3191,ZFP90,ZFP90,Paternal,rs1728785-<b>C</b>,5 x 10-6,(EA),0.78,1.0728852,'-,'-,ZFP90,Ulcerative colitis,ulcerative colitis,GCST003045,16:68557327,Digestive System
3833,SNORD116,SNORD116,Paternal,rs9548988-<b>T</b>,3 x 10-7,,0.46,1.1,'-,[1.03-1.19],SNORD116,Ulcerative colitis,ulcerative colitis,GCST000527,13:39931373,Digestive System
177,DLGAP2,DLGAP2,Paternal,rs17062789-<b>?</b>,3 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203198,Drug Response
178,DLGAP2,DLGAP2,Paternal,rs17062791-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431,Drug Response
179,DLGAP2,DLGAP2,Paternal,rs17062791-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431,Drug Response
180,DLGAP2,DLGAP2,Paternal,rs73670671-<b>?</b>,3 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203645,Drug Response
181,DLGAP2,DLGAP2,Paternal,rs34003842-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1206131,Drug Response
182,DLGAP2,DLGAP2,Paternal,rs80058639-<b>?</b>,9 x 10-6,(MLM),NR,'-,'-,'-,DLGAP2,Response to paliperidone in schizophrenia (Multivariate),"schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,8:1214070,Drug Response
183,DLGAP2,DLGAP2,Paternal,rs182302106-<b>G</b>,2 x 10-6,(AA),0.999,'-,0.45 unit increase,'-,DLGAP2,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507009,Drug Response
184,DLGAP2,DLGAP2,Paternal,rs192316701-<b>C</b>,5 x 10-6,(AA),0.997,'-,0.163 unit increase,'-,DLGAP2,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507902,Drug Response
185,DLGAP2,DLGAP2,Paternal,rs139288166-<b>?</b>,7 x 10-8,,0.03,4.3,'-,[2.53-7.31],DLGAP2,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),"Hematochezia, response to radiation, prostate carcinoma",GCST008381,8:755922,Drug Response
186,DLGAP2,DLGAP2,Paternal,rs17739794-<b>?</b>,6 x 10-6,(AUC),NR,'-,'-,'-,DLGAP2,Clozapine-induced cytotoxicity,"cytotoxicity measurement, response to clozapine",GCST002777,8:862946,Drug Response
255,DLK1,DLK1,Paternal,rs7149242-<b>T</b>,4 x 10-8,,0.281233,'-,0.03672875 unit decrease,[0.024-0.05],"DLK1, AL132711.1",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,14:100693079,Drug Response
256,DLK1,DLK1,Paternal,rs2400940-<b>T</b>,4 x 10-8,(EA),NR,'-,2.5285 unit increase,NR,"MEG3, DLK1",Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension,"response to diuretic, diastolic blood pressure change measurement, hypertension",GCST009646,14:100758585,Drug Response
315,DNMT1,DNMT1,Paternal,rs2116940-<b>G</b>,3 x 10-6,(AA-triglyceride response),0.19,'-,19.71 mg/dL decrease,[11.4-28.02],DNMT1,Thiazide-induced adverse metabolic effects in hypertensive patients,"response to hydrochlorothiazide, triglyceride measurement",GCST001859,19:10199716,Drug Response
420,GDAP1L1,GDAP1L1,Paternal,rs11907319-<b>T</b>,9 x 10-6,,0.8099,'-,14.3351 unit increase,[8.45-20.22],"GDAP1L1, FITM2",Response to ketamine in bipolar disorder or major depression (dissociation effects),"unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,20:44294659,Drug Response
503,GLI3,GLI3,Paternal,rs12532960-<b>?</b>,3 x 10-7,(hsCRP-IL6 pattern prefenofibrate),NR,'-,'-,'-,"LINC01448, GLI3",Inflammatory biomarkers,response to fenofibrate,GCST001371,7:42286026,Drug Response
629,GLIS3,GLIS3,Paternal,rs183726757-<b>T</b>,5 x 10-6,(AA),1,'-,2.616 unit increase,NR,"RFX3-AS1, GLIS3",Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,9:3795100,Drug Response
630,GLIS3,GLIS3,Paternal,rs717423-<b>?</b>,4 x 10-6,(Hispanic),'-,14.1,'-,[NR],GLIS3,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),"response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,9:3844061,Drug Response
631,GLIS3,GLIS3,Paternal,rs1017568-<b>?</b>,3 x 10-7,(AA),NR,'-,0.265 unit increase,'-,GLIS3,Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,"triglyceride change measurement, response to simvastatin, type II diabetes mellitus, response to fenofibrate",GCST004766,9:3948365,Drug Response
632,GLIS3,GLIS3,Paternal,rs564816-<b>C</b>,3 x 10-7,,0.04,'-,'-,[NR],GLIS3,Methotrexate phramacokinetics (acute lymphoblastic leukemia),response to antineoplastic agent,GCST000523,9:4015370,Drug Response
633,GLIS3,GLIS3,Paternal,rs10814834-<b>?</b>,7 x 10-6,"(endpoint 6, dominant)",'-,2.173913,'-,[NR],GLIS3,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,"response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:4086370,Drug Response
634,GLIS3,GLIS3,Paternal,rs10814853-<b>T</b>,3 x 10-8,,0.311041,'-,0.053840246 unit decrease,[0.035-0.073],GLIS3,"Medication use (adrenergics, inhalants)",Inhalant adrenergic use measurement,GCST007941,9:4144996,Drug Response
773,DIRAS3,GNG12-AS1,Paternal,rs1367448-<b>C</b>,5 x 10-6,(Dominant model),0.526,1.554,'-,[1.212-1.993],"GNG12-AS1, WLS",Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),"response to antineoplastic agent, response to anthracycline-based chemotherapy",GCST002008,1:68168241,Drug Response
774,DIRAS3,GNG12-AS1,Paternal,rs17130567-<b>G</b>,2 x 10-9,,0.254436,'-,0.10955559 unit decrease,[0.074-0.146],"WLS, GNG12-AS1",Medication use (drugs affecting bone structure and mineralization),Drugs affecting bone structure and mineralization use measurement,GCST007935,1:68198164,Drug Response
2561,PLAGL1,PLAGL1,Paternal,rs150612539-<b>C</b>,2 x 10-6,(AA),1,'-,0.441 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:143952786,Drug Response
2562,PLAGL1,PLAGL1,Paternal,rs150029151-<b>A</b>,2 x 10-6,(AA),1,'-,0.432 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:144025056,Drug Response
2563,PLAGL1,PLAGL1,Paternal,rs192748541-<b>A</b>,1 x 10-6,(AA),1,'-,0.434 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:144052556,Drug Response
2876,SNRPN,SNRPN,Paternal,rs12592731-<b>?</b>,8 x 10-6,(Hispanic),'-,'-,'-,'-,SNRPN,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,15:24925023,Drug Response
2882,ST8SIA1,ST8SIA1,Paternal,rs184061709-<b>G</b>,3 x 10-6,(AA),1,'-,0.38 unit increase,'-,ST8SIA1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,12:22309344,Drug Response
2883,ST8SIA1,ST8SIA1,Paternal,rs182272664-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.383 unit increase,'-,ST8SIA1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,12:22312006,Drug Response
3061,WT1,WT1,Paternal,rs7110547-<b>G</b>,5 x 10-10,,0.380033,'-,0.050580226 unit increase,[0.035-0.067],WT1,Medication use (diuretics),Diuretic use measurement,GCST007928,11:32425801,Drug Response
3062,WT1,WT1,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Drug Response
3063,WT1,WT1,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Drug Response
3064,WT1,WT1,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Drug Response
3077,WT1,WT1-AS,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Drug Response
3078,WT1,WT1-AS,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Drug Response
3079,WT1,WT1-AS,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Drug Response
3091,WT1-AS,WT1-AS,Paternal,rs10835916-<b>C</b>,1 x 10-8,,0.406175,'-,0.046684857 unit increase,[0.031-0.063],"EIF3M, WT1-AS",Medication use (calcium channel blockers),Calcium channel blocker use measurement,GCST007929,11:32461773,Drug Response
3092,WT1-AS,WT1-AS,Paternal,rs3858461-<b>C</b>,1 x 10-8,,0.448978,'-,0.044241406 unit decrease,[0.029-0.059],"EIF3M, WT1-AS",Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease),Peptic ulcer and gastro-oesophageal reflux disease (GORD) drug use measurement,GCST007922,11:32473416,Drug Response
3093,WT1-AS,WT1-AS,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Drug Response
3182,ZFAT,ZFAT,Paternal,rs17768250-<b>?</b>,7 x 10-7,,NR,2.3758,'-,NR,ZFAT,Response to SSRI (symptom remission),response to selective serotonin reuptake inhibitor,GCST007060,8:134558431,Drug Response
3183,ZFAT,ZFAT,Paternal,rs17768250-<b>?</b>,7 x 10-7,,NR,2.1933,'-,NR,ZFAT,Response to antidepressants (symptom remission),response to antidepressant,GCST007061,8:134558431,Drug Response
3207,ZFP90,ZFP90,Paternal,rs17689437-<b>?</b>,1 x 10-6,(risperidone),0.13,'-,'-,'-,ZFP90,Response to antipsychotic treatment in schizophrenia (reasoning),reasoning,GCST000885,16:68566448,Drug Response
3834,FAM50B,FAM50B,Paternal,rs146807753-<b>?</b>,7 x 10-7,(AA),NR,'-,0.06 unit increase,'-,"TDGF1P4, FAM50B",Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,"response to simvastatin, type II diabetes mellitus, total cholesterol change measurement, response to fenofibrate",GCST004765,6:3904005,Drug Response
3836,FAM50B,FAM50B,Paternal,rs187885921-<b>C</b>,4 x 10-6,(AA),0.999,'-,0.366 unit increase,'-,"TDGF1P4, FAM50B",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:3894081,Drug Response
3840,FAM50B,FAM50B,Paternal,rs187885921-<b>C</b>,5 x 10-6,(AA),0.999,'-,1.821 unit increase,NR,"TDGF1P4, FAM50B",Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,6:3894081,Drug Response
3843,FAM50B,FAM50B,Paternal,rs17318866-<b>G</b>,1 x 10-6,(Allelic model),0.79,7.559,'-,[2.689-21.263],"PXDC1, FAM50B",Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),"response to camptothecin, response to antineoplastic agent",GCST001993,6:3836964,Drug Response
3845,PXDC1,PXDC1,Paternal,rs17318866-<b>G</b>,1 x 10-6,(Allelic model),0.79,7.559,'-,[2.689-21.263],"PXDC1, FAM50B",Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin),"response to camptothecin, response to antineoplastic agent",GCST001993,6:3836964,Drug Response
1943,KCNQ1OT1,KCNQ1OT1,Paternal,rs231361-<b>A</b>,4 x 10-8,,0.250479,'-,0.073669426 unit increase,[0.047-0.1],"KCNQ1, KCNQ1OT1",Medication use (drugs used in diabetes),Drugs used in diabetes use measurement,GCST007923,11:2670270,Drug Response
131,DIO3,DIO3,Paternal,rs2895917-<b>T</b>,2 x 10-8,(MTAG),0.3432,'-,0.0106 unit increase,[0.0069-0.0143],"LINC02320, DIO3",Self-reported math ability (MTAG),mathematical ability,GCST006569,14:101586438,Educational and Intelligence
132,DIO3,DIO3,Paternal,rs6575858-<b>C</b>,3 x 10-9,(MTAG),0.611,'-,0.0101 unit decrease,[0.0068-0.0134],"DIO3, LINC02320",Highest math class taken (MTAG),mathematical ability,GCST006568,14:101624585,Educational and Intelligence
135,DIO3,DIO3OS,Paternal,rs10134381-<b>C</b>,2 x 10-9,(MTAG),0.1574,'-,0.0109 unit increase,[0.0074-0.0144],"AL049836.2, DIO3OS",Educational attainment (MTAG),self reported educational attainment,GCST006571,14:101529062,Educational and Intelligence
145,DLGAP2,DLGAP2,Paternal,rs73526541-<b>A</b>,3 x 10-6,,NR,'-,'-,'-,DLGAP2,Verbal memory performance (immediate recall change),memory performance,GCST004827,8:1124467,Educational and Intelligence
146,DLGAP2,DLGAP2,Paternal,rs75416360-<b>T</b>,5 x 10-8,(MTAG),0.0589,'-,0.0153 unit increase,[0.0098-0.0208],DLGAP2,Educational attainment (MTAG),self reported educational attainment,GCST006571,8:1207180,Educational and Intelligence
147,DLGAP2,DLGAP2,Paternal,rs34130287-<b>C</b>,4 x 10-6,,0.21,'-,0.25 z score decrease,[NR],DLGAP2,Residual cognition,"cognition, aging",GCST004291,8:1266767,Educational and Intelligence
148,DLGAP2,DLGAP2,Paternal,rs17747701-<b>?</b>,3 x 10-6,,NR,'-,4.705 z-score increase,'-,"AF067845.2, DLGAP2",General cognitive ability,intelligence,GCST006269,8:1300141,Educational and Intelligence
149,DLGAP2,DLGAP2,Paternal,rs12676895-<b>A</b>,2 x 10-8,(MTAG),0.7482,'-,0.0085 unit increase,[0.0056-0.0114],DLGAP2,Educational attainment (MTAG),self reported educational attainment,GCST006571,8:813540,Educational and Intelligence
150,DLGAP2,DLGAP2,Paternal,rs7002351-<b>A</b>,9 x 10-6,,NR,'-,0.02616 unit increase,[0.015-0.038],DLGAP2,Health literacy,health literacy measurement,GCST008513,8:871585,Educational and Intelligence
323,DSCAM,DSCAM,Paternal,rs9974899-<b>T</b>,1 x 10-8,,0.2538,'-,0.0093 unit decrease,[0.0062-0.0124],DSCAM,Educational attainment (years of education),self reported educational attainment,GCST006442,21:40634515,Educational and Intelligence
324,DSCAM,DSCAM,Paternal,rs4818184-<b>A</b>,7 x 10-6,(15-18 months),0.13,'-,0.1 unit decrease,[0.057-0.143],DSCAM,Expressive vocabulary in infants,infant expressive language ability,GCST002611,21:40830505,Educational and Intelligence
479,GLI3,GLI3,Paternal,rs7796103-<b>C</b>,4 x 10-8,,0.5168,'-,0.0077 unit decrease,[0.005-0.0104],"GLI3, INHBA-AS1",Educational attainment (years of education),self reported educational attainment,GCST006442,7:41780557,Educational and Intelligence
480,GLI3,GLI3,Paternal,rs2051935-<b>A</b>,2 x 10-8,(MTAG),0.3532,'-,0.0136 unit increase,[0.0089-0.0183],GLI3,Cognitive performance (MTAG),cognitive function measurement,GCST006570,7:41963902,Educational and Intelligence
481,GLI3,GLI3,Paternal,rs2051935-<b>A</b>,5 x 10-11,(MTAG),0.3579,'-,0.009 unit increase,[0.0063-0.0117],GLI3,Educational attainment (MTAG),self reported educational attainment,GCST006571,7:41963902,Educational and Intelligence
482,GLI3,GLI3,Paternal,rs2051935-<b>A</b>,6 x 10-13,(MTAG),0.3572,'-,0.0124 unit increase,[0.0091-0.0157],GLI3,Highest math class taken (MTAG),mathematical ability,GCST006568,7:41963902,Educational and Intelligence
483,GLI3,GLI3,Paternal,rs2051935-<b>A</b>,9 x 10-10,(MTAG),0.357,'-,0.0115 unit increase,[0.0078-0.0152],GLI3,Self-reported math ability (MTAG),mathematical ability,GCST006569,7:41963902,Educational and Intelligence
484,GLI3,GLI3,Paternal,rs4724083-<b>T</b>,4 x 10-8,,0.3227,'-,0.0083 unit increase,[0.0054-0.0112],GLI3,Educational attainment (years of education),self reported educational attainment,GCST006442,7:41967473,Educational and Intelligence
485,GLI3,GLI3,Paternal,rs146961637-<b>T</b>,6 x 10-6,,NR,'-,0.5761249 unit decrease,[0.32-0.83],GLI3,Emotional recognition,cognitive function measurement,GCST009308,7:42137274,Educational and Intelligence
486,GLI3,GLI3,Paternal,rs79099151-<b>T</b>,8 x 10-7,,NR,'-,0.02936 unit increase,[0.018-0.041],GLI3,Health literacy,health literacy measurement,GCST008513,7:42144484,Educational and Intelligence
487,GLI3,GLI3,Paternal,rs3801203-<b>A</b>,3 x 10-9,,0.19,'-,0.261 unit decrease,[0.17-0.35],GLI3,Language performance in older adults (adjusted for episodic memory),"cognitive decline measurement, memory performance, language measurement",GCST004372,7:42148801,Educational and Intelligence
488,GLI3,GLI3,Paternal,rs71538647-<b>C</b>,4 x 10-6,,NR,'-,0.0275 unit increase,[0.016-0.039],GLI3,Health literacy,health literacy measurement,GCST008513,7:42164686,Educational and Intelligence
523,GLIS3,GLIS3,Paternal,rs10974256-<b>A</b>,4 x 10-10,,0.3411,'-,0.0093 unit decrease,[0.0064-0.0122],GLIS3,Educational attainment (years of education),self reported educational attainment,GCST006442,9:3952892,Educational and Intelligence
524,GLIS3,GLIS3,Paternal,rs10974256-<b>A</b>,2 x 10-10,(MTAG),0.3411,'-,0.0088 unit decrease,[0.0061-0.0115],GLIS3,Educational attainment (MTAG),self reported educational attainment,GCST006571,9:3952892,Educational and Intelligence
525,GLIS3,GLIS3,Paternal,rs10974256-<b>A</b>,2 x 10-9,(MTAG),0.342,'-,0.0105 unit decrease,[0.0072-0.0138],GLIS3,Highest math class taken (MTAG),mathematical ability,GCST006568,9:3952892,Educational and Intelligence
526,GLIS3,GLIS3,Paternal,rs73643713-<b>T</b>,1 x 10-9,,0.928,'-,0.0165 unit decrease,[0.011-0.022],GLIS3,Educational attainment (years of education),self reported educational attainment,GCST006442,9:4163612,Educational and Intelligence
527,GLIS3,GLIS3,Paternal,rs73643713-<b>T</b>,3 x 10-9,(MTAG),0.928,'-,0.015 unit decrease,[0.01-0.02],GLIS3,Educational attainment (MTAG),self reported educational attainment,GCST006571,9:4163612,Educational and Intelligence
528,GLIS3,GLIS3,Paternal,rs10974399-<b>T</b>,4 x 10-8,(MTAG),0.4179,'-,0.0099 unit increase,[0.0064-0.0134],GLIS3,Self-reported math ability (MTAG),mathematical ability,GCST006569,9:4232588,Educational and Intelligence
529,GLIS3,GLIS3,Paternal,rs10974406-<b>T</b>,3 x 10-8,(MTAG),0.6759,'-,0.0098 unit decrease,[0.0063-0.0133],GLIS3,Highest math class taken (MTAG),mathematical ability,GCST006568,9:4237041,Educational and Intelligence
530,GLIS3,GLIS3,Paternal,rs10974483-<b>A</b>,4 x 10-8,(MTAG),0.5134,'-,0.0072 unit increase,[0.0047-0.0097],GLIS3,Educational attainment (MTAG),self reported educational attainment,GCST006571,9:4346226,Educational and Intelligence
769,DIRAS3,GNG12-AS1,Paternal,rs80032087-<b>?</b>,9 x 10-6,,NR,'-,0.219 unit increase,[0.12-0.32],GNG12-AS1,Cognitive performance (processing speed),information processing speed,GCST008891,1:68083270,Educational and Intelligence
1529,IRAIN,IRAIN,Paternal,rs7176647-<b>C</b>,3 x 10-8,(MTAG),0.402,'-,0.0075 unit increase,[0.005-0.01],"FAM169B, IRAIN",Educational attainment (MTAG),self reported educational attainment,GCST006571,15:98634366,Educational and Intelligence
2082,L3MBTL1,L3MBTL1,Paternal,rs6103366-<b>?</b>,5 x 10-6,,NR,'-,4.55 z-score decrease,'-,"L3MBTL1, AL031681.3",General cognitive ability,intelligence,GCST006269,20:43531517,Educational and Intelligence
2671,RTL1,RTL1,Paternal,rs2180386-<b>A</b>,7 x 10-6,,0.38,'-,0.21 unit decrease,[NR],"RTL1, MEG8, AL117190.1",Developmental language disorder (linguistic errors),"linguistic error measurement, specific language impairment",GCST003397,14:100898928,Educational and Intelligence
3155,ZFAT,ZFAT,Paternal,rs10448005-<b>T</b>,3 x 10-11,(MTAG),0.1228,'-,0.0133 unit decrease,[0.0094-0.0172],"AC105180.2, ZFAT",Educational attainment (MTAG),self reported educational attainment,GCST006571,8:134415514,Educational and Intelligence
3156,ZFAT,ZFAT,Paternal,rs74545339-<b>?</b>,6 x 10-6,,NR,'-,0.0077942 unit decrease,[0.0044-0.0112],"ZFAT, AC105180.2",Reaction time,reaction time measurement,GCST006268,8:134428365,Educational and Intelligence
3157,ZFAT,ZFAT,Paternal,rs74545339-<b>A</b>,9 x 10-13,,0.1142,'-,0.0158 unit decrease,[0.011-0.02],"ZFAT, AC105180.2",Educational attainment (years of education),self reported educational attainment,GCST006442,8:134428365,Educational and Intelligence
3158,ZFAT,ZFAT,Paternal,rs1550582-<b>A</b>,7 x 10-6,,0.262,'-,0.022 unit increase,[NR],ZFAT,Educational attainment,self reported educational attainment,GCST002598,8:134529841,Educational and Intelligence
489,GLI3,GLI3,Paternal,rs846274-<b>?</b>,4 x 10-8,"(Quadrant II (Nose), Segment 45)",NR,'-,0.023222925 unit decrease,NR,GLI3,Facial morphology traits (59 NSCL/P endophenotypic segments),facial morphology measurement,GCST011429,7:42022387,Facial Morphology
490,GLI3,GLI3,Paternal,rs17640804-<b>T</b>,5 x 10-10,(Nose wing breadth),NR,'-,0.00049 NR decrease,'-,GLI3,middle facial morphology traits (quantitative measurement),nose morphology measurement,GCST003635,7:42091791,Facial Morphology
491,GLI3,GLI3,Paternal,rs17640804-<b>?</b>,3 x 10-7,,'-,'-,'-,'-,GLI3,facial morphology traits (multivariate analysis),facial morphology measurement,GCST003637,7:42091791,Facial Morphology
531,GLIS3,GLIS3,Paternal,rs4237150-<b>?</b>,6 x 10-19,,NR,1.1376565,'-,[1.1-1.17],GLIS3,Chin dimples,chin morphology measurement,GCST003989,9:4290085,Facial Morphology
635,GLIS3,GLIS3,Paternal,rs35880221-<b>T</b>,8 x 10-11,,0.0868468,'-,0.0356656 unit decrease,[0.025-0.046],GLIS3,Male-pattern baldness,balding measurement,GCST007020,9:3906221,Facial Morphology
636,GLIS3,GLIS3,Paternal,rs539206-<b>A</b>,5 x 10-11,,0.202437,'-,0.0254168 unit increase,[0.018-0.033],GLIS3,Male-pattern baldness,balding measurement,GCST007020,9:4036719,Facial Morphology
637,GLIS3,GLIS3,Paternal,rs7020673-<b>C</b>,4 x 10-8,,0.499652,'-,0.0169148 unit increase,[0.011-0.023],GLIS3,Male-pattern baldness,balding measurement,GCST007020,9:4291747,Facial Morphology
638,GLIS3,GLIS3,Paternal,rs10814917-<b>?</b>,4 x 10-9,,NR,'-,'-,'-,GLIS3,Balding type 1,balding measurement,GCST007038,9:4296430,Facial Morphology
2532,WT1,PAWR,Paternal,rs80010377-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,PAWR,Hair color,hair colour measurement,GCST007082,12:79646354,Facial Morphology
133,DIO3,DIO3,Paternal,rs11621975-<b>?</b>,5 x 10-6,,NR,2.31,'-,'-,"DIO3, LINC02320",Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin,"overall survival, ovarian carcinoma, response to cisplatin, response to paclitaxel",GCST004896,14:101565415,Female Reproductive System
151,DLGAP2,DLGAP2,Paternal,rs17669535-<b>C</b>,6 x 10-7,(AA),0.97,'-,14.5 unit increase,[8.80-20.20],DLGAP2,Menarche (age at onset),age at menarche,GCST001973,8:1295964,Female Reproductive System
207,DLK1,DLK1,Paternal,rs7141210-<b>T</b>,6 x 10-9,,0.34,'-,0.03 unit increase,[0.02-0.04],"DLK1, AL132711.1",Menarche (age at onset),age at menarche,GCST002541,14:100716133,Female Reproductive System
208,DLK1,DLK1,Paternal,rs1555406-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,DLK1,Menarche (age at onset),age at menarche,GCST007078,14:100737898,Female Reproductive System
346,DSCAM,DSCAM,Paternal,rs727333-<b>?</b>,1 x 10-6,,0.081,'-,1.542 unit increase,[1.295-1.837],DSCAM,Estradiol plasma levels (breast cancer),estradiol measurement,GCST001914,21:40331020,Female Reproductive System
500,GLI3,GLI3,Paternal,rs9791676-<b>?</b>,8 x 10-6,(clearcell),NR,1.96,'-,'-,GLI3,Epithelial ovarian cancer,ovarian carcinoma,GCST007728,7:42053156,Female Reproductive System
532,GLIS3,GLIS3,Paternal,rs1929353-<b>G</b>,1 x 10-5,,0.24,'-,0.35 unit increase,NR,"GLIS3, RFX3-AS1",Vaginal microbiome composition (community state type),vaginal microbiome measurement,GCST011384,9:3759975,Female Reproductive System
621,GLIS3,GLIS3,Paternal,rs199600662-<b>?</b>,5 x 10-6,,NR,0.8728601,'-,[0.82-0.93],"GLIS3, RFX3-AS1",Breast cancer specific mortality in breast cancer,"breast carcinoma, mortality",GCST007477,9:3708602,Female Reproductive System
1251,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1252,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1253,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1254,IGF2,IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1279,IGF2,IGF2,Paternal,rs6578985-<b>?</b>,6 x 10-6,"(AAM-CT, EA)",NR,'-,'-,'-,IGF2,Femoral neck bone geometry and menarche (age at onset),age at menopause,GCST001950,11:2116909,Female Reproductive System
1280,IGF2,IGF2,Paternal,rs6578987-<b>?</b>,3 x 10-6,"(AAM-CT, Chinese)",NR,'-,'-,'-,IGF2,Femoral neck bone geometry and menarche (age at onset),age at menopause,GCST001950,11:2116909,Female Reproductive System
1301,IGF2,IGF2,Paternal,rs11042596-<b>G</b>,5 x 10-8,,0.34,'-,0.04 unit increase,[0.020-0.060],"H19, IGF2",Length of menstrual cycle,menstrual cycle measurement,GCST006958,11:2097630,Female Reproductive System
1330,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1331,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1332,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1333,IGF2,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1405,INS,INS,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1406,INS,INS,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1407,INS,INS,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1408,INS,INS,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1461,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1462,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,8 x 10-8,,'-,1.19,'-,[1.12-1.26],INS-IGF2,Cervical cancer (MTAG),cervical carcinoma,GCST009825,11:2158112,Female Reproductive System
1463,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
1464,INS,INS-IGF2,Paternal,rs150806792-<b>?</b>,5 x 10-8,,'-,4.96,'-,[2.79-8.83],INS-IGF2,Cervical cancer,cervical carcinoma,GCST009826,11:2158112,Female Reproductive System
2149,LIN28B,LIN28B,Paternal,rs395962-<b>T</b>,5 x 10-16,(Japanese),0.2826,'-,0.079 year increase,[0.059-0.099],LIN28B,Menopause (age at onset),age at menopause,GCST005863,6:104949543,Female Reproductive System
2150,LIN28B,LIN28B,Paternal,rs7766336-<b>?</b>,4 x 10-57,,NR,'-,0.074 unit increase,[0.065-0.083],"LIN28B-AS1, LIN28B",Menarche (age at onset),age at menarche,GCST003993,6:104940530,Female Reproductive System
2151,LIN28B,LIN28B,Paternal,rs2153127-<b>T</b>,6 x 10-59,,0.52,'-,0.08 unit increase,[0.07-0.09],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST002541,6:104900669,Female Reproductive System
2152,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,8 x 10-110,,0.32,'-,0.12 unit increase,[0.11-0.13],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST002541,6:104931079,Female Reproductive System
2153,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,4 x 10-16,(Japanese),0.28,'-,0.079 year increase,[0.059-0.099],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST005867,6:104931079,Female Reproductive System
2154,LIN28B,LIN28B,Paternal,rs1933801-<b>?</b>,1 x 10-202,,NR,'-,'-,'-,LIN28B-AS1,Menarche (age at onset),age at menarche,GCST007078,6:104917850,Female Reproductive System
2155,LIN28B,LIN28B,Paternal,rs314276-<b>C</b>,4 x 10-16,,0.67,'-,0.14 year decrease,[0.11-0.17],LIN28B,Menarche (age at onset),age at menarche,GCST000405,6:104960124,Female Reproductive System
2156,LIN28B,LIN28B,Paternal,rs314277-<b>A</b>,3 x 10-13,(age at menarche),0.14,'-,0.16 years increase,[0.12-0.20],LIN28B,Menarche and menopause (age at onset),age at menarche,GCST000403,6:104959787,Female Reproductive System
2157,LIN28B,LIN28B,Paternal,rs314280-<b>T</b>,2 x 10-14,,0.48,'-,1.2 months increase,[0.9-1.5],LIN28B,Menarche (age at onset),age at menarche,GCST000400,6:104952962,Female Reproductive System
2158,LIN28B,LIN28B,Paternal,rs364663-<b>A</b>,5 x 10-7,,0.72,'-,0.089 year decrease,[0.054-0.124],LIN28B,Menarche (age at onset),age at menarche,GCST002013,6:104995314,Female Reproductive System
2159,LIN28B,LIN28B,Paternal,rs11285463-<b>AT</b>,3 x 10-16,(japanese),0.29,'-,0.08 year increase,[0.06-0.1],LIN28B,Menarche (age at onset),age at menarche,GCST005867,6:104944130,Female Reproductive System
2160,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,7 x 10-9,,0.33,'-,0.09 years increase,[0.05-0.13],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST000404,6:104931079,Female Reproductive System
2161,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,5 x 10-60,,0.32,'-,6.4 week increase,[5.62-7.18],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST000880,6:104931079,Female Reproductive System
2162,LIN28B,LIN28B,Paternal,rs9391253-<b>T</b>,3 x 10-7,,0.33,'-,0.088 unit decrease,[0.055-0.121],LIN28B-AS1,Puberty onset (breast development),puberty onset measurement,GCST002427,6:104919741,Female Reproductive System
2238,LIN28B,LIN28B-AS1,Paternal,rs2153127-<b>T</b>,6 x 10-59,,0.52,'-,0.08 unit increase,[0.07-0.09],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST002541,6:104900669,Female Reproductive System
2239,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,8 x 10-110,,0.32,'-,0.12 unit increase,[0.11-0.13],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST002541,6:104931079,Female Reproductive System
2240,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,4 x 10-16,(Japanese),0.28,'-,0.079 year increase,[0.059-0.099],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST005867,6:104931079,Female Reproductive System
2241,LIN28B,LIN28B-AS1,Paternal,rs1933801-<b>?</b>,1 x 10-202,,NR,'-,'-,'-,LIN28B-AS1,Menarche (age at onset),age at menarche,GCST007078,6:104917850,Female Reproductive System
2242,LIN28B,LIN28B-AS1,Paternal,rs7766336-<b>?</b>,4 x 10-57,,NR,'-,0.074 unit increase,[0.065-0.083],"LIN28B-AS1, LIN28B",Menarche (age at onset),age at menarche,GCST003993,6:104940530,Female Reproductive System
2243,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,7 x 10-9,,0.33,'-,0.09 years increase,[0.05-0.13],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST000404,6:104931079,Female Reproductive System
2244,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,5 x 10-60,,0.32,'-,6.4 week increase,[5.62-7.18],LIN28B-AS1,Menarche (age at onset),age at menarche,GCST000880,6:104931079,Female Reproductive System
2245,LIN28B,LIN28B-AS1,Paternal,rs9391253-<b>T</b>,3 x 10-7,,0.33,'-,0.088 unit decrease,[0.055-0.121],LIN28B-AS1,Puberty onset (breast development),puberty onset measurement,GCST002427,6:104919741,Female Reproductive System
2368,MKRN3,MKRN3,Paternal,rs6576457-<b>?</b>,6 x 10-20,,NR,'-,'-,'-,"MIR4508, MKRN3",Menarche (age at onset),age at menarche,GCST007078,15:23564729,Female Reproductive System
2672,RTL1,RTL1,Paternal,rs6575806-<b>?</b>,2 x 10-10,,NR,'-,'-,'-,"AL117190.1, RTL1",Menarche (age at onset),age at menarche,GCST007078,14:100886874,Female Reproductive System
2674,SGCE,SGCE,Paternal,rs111307654-<b>GAAA</b>,1 x 10-12,(EA),0.7248,'-,0.0497 unit decrease,[0.036-0.063],SGCE,Breast cancer,breast carcinoma,GCST004988,7:94655778,Female Reproductive System
3041,WT1,WT1,Paternal,rs11031731-<b>A</b>,5 x 10-16,,0.15803,1.14,'-,[1.1-1.17],"WT1, THEM7P",Uterine fibroids,uterine fibroid,GCST006462,11:32343884,Female Reproductive System
3042,WT1,WT1,Paternal,rs61889186-<b>C</b>,1 x 10-25,,0.86,1.12,'-,[1.10-1.15],"WT1, THEM7P",Uterine fibroids,uterine fibroid,GCST009158,11:32346024,Female Reproductive System
3043,WT1,WT1,Paternal,rs61889186-<b>C</b>,1 x 10-25,,0.8457,'-,0.1167 unit decrease,[0.095-0.139],"WT1, THEM7P",Uterine fibroids,uterine fibroid,GCST009158,11:32346024,Female Reproductive System
3044,WT1,WT1,Paternal,rs10835889-<b>A</b>,1 x 10-24,,0.18,1.16,'-,[1.13-1.19],"THEM7P, WT1",Uterine fibroids,uterine fibroid,GCST008423,11:32348834,Female Reproductive System
3045,WT1,WT1,Paternal,rs10734411-<b>A</b>,3 x 10-9,,0.47,'-,0.12 years decrease,[0.081-0.159],"EIF3M, WT1-AS",Menopause (age at onset),age at menopause,GCST005312,11:32520238,Female Reproductive System
3046,WT1,WT1,Paternal,rs10734411-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,"EIF3M, WT1-AS",Age at menopause,age at menopause,GCST007079,11:32520238,Female Reproductive System
3054,WT1,WT1,Paternal,rs3809060-<b>G</b>,8 x 10-7,,0.63,1.07,'-,[1.04-1.09],WT1-AS,Pelvic organ prolapse,pelvic organ prolapse,GCST010174,11:32437261,Female Reproductive System
3059,WT1,WT1,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Female Reproductive System
3060,WT1,WT1,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Female Reproductive System
3068,WT1,WT1-AS,Paternal,rs10734411-<b>A</b>,3 x 10-9,,0.47,'-,0.12 years decrease,[0.081-0.159],"EIF3M, WT1-AS",Menopause (age at onset),age at menopause,GCST005312,11:32520238,Female Reproductive System
3069,WT1,WT1-AS,Paternal,rs10734411-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,"EIF3M, WT1-AS",Age at menopause,age at menopause,GCST007079,11:32520238,Female Reproductive System
3073,WT1,WT1-AS,Paternal,rs3809060-<b>G</b>,8 x 10-7,,0.63,1.07,'-,[1.04-1.09],WT1-AS,Pelvic organ prolapse,pelvic organ prolapse,GCST010174,11:32437261,Female Reproductive System
3075,WT1,WT1-AS,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Female Reproductive System
3076,WT1,WT1-AS,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Female Reproductive System
3082,WT1-AS,WT1-AS,Paternal,rs10734411-<b>A</b>,3 x 10-9,,0.47,'-,0.12 years decrease,[0.081-0.159],"EIF3M, WT1-AS",Menopause (age at onset),age at menopause,GCST005312,11:32520238,Female Reproductive System
3083,WT1-AS,WT1-AS,Paternal,rs10734411-<b>?</b>,4 x 10-10,,NR,'-,'-,'-,"EIF3M, WT1-AS",Age at menopause,age at menopause,GCST007079,11:32520238,Female Reproductive System
3087,WT1-AS,WT1-AS,Paternal,rs3809060-<b>G</b>,8 x 10-7,,0.63,1.07,'-,[1.04-1.09],WT1-AS,Pelvic organ prolapse,pelvic organ prolapse,GCST010174,11:32437261,Female Reproductive System
3089,WT1-AS,WT1-AS,Paternal,rs10835920-<b>T</b>,2 x 10-6,,0.380414,1.1,'-,[1.05-1.14],"EIF3M, WT1-AS",Endometrial cancer (endometrioid histology),endometrial carcinoma,GCST006465,11:32468118,Female Reproductive System
3090,WT1-AS,WT1-AS,Paternal,rs10835920-<b>T</b>,1 x 10-8,,0.38,1.09,'-,[1.06-1.13],"EIF3M, WT1-AS",Endometrial cancer,endometrial carcinoma,GCST006464,11:32468118,Female Reproductive System
3205,ZFP90,ZFP90,Paternal,rs137866923-<b>?</b>,8 x 10-7,,'-,1.15,'-,[1.09-1.22],"RPL35AP33, ZFP90",Ovarian cancer (MTAG),ovarian carcinoma,GCST009829,16:68497433,Female Reproductive System
3206,ZFP90,ZFP90,Paternal,rs137866923-<b>?</b>,3 x 10-7,,'-,3.82,'-,[2.29-6.36],"RPL35AP33, ZFP90",Ovarian cancer,ovarian carcinoma,GCST009830,16:68497433,Female Reproductive System
3209,ZIM2,ZIM2,Paternal,rs10414170-<b>C</b>,7 x 10-6,,0.3,'-,0.62 unit decrease,NR,"ZIM2-AS1, AC006115.2",Vaginal microbiome composition (G. vaginalis),vaginal microbiome measurement,GCST011386,19:56734941,Female Reproductive System
3224,ZIM2,ZIM2-AS1,Paternal,rs10414170-<b>C</b>,7 x 10-6,,0.3,'-,0.62 unit decrease,NR,"ZIM2-AS1, AC006115.2",Vaginal microbiome composition (G. vaginalis),vaginal microbiome measurement,GCST011386,19:56734941,Female Reproductive System
3829,SNORD116,SNORD116,Paternal,rs9548980-<b>T</b>,4 x 10-7,,0.413,'-,0.0422 unit decrease,[0.026-0.058],SNORD116,Uterine fibroids,uterine fibroid,GCST009158,13:39921324,Female Reproductive System
209,DLK1,DLK1,Paternal,rs137952017-<b>C</b>,4 x 10-15,,0.85,'-,0.003 unit decrease,NR,"AL132711.1, DLK1",Mosaic loss of chromosome Y (Y chromosome dosage),mosaic loss of chromosome Y measurement,GCST009375,14:100709754,Genetic Regulation
210,DLK1,DLK1,Paternal,rs72698721-<b>A</b>,4 x 10-33,,0.32,'-,0.055 unit increase,NR,"DLK1, AL132711.1",Mosaic loss of chromosome Y (Y chromosome dosage),mosaic loss of chromosome Y measurement,GCST009066,14:100714852,Genetic Regulation
211,DLK1,DLK1,Paternal,rs72698721-<b>G</b>,1 x 10-52,,0.87,'-,0.026 unit increase,'-,"DLK1, AL132711.1",Mosaic loss of chromosome Y (Y chromosome dosage),mosaic loss of chromosome Y measurement,GCST009067,14:100714852,Genetic Regulation
495,GLI3,GLI3,Paternal,rs192098482-<b>?</b>,5 x 10-10,,NR,'-,'-,'-,"LINC01448, GLI3",DNA methylation variation (age effect),DNA methylation,GCST006660,7:42546557,Genetic Regulation
3160,ZFAT,ZFAT,Paternal,rs113928546-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,ZFAT,DNA methylation variation (age effect),DNA methylation,GCST006660,8:134538790,Genetic Regulation
136,DIO3,DIO3OS,Paternal,rs11626434-<b>C</b>,2 x 10-16,,0.36,'-,0.053 unit increase,[0.039-0.067],"AL049836.2, DIO3OS",Free thyroxine concentration,thyroxine measurement,GCST006896,14:101532106,Hormone
255,DLK1,DLK1,Paternal,rs7149242-<b>T</b>,4 x 10-8,,0.281233,'-,0.03672875 unit decrease,[0.024-0.05],"DLK1, AL132711.1",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,14:100693079,Hormone
337,DSCAM,DSCAM,Paternal,rs2837671-<b>?</b>,9 x 10-6,(TAG 44:1),NR,'-,0.2572213 unit decrease,[0.14-0.37],DSCAM,Metabolite levels,triacylglycerol 44:1 measurement,GCST009391,21:40524015,Hormone
338,DSCAM,DSCAM,Paternal,rs2837693-<b>?</b>,2 x 10-6,(TAG 48:4),NR,'-,0.2769407 unit decrease,[0.16-0.39],DSCAM,Metabolite levels,triacylglycerol 48:4 measurement,GCST009391,21:40538435,Hormone
583,GLIS3,GLIS3,Paternal,rs1373851-<b>T</b>,6 x 10-9,,0.943523085,'-,0.0611 SD decrease,[0.04-0.082],GLIS3,Thyroid stimulating hormone levels,thyroid stimulating hormone measurement,GCST010653,9:3902718,Hormone
584,GLIS3,GLIS3,Paternal,rs568656-<b>C</b>,4 x 10-18,,0.351139,'-,0.0115768 unit increase,[0.0089-0.0142],GLIS3,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,9:4133874,Hormone
585,GLIS3,GLIS3,Paternal,rs568656-<b>C</b>,3 x 10-12,,0.351139,'-,0.0110565 unit increase,[0.008-0.0141],GLIS3,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,9:4133874,Hormone
586,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,3 x 10-22,,0.423003,'-,0.00882246 unit increase,[0.007-0.0107],GLIS3,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,9:4143749,Hormone
587,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,4 x 10-26,,0.423003,'-,0.00855474 unit increase,[0.0069-0.0102],GLIS3,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,9:4143749,Hormone
588,GLIS3,GLIS3,Paternal,rs10116426-<b>C</b>,9 x 10-13,,0.431749,'-,0.00808468 unit increase,[0.0058-0.0104],GLIS3,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012108,9:4145648,Hormone
589,GLIS3,GLIS3,Paternal,rs10116426-<b>C</b>,6 x 10-13,,0.431749,'-,0.00889555 unit increase,[0.0064-0.0113],GLIS3,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012109,9:4145648,Hormone
590,GLIS3,GLIS3,Paternal,rs7873463-<b>C</b>,1 x 10-22,,0.732353927,'-,0.0504 SD decrease,[0.04-0.061],GLIS3,Thyroid stimulating hormone levels,thyroid stimulating hormone measurement,GCST010653,9:4221298,Hormone
591,GLIS3,GLIS3,Paternal,rs1571583-<b>A</b>,3 x 10-8,(TSH),0.249,'-,0.057 unit increase,[0.037-0.077],GLIS3,Thyroid hormone levels,"hormone measurement, thyroid stimulating hormone measurement",GCST001856,9:4267209,Hormone
592,GLIS3,GLIS3,Paternal,rs1571583-<b>A</b>,1 x 10-6,(TSH - Males),0.249,'-,0.074 unit increase,[0.045-0.103],GLIS3,Thyroid hormone levels,"hormone measurement, thyroid stimulating hormone measurement",GCST001856,9:4267209,Hormone
593,GLIS3,GLIS3,Paternal,rs10814915-<b>C</b>,1 x 10-29,,0.553179489,'-,0.0517 SD decrease,[0.043-0.061],GLIS3,Thyroid stimulating hormone levels,thyroid stimulating hormone measurement,GCST010653,9:4290544,Hormone
594,GLIS3,GLIS3,Paternal,rs1330307-<b>A</b>,1 x 10-12,,0.514883,'-,0.00786625 unit increase,[0.0054-0.0103],"GLIS3, AL162419.1",Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,9:4305064,Hormone
595,GLIS3,GLIS3,Paternal,rs1330307-<b>A</b>,2 x 10-11,,0.514883,'-,0.00875617 unit increase,[0.006-0.0116],"GLIS3, AL162419.1",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,9:4305064,Hormone
596,GLIS3,GLIS3,Paternal,rs1330307-<b>A</b>,8 x 10-18,,0.514403,'-,0.00696648 unit increase,[0.0053-0.0086],"GLIS3, AL162419.1",Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,9:4305064,Hormone
597,GLIS3,GLIS3,Paternal,rs1330307-<b>A</b>,4 x 10-18,,0.514403,'-,0.00767987 unit increase,[0.0058-0.0095],"GLIS3, AL162419.1",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,9:4305064,Hormone
550,GLIS3,GLIS3,Paternal,rs4237150-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,GLIS3,Circulating leptin levels or type 2 diabetes,"leptin measurement, type II diabetes mellitus",GCST010272,9:4290085,Hormone
608,GLIS3,GLIS3,Paternal,rs10119187-<b>T</b>,8 x 10-10,,0.81,'-,0.048 unit increase,[0.032-0.064],GLIS3,Free thyroxine concentration,thyroxine measurement,GCST006896,9:4223660,Hormone
1232,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,2 x 10-138,,NR,'-,0.0705 unit increase,[0.065-0.076],IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2128634,Hormone
1233,IGF2,IGF2,Paternal,rs74050111-<b>C</b>,3 x 10-39,,NR,'-,0.0561 unit decrease,[0.048-0.065],IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2115727,Hormone
1234,IGF2,IGF2,Paternal,rs116862756-<b>G</b>,3 x 10-17,,NR,'-,0.0716 unit increase,[0.055-0.088],IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2102480,Hormone
1236,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,8 x 10-12,,NR,'-,0.0201 unit decrease,[0.014-0.026],IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,11:2128634,Hormone
1258,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.011816 unit increase,[0.0089-0.0147],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,11:2158635,Hormone
1259,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.0138844 unit increase,[0.011-0.017],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,11:2158635,Hormone
1260,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,6 x 10-14,,0.239008,'-,0.00973145 unit increase,[0.0068-0.0126],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012109,11:2158635,Hormone
1261,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,2 x 10-29,,0.239577,'-,0.0109511 unit increase,[0.009-0.0129],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,11:2158635,Hormone
1262,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-26,,0.239577,'-,0.0114739 unit increase,[0.0093-0.0137],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,11:2158635,Hormone
1265,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,1 x 10-76,,NR,'-,0.056 unit increase,[0.05-0.062],INS-IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2151600,Hormone
1266,IGF2,IGF2,Paternal,rs77124198-<b>T</b>,5 x 10-28,,NR,'-,0.0675 unit decrease,[0.056-0.079],"H19, IGF2",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2098893,Hormone
1285,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-98,,NR,'-,0.0602 unit increase,[0.055-0.066],"INS-IGF2, INS",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2159843,Hormone
1288,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,6 x 10-10,,NR,'-,0.0186 unit decrease,[0.013-0.024],"INS-IGF2, INS",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,11:2159843,Hormone
1305,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,4 x 10-16,,0.239008,'-,0.00998903 unit increase,[0.0073-0.0127],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012108,11:2158635,Hormone
1337,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.011816 unit increase,[0.0089-0.0147],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,11:2158635,Hormone
1338,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.0138844 unit increase,[0.011-0.017],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,11:2158635,Hormone
1339,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,6 x 10-14,,0.239008,'-,0.00973145 unit increase,[0.0068-0.0126],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012109,11:2158635,Hormone
1342,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,2 x 10-29,,0.239577,'-,0.0109511 unit increase,[0.009-0.0129],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,11:2158635,Hormone
1343,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-26,,0.239577,'-,0.0114739 unit increase,[0.0093-0.0137],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,11:2158635,Hormone
1346,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,1 x 10-76,,NR,'-,0.056 unit increase,[0.05-0.062],INS-IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2151600,Hormone
1363,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-98,,NR,'-,0.0602 unit increase,[0.055-0.066],"INS-IGF2, INS",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2159843,Hormone
1371,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,6 x 10-10,,NR,'-,0.0186 unit decrease,[0.013-0.024],"INS-IGF2, INS",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,11:2159843,Hormone
1380,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,4 x 10-16,,0.239008,'-,0.00998903 unit increase,[0.0073-0.0127],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012108,11:2158635,Hormone
1396,INS,INS,Paternal,rs3842752-<b>A</b>,3 x 10-98,,NR,'-,0.0602 unit increase,[0.055-0.066],"INS-IGF2, INS",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2159843,Hormone
1399,INS,INS,Paternal,rs3842752-<b>A</b>,6 x 10-10,,NR,'-,0.0186 unit decrease,[0.013-0.024],"INS-IGF2, INS",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,11:2159843,Hormone
1412,INS,INS,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.011816 unit increase,[0.0089-0.0147],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,11:2158635,Hormone
1413,INS,INS,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.0138844 unit increase,[0.011-0.017],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,11:2158635,Hormone
1414,INS,INS,Paternal,rs775181992-<b>A</b>,6 x 10-14,,0.239008,'-,0.00973145 unit increase,[0.0068-0.0126],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012109,11:2158635,Hormone
1417,INS,INS,Paternal,rs775181992-<b>A</b>,2 x 10-29,,0.239577,'-,0.0109511 unit increase,[0.009-0.0129],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,11:2158635,Hormone
1420,INS,INS,Paternal,rs7948458-<b>C</b>,1 x 10-76,,NR,'-,0.056 unit increase,[0.05-0.062],INS-IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2151600,Hormone
1451,INS,INS,Paternal,rs775181992-<b>A</b>,4 x 10-16,,0.239008,'-,0.00998903 unit increase,[0.0073-0.0127],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012108,11:2158635,Hormone
1453,INS,INS,Paternal,rs775181992-<b>A</b>,1 x 10-26,,0.239577,'-,0.0114739 unit increase,[0.0093-0.0137],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,11:2158635,Hormone
1468,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.011816 unit increase,[0.0089-0.0147],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012106,11:2158635,Hormone
1469,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-16,,0.240111,'-,0.0138844 unit increase,[0.011-0.017],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012107,11:2158635,Hormone
1470,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,6 x 10-14,,0.239008,'-,0.00973145 unit increase,[0.0068-0.0126],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012109,11:2158635,Hormone
1473,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,2 x 10-29,,0.239577,'-,0.0109511 unit increase,[0.009-0.0129],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012110,11:2158635,Hormone
1474,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-26,,0.239577,'-,0.0114739 unit increase,[0.0093-0.0137],INS-IGF2,Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90012111,11:2158635,Hormone
1477,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,1 x 10-76,,NR,'-,0.056 unit increase,[0.05-0.062],INS-IGF2,Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2151600,Hormone
1494,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-98,,NR,'-,0.0602 unit increase,[0.055-0.066],"INS-IGF2, INS",Insulin-like growth factor 1 levels,IGF-1 measurement,GCST90019511,11:2159843,Hormone
1502,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,6 x 10-10,,NR,'-,0.0186 unit decrease,[0.013-0.024],"INS-IGF2, INS",Sex hormone-binding globulin levels,sex hormone-binding globulin measurement,GCST90019518,11:2159843,Hormone
1511,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,4 x 10-16,,0.239008,'-,0.00998903 unit increase,[0.0073-0.0127],INS-IGF2,Sex hormone-binding globulin levels adjusted for BMI,sex hormone-binding globulin measurement,GCST90012108,11:2158635,Hormone
2164,LIN28B,LIN28B,Paternal,rs314276-<b>C</b>,2 x 10-8,,0.66,'-,0.08 unit increase,[0.053-0.107],LIN28B,Puberty onset,puberty onset measurement,GCST002425,6:104960124,Hormone
2165,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,4 x 10-9,(Late pubertal growth),0.32,'-,0.11 unit increase,[0.079-0.141],LIN28B-AS1,Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,6:104931079,Hormone
2166,LIN28B,LIN28B,Paternal,rs11156429-<b>G</b>,2 x 10-7,"(Late pubertal growth, females)",0.55,'-,0.11 unit decrease,[0.071-0.149],LIN28B-AS1,Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,6:104916546,Hormone
2246,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,4 x 10-9,(Late pubertal growth),0.32,'-,0.11 unit increase,[0.079-0.141],LIN28B-AS1,Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,6:104931079,Hormone
2247,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>G</b>,2 x 10-7,"(Late pubertal growth, females)",0.55,'-,0.11 unit decrease,[0.071-0.149],LIN28B-AS1,Pubertal anthropometrics,"puberty, height growth measurement",GCST001876,6:104916546,Hormone
3064,WT1,WT1,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Hormone
3079,WT1,WT1-AS,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Hormone
3093,WT1-AS,WT1-AS,Paternal,rs7483826-<b>G</b>,2 x 10-8,,0.487817,'-,0.034207698 unit increase,[0.022-0.046],"WT1-AS, EIF3M",Medication use (agents acting on the renin-angiotensin system),Agents acting on the renin-angiotensin system use measurement,GCST007930,11:32505692,Hormone
3097,WT1,WTIP,Paternal,rs16969368-<b>?</b>,3 x 10-6,(TAG 58:11),NR,'-,0.5476408 unit decrease,[0.32-0.78],WTIP,Metabolite levels,triacylglycerol 58:10 measurement,GCST009391,19:34494550,Hormone
3098,WT1,WTIP,Paternal,rs16969368-<b>?</b>,7 x 10-6,(TAG 58:12),NR,'-,0.5265684 unit decrease,[0.3-0.76],WTIP,Metabolite levels,triacylglycerol 58:12 measurement,GCST009391,19:34494550,Hormone
3099,WT1,WTIP,Paternal,rs16969368-<b>?</b>,3 x 10-6,(TAG 60:12),NR,'-,0.5479422 unit decrease,[0.32-0.78],WTIP,Metabolite levels,triacylglycerol 60:12 measurement,GCST009391,19:34494550,Hormone
3108,ZC3H12C,ZC3H12C,Paternal,rs661171-<b>G</b>,9 x 10-7,(female),0.71,'-,0.2 unit increase,[0.12-0.28],"ZC3H12C, RDX",Plasma parathyroid hormone levels,parathyroid hormone measurement,GCST006431,11:110145794,Hormone
3100,WT1,WTIP,Paternal,rs16969368-<b>?</b>,5 x 10-6,(TAG 58:10),NR,'-,0.5285057 unit decrease,[0.3-0.76],WTIP,Metabolite levels,triacylglycerol 58:10 measurement,GCST009391,19:34494550,Hormone
3197,ZFP90,ZFP90,Paternal,rs142674134-<b>?</b>,5 x 10-10,(AGRP),NR,'-,1.67397 unit increase,[1.15-2.2],"ZFP90, RPL35AP33",Blood protein levels,Agouti-related protein measurement,GCST009696,16:68521135,Hormone
153,DLGAP2,DLGAP2,Paternal,rs139682541-<b>?</b>,9 x 10-6,,NR,'-,0.2896 unit decrease,[0.16-0.42],DLGAP2,Mononucleosis,susceptibility to mononucleosis measurement,GCST005002,8:1088714,Immune
154,DLGAP2,DLGAP2,Paternal,rs138808635-<b>C</b>,9 x 10-6,,'-,'-,0.6906 SD units decrease,[0.39-0.99],DLGAP2,Tumor necrosis factor alpha levels,tumor necrosis factor-alpha measurement,GCST004426,8:1135584,Immune
155,DLGAP2,DLGAP2,Paternal,rs34582125-<b>G</b>,9 x 10-6,,'-,'-,0.1617 SD units increase,[0.09-0.233],DLGAP2,Tumor necrosis factor beta levels,tumor necrosis factor beta measurement,GCST004425,8:1188292,Immune
174,DLGAP2,DLGAP2,Paternal,rs28367414-<b>?</b>,3 x 10-6,,'-,'-,'-,'-,DLGAP2,Clostridium difficile infection in multiple myeloma,"clostridium difficile infection, multiple myeloma",GCST005686,8:1470728,Immune
177,DLGAP2,DLGAP2,Paternal,rs17062789-<b>?</b>,3 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203198,Immune
178,DLGAP2,DLGAP2,Paternal,rs17062791-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431,Immune
179,DLGAP2,DLGAP2,Paternal,rs17062791-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203431,Immune
180,DLGAP2,DLGAP2,Paternal,rs73670671-<b>?</b>,3 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1203645,Immune
181,DLGAP2,DLGAP2,Paternal,rs34003842-<b>?</b>,2 x 10-7,(Hispanic),'-,'-,'-,'-,DLGAP2,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,8:1206131,Immune
186,DLGAP2,DLGAP2,Paternal,rs17739794-<b>?</b>,6 x 10-6,(AUC),NR,'-,'-,'-,DLGAP2,Clozapine-induced cytotoxicity,"cytotoxicity measurement, response to clozapine",GCST002777,8:862946,Immune
331,DSCAM,DSCAM,Paternal,rs9981861-<b>C</b>,9 x 10-6,,'-,'-,0.0722 SD units increase,[0.04-0.104],DSCAM,Interleukin-10 levels,interleukin 10 measurement,GCST004444,21:40043117,Immune
332,DSCAM,DSCAM,Paternal,rs11702781-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,"DSCAM-IT1, DSCAM",Tuberculosis,Tuberculosis,GCST004922,21:40630550,Immune
333,DSCAM,DSCAM,Paternal,rs2837857-<b>T</b>,2 x 10-6,,0.7,3.3333,'-,[NR],DSCAM,Tuberculosis,Tuberculosis,GCST002198,21:40845029,Immune
356,DSCAM,DSCAM-IT1,Paternal,rs11702781-<b>?</b>,9 x 10-6,,NR,'-,'-,'-,"DSCAM-IT1, DSCAM",Tuberculosis,Tuberculosis,GCST004922,21:40630550,Immune
360,ERAP2,ERAP2,Paternal,rs2549794-<b>C</b>,1 x 10-10,,0.409,1.05,'-,[1.02-1.09],"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST000879,5:96908845,Immune
361,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,6 x 10-13,,0.411,1.068,'-,[1.037-1.099],"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST001725,5:96917099,Immune
362,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,4 x 10-16,(EA),0.4212,1.10802,'-,[1.08-1.13],"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST003044,5:96917099,Immune
363,ERAP2,ERAP2,Paternal,rs1363907-<b>A</b>,5 x 10-15,(EA),0.4212,1.084916,'-,[1.06-1.11],"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST003043,5:96917099,Immune
364,ERAP2,ERAP2,Paternal,rs1363907-<b>?</b>,1 x 10-14,,'-,'-,'-,'-,"ERAP2, AC009126.1",Crohn's disease,Crohn's disease,GCST004132,5:96917099,Immune
373,ERAP2,ERAP2,Paternal,rs4869313-<b>T</b>,9 x 10-8,,0.42,'-,'-,'-,"ERAP2, AC009126.1",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,5:96888176,Immune
365,ERAP2,ERAP2,Paternal,rs1363907-<b>?</b>,1 x 10-10,,'-,'-,'-,'-,"ERAP2, AC009126.1",Inflammatory bowel disease,inflammatory bowel disease,GCST004131,5:96917099,Immune
374,ERAP2,ERAP2,Paternal,rs2910686-<b>?</b>,2 x 10-21,(subset analysis),NR,'-,'-,'-,"AC009126.1, ERAP2","Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:96916885,Immune
377,ERAP2,ERAP2,Paternal,rs2910686-<b>C</b>,5 x 10-17,"(conditioned on rs30187, EA)",0.44,1.17,'-,'-,"AC009126.1, ERAP2",Ankylosing spondylitis,ankylosing spondylitis,GCST005529,5:96916885,Immune
496,GLI3,GLI3,Paternal,rs846271-<b>C</b>,2 x 10-6,(IGP30),0.628956224,'-,0.1538 unit decrease,[0.09-0.218],GLI3,IgG glycosylation,serum IgG glycosylation measurement,GCST001848,7:41997238,Immune
503,GLI3,GLI3,Paternal,rs12532960-<b>?</b>,3 x 10-7,(hsCRP-IL6 pattern prefenofibrate),NR,'-,'-,'-,"LINC01448, GLI3",Inflammatory biomarkers,response to fenofibrate,GCST001371,7:42286026,Immune
598,GLIS3,GLIS3,Paternal,rs6476839-<b>T</b>,1 x 10-9,,0.4,1.12,'-,'-,GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST005536,9:4290823,Immune
599,GLIS3,GLIS3,Paternal,rs7020673-<b>?</b>,5 x 10-12,,0.5,1.14,'-,[1.08-1.20],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST000392,9:4291747,Immune
600,GLIS3,GLIS3,Paternal,rs10974438-<b>C</b>,1 x 10-6,,'-,'-,0.12805976 unit increase,[0.076-0.18],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST90000529,9:4291928,Immune
601,GLIS3,GLIS3,Paternal,rs10758593-<b>A</b>,3 x 10-6,,NR,1.13,'-,[1.07-1.19],GLIS3,Type 1 diabetes,type I diabetes mellitus,GCST000244,9:4292083,Immune
630,GLIS3,GLIS3,Paternal,rs717423-<b>?</b>,4 x 10-6,(Hispanic),'-,14.1,'-,[NR],GLIS3,Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy),"response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy",GCST002365,9:3844061,Immune
633,GLIS3,GLIS3,Paternal,rs10814834-<b>?</b>,7 x 10-6,"(endpoint 6, dominant)",'-,2.173913,'-,[NR],GLIS3,Peginterferon alfa-2a treatment response in chronic hepatitis B infection,"response to peginterferon alfa-2a, chronic hepatitis B virus infection",GCST008514,9:4086370,Immune
1239,IGF2,IGF2,Paternal,rs17885785-<b>T</b>,8 x 10-11,,0.2,'-,'-,'-,"IGF2-AS, INS-IGF2",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,11:2146620,Immune
1241,IGF2,IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Immune
1267,IGF2,IGF2,Paternal,rs78896587-<b>T</b>,1 x 10-9,,'-,'-,0.20937194 unit decrease,[0.14-0.28],"IGF2, H19",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2055620,Immune
1276,IGF2,IGF2,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Immune
1294,IGF2,IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1303,IGF2,IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Immune
1304,IGF2,IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Immune
1311,IGF2,IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Immune
1312,IGF2,IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Immune
1313,IGF2,IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Immune
1318,IGF2,IGF2-AS,Paternal,rs17885785-<b>T</b>,8 x 10-11,,0.2,'-,'-,'-,"IGF2-AS, INS-IGF2",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,11:2146620,Immune
1320,IGF2,IGF2-AS,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Immune
1324,IGF2,IGF2-AS,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Immune
1327,IGF2,IGF2-AS,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1327,IGF2,IGF2-AS,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1357,IGF2,INS-IGF2,Paternal,rs17885785-<b>T</b>,8 x 10-11,,0.2,'-,'-,'-,"IGF2-AS, INS-IGF2",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,11:2146620,Immune
1354,IGF2,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Immune
1365,IGF2,INS-IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Immune
1370,IGF2,INS-IGF2,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Immune
1378,IGF2,INS-IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Immune
1379,IGF2,INS-IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Immune
1382,IGF2,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Immune
1386,IGF2,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Immune
1387,IGF2,INS-IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1388,IGF2,INS-IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Immune
1389,IGF2,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Immune
1391,INS,INS,Paternal,rs689-<b>T</b>,1 x 10-100,,0.7,2.3809524,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST005536,11:2160994,Immune
1430,INS,INS,Paternal,rs17885785-<b>T</b>,8 x 10-11,,0.2,'-,'-,'-,"IGF2-AS, INS-IGF2",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,11:2146620,Immune
1432,INS,INS,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Immune
1436,INS,INS,Paternal,rs4244808-<b>G</b>,4 x 10-27,,0.46,1.28,'-,'-,"INS-IGF2, IGF2-AS",Type 1 diabetes,type II diabetes mellitus,GCST009875,11:2141880,Immune
1438,INS,INS,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Immune
1439,INS,INS,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Immune
1440,INS,INS,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Immune
1441,INS,INS,Paternal,rs689-<b>?</b>,1 x 10-18,,0.715,1.473,'-,[1.352-1.605],"INS, INS-IGF2",Latent autoimmune diabetes vs. type 2 diabetes,"latent autoimmune diabetes in adults, type II diabetes mellitus",GCST007246,11:2160994,Immune
1443,INS,INS,Paternal,rs3842727-<b>A</b>,3 x 10-7,,0.716,1.9841269,'-,'-,"TH, INS",Type 1 diabetes in high risk HLA genotype individuals (time to event),"disease free survival, type I diabetes mellitus, carrier status",GCST006196,11:2163618,Immune
1444,INS,INS,Paternal,rs3842727-<b>A</b>,1 x 10-7,(multiple-IA),0.716,1.6638935,'-,'-,"TH, INS",Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),"event free survival time, type I diabetes mellitus, carrier status, autoantibody measurement",GCST006197,11:2163618,Immune
1445,INS,INS,Paternal,rs3842727-<b>A</b>,6 x 10-6,(IAA-first),0.716,1.7513134,'-,'-,"TH, INS",Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),"event free survival time, type I diabetes mellitus, carrier status, autoantibody measurement",GCST006197,11:2163618,Immune
1449,INS,INS,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Immune
1450,INS,INS,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Immune
1452,INS,INS,Paternal,rs3842727-<b>T</b>,1 x 10-13,,0.26,1.53,'-,[1.37–1.72],"TH, INS",Type 1 diabetes,type I diabetes mellitus,GCST009916,11:2163618,Immune
1458,INS,INS,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1488,INS,INS-IGF2,Paternal,rs17885785-<b>T</b>,8 x 10-11,,0.2,'-,'-,'-,"IGF2-AS, INS-IGF2",Pediatric autoimmune diseases,"autoimmune thyroid disease, type I diabetes mellitus, Common variable immunodeficiency, ankylosing spondylitis, psoriasis, celiac disease, ulcerative colitis, Crohn's disease, autoimmune disease, juvenile idiopathic arthritis, systemic lupus erythematosus",GCST003097,11:2146620,Immune
1496,INS,INS-IGF2,Paternal,rs4366464-<b>C</b>,1 x 10-9,,'-,'-,0.403326 unit increase,[0.27-0.53],"INS-IGF2, IGF2-AS",Type 1 diabetes,type I diabetes mellitus,GCST90000529,11:2143569,Immune
1509,INS,INS-IGF2,Paternal,rs1004446-<b>C</b>,4 x 10-9,,0.65,1.61,'-,[1.37-1.89],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST000054,11:2148913,Immune
1510,INS,INS-IGF2,Paternal,rs1004446-<b>G</b>,3 x 10-23,,NR,1.4,'-,[NR],INS-IGF2,Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2148913,Immune
1513,INS,INS-IGF2,Paternal,rs689-<b>?</b>,1 x 10-6,,NR,2.44,'-,[1.69-3.45],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST008377,11:2160994,Immune
1517,INS,INS-IGF2,Paternal,rs689-<b>T</b>,1 x 10-160,,0.71,2.21,'-,[2.08-2.34],"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST010681,11:2160994,Immune
1518,INS,INS-IGF2,Paternal,rs3741208-<b>T</b>,2 x 10-7,,0.38,1.25,'-,[1.15-1.35],"IGF2-AS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST000038,11:2148544,Immune
1519,INS,INS-IGF2,Paternal,rs689-<b>A</b>,5 x 10-196,,NR,'-,'-,'-,"INS, INS-IGF2",Type 1 diabetes,type I diabetes mellitus,GCST001191,11:2160994,Immune
2369,MKRN3,MKRN3,Paternal,rs6576462-<b>C</b>,1 x 10-15,,0.937,'-,0.39 unit increase,[0.29-0.48],"AC126407.1, MKRN3",Pre-treatment viral load in HIV-1 infection,"HIV-1 infection, viral load",GCST008758,15:23569519,Immune
2370,MKRN3,MKRN3,Paternal,rs2900-<b>G</b>,4 x 10-6,(IGP14),0.860145731,'-,0.2021 unit decrease,[0.12-0.29],MKRN3,IgG glycosylation,serum IgG glycosylation measurement,GCST001848,15:23572574,Immune
2380,NDN,NDN,Paternal,rs12148636-<b>T</b>,9 x 10-6,,'-,'-,0.0805 SD units increase,[0.045-0.116],"NDN, AC087490.1",Interleukin-12p70 levels,interleukin 12 measurement,GCST004439,15:23729711,Immune
2558,PLAGL1,PLAGL1,Paternal,rs76996465-<b>T</b>,2 x 10-6,,NR,1.165,'-,'-,"SF3B5, PLAGL1",Leprosy,leprosy,GCST004009,6:144068802,Immune
2594,RASGRF1,RASGRF1,Paternal,rs62013236-<b>C</b>,9 x 10-17,,NR,1.106,'-,NR,"CTSH, RASGRF1",Multiple sclerosis,multiple sclerosis,GCST009597,15:78955140,Immune
2874,SNRPN,SNRPN,Paternal,rs11634944-<b>C</b>,1 x 10-6,,'-,'-,0.1214 SD units increase,[0.072-0.171],SNRPN,Interleukin-8 levels,interleukin-8 measurement,GCST004445,15:24937946,Immune
2876,SNRPN,SNRPN,Paternal,rs12592731-<b>?</b>,8 x 10-6,(Hispanic),'-,'-,'-,'-,SNRPN,Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection (time and treatment arm interaction),"response to tenofovir, HIV infection, creatinine clearance measurement",GCST006069,15:24925023,Immune
3052,WT1,WT1,Paternal,rs4986811-<b>G</b>,5 x 10-8,,0.20504,'-,'-,'-,WT1,Rubella-specific interleukin-6 secretion,"interleukin-6 measurement, response to vaccine",GCST005176,11:32429547,Immune
3198,ZFP90,ZFP90,Paternal,rs1749792-<b>?</b>,4 x 10-11,,NR,1.14,'-,[1.10-1.19],"RNU4-36P, ZFP90",Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,16:68535537,Immune
3199,ZFP90,ZFP90,Paternal,rs17689437-<b>?</b>,6 x 10-6,,NR,'-,'-,'-,ZFP90,HIV-1 viral setpoint,HIV viral set point measurement,GCST001352,16:68566448,Immune
3200,ZFP90,ZFP90,Paternal,rs1170426-<b>C</b>,4 x 10-8,(Chinese),0.176,1.2,'-,[1.12-1.28],ZFP90,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003622,16:68569895,Immune
3201,ZFP90,ZFP90,Paternal,rs1170426-<b>C</b>,2 x 10-8,,0.235,1.12,'-,[1.08-1.17],ZFP90,Systemic lupus erythematosus,systemic lupus erythematosus,GCST003622,16:68569895,Immune
3202,ZFP90,ZFP90,Paternal,rs1170436-<b>?</b>,9 x 10-7,,NR,1.17,'-,[1.10-1.25],ZFP90,Systemic lupus erythematosus,systemic lupus erythematosus,GCST007400,16:68573583,Immune
3203,ZFP90,ZFP90,Paternal,rs1170436-<b>?</b>,8 x 10-7,(AA),NR,1.31,'-,[1.18-1.46],ZFP90,Systemic lupus erythematosus,systemic lupus erythematosus,GCST005752,16:68573583,Immune
3211,ZIM2,ZIM2,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Immune
3226,ZIM2,ZIM2-AS1,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Immune
3236,ZNF396,ZNF396,Paternal,rs116303449-<b>?</b>,6 x 10-7,,NR,'-,'-,'-,ZNF396,Parasitemia in Tripanosoma cruzi seropositivity,"parasitemia measurement, Trypanosoma cruzi seropositivity",GCST002282,18:35376967,Immune
3833,SNORD116,SNORD116,Paternal,rs9548988-<b>T</b>,3 x 10-7,,0.46,1.1,'-,[1.03-1.19],SNORD116,Ulcerative colitis,ulcerative colitis,GCST000527,13:39931373,Immune
156,DLGAP2,DLGAP2,Paternal,rs2404298-<b>?</b>,4 x 10-7,,NR,1.76,'-,'-,DLGAP2,End stage renal disease in APOL1 risk genotype-negative individuals,"chronic kidney disease, APOL1 risk genotype carrier status",GCST006815,8:1420853,Kidney
157,DLGAP2,DLGAP2,Paternal,rs2404298-<b>?</b>,1 x 10-6,,'-,1.55,'-,[1.29-1.85],DLGAP2,End-stage renal disease,chronic kidney disease,GCST006814,8:1420853,Kidney
334,DSCAM,DSCAM,Paternal,rs2837554-<b>G</b>,3 x 10-7,,0.701,1.16,'-,[1.10-1.24],DSCAM,Mild to moderate chronic kidney disease,chronic kidney disease,GCST008394,21:40295451,Kidney
607,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,2 x 10-8,,0.6,'-,0.0107 unit decrease,[0.0069-0.0145],GLIS3,Urate levels,urate measurement,GCST011119,9:4118111,Kidney
881,HECW1,HECW1,Paternal,rs978056-<b>A</b>,6 x 10-6,,NR,'-,0.13 unit decrease,[0.071-0.189],HECW1,Serum galactose-deficient IgA1 levels,serum galactose-deficient IgA1 measurement,GCST004159,7:43339245,Kidney
1229,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,2 x 10-12,,NR,'-,0.0198 unit increase,[0.014-0.025],IGF2,Creatinine levels,creatinine measurement,GCST90019502,11:2128634,Kidney
1230,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,2 x 10-9,,NR,'-,0.0169 unit increase,[0.011-0.022],IGF2,Cystatin C levels,cystatin C measurement,GCST90019504,11:2128634,Kidney
1231,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,2 x 10-12,,NR,'-,0.0197 unit decrease,[0.014-0.025],IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2128634,Kidney
1235,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,8 x 10-17,,NR,'-,0.0234 unit increase,[0.018-0.029],IGF2,Urate levels,urate measurement,GCST90019524,11:2128634,Kidney
1242,IGF2,IGF2,Paternal,rs3741205-<b>C</b>,3 x 10-12,,0.3997,'-,7.002 z score increase,NR,"IGF2-AS, INS-IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007876,11:2148654,Kidney
1243,IGF2,IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Kidney
1248,IGF2,IGF2,Paternal,rs7482894-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"H19, IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007344,11:2100034,Kidney
1249,IGF2,IGF2,Paternal,rs10840341-<b>?</b>,1 x 10-9,,NR,'-,0.02327 unit increase,[0.016-0.031],"H19, IGF2",Creatinine levels,creatinine measurement,GCST005985,11:2095263,Kidney
1250,IGF2,IGF2,Paternal,rs11564722-<b>T</b>,1 x 10-21,,0.2396,'-,0.0038 unit increase,[0.003-0.0046],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008059,11:2157100,Kidney
1244,IGF2,IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Kidney
1263,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,4 x 10-16,,NR,'-,0.0245 unit increase,[0.019-0.03],INS-IGF2,Cystatin C levels,cystatin C measurement,GCST90019504,11:2151600,Kidney
1264,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-15,,NR,'-,0.024 unit decrease,[0.018-0.03],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2151600,Kidney
1271,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Kidney
1283,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,9 x 10-14,,NR,'-,0.0213 unit increase,[0.016-0.027],"INS-IGF2, INS",Creatinine levels,creatinine measurement,GCST90019502,11:2159843,Kidney
1284,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-12,,NR,'-,0.0202 unit decrease,[0.015-0.026],"INS-IGF2, INS",Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2159843,Kidney
1289,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-10,,NR,'-,0.018 unit increase,[0.012-0.024],"INS-IGF2, INS",Urea levels,serum urea measurement,GCST90019525,11:2159843,Kidney
1290,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Kidney
1295,IGF2,IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-23,,0.311,'-,0.0033 unit increase,[0.0025-0.0041],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,11:2157100,Kidney
1296,IGF2,IGF2,Paternal,rs10840341-<b>?</b>,5 x 10-8,,NR,'-,0.02131 unit decrease,[0.014-0.029],"H19, IGF2",Glomerular filtration rate,glomerular filtration rate,GCST005984,11:2095263,Kidney
1309,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,5 x 10-17,,NR,'-,0.0253 unit increase,[0.019-0.031],INS-IGF2,Creatinine levels,creatinine measurement,GCST90019502,11:2151600,Kidney
1310,IGF2,IGF2,Paternal,rs7482894-<b>T</b>,4 x 10-14,,0.65,'-,0.0147 unit increase,[0.011-0.019],"H19, IGF2",Urate levels,urate measurement,GCST011119,11:2100034,Kidney
1315,IGF2,IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Kidney
1321,IGF2,IGF2-AS,Paternal,rs3741205-<b>C</b>,3 x 10-12,,0.3997,'-,7.002 z score increase,NR,"IGF2-AS, INS-IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007876,11:2148654,Kidney
1322,IGF2,IGF2-AS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Kidney
1323,IGF2,IGF2-AS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Kidney
1328,IGF2,INS-IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-23,,0.311,'-,0.0033 unit increase,[0.0025-0.0041],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,11:2157100,Kidney
1329,IGF2,INS-IGF2,Paternal,rs11564722-<b>T</b>,1 x 10-21,,0.2396,'-,0.0038 unit increase,[0.003-0.0046],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008059,11:2157100,Kidney
1344,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,4 x 10-16,,NR,'-,0.0245 unit increase,[0.019-0.03],INS-IGF2,Cystatin C levels,cystatin C measurement,GCST90019504,11:2151600,Kidney
1345,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-15,,NR,'-,0.024 unit decrease,[0.018-0.03],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2151600,Kidney
1350,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Kidney
1360,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,9 x 10-14,,NR,'-,0.0213 unit increase,[0.016-0.027],"INS-IGF2, INS",Creatinine levels,creatinine measurement,GCST90019502,11:2159843,Kidney
1361,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-12,,NR,'-,0.0202 unit decrease,[0.015-0.026],"INS-IGF2, INS",Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2159843,Kidney
1367,IGF2,INS-IGF2,Paternal,rs3741205-<b>C</b>,3 x 10-12,,0.3997,'-,7.002 z score increase,NR,"IGF2-AS, INS-IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007876,11:2148654,Kidney
1368,IGF2,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Kidney
1369,IGF2,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Kidney
1372,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-10,,NR,'-,0.018 unit increase,[0.012-0.024],"INS-IGF2, INS",Urea levels,serum urea measurement,GCST90019525,11:2159843,Kidney
1373,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Kidney
1381,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,5 x 10-17,,NR,'-,0.0253 unit increase,[0.019-0.031],INS-IGF2,Creatinine levels,creatinine measurement,GCST90019502,11:2151600,Kidney
1390,IGF2,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Kidney
1394,INS,INS,Paternal,rs3842752-<b>A</b>,9 x 10-14,,NR,'-,0.0213 unit increase,[0.016-0.027],"INS-IGF2, INS",Creatinine levels,creatinine measurement,GCST90019502,11:2159843,Kidney
1395,INS,INS,Paternal,rs3842752-<b>A</b>,1 x 10-12,,NR,'-,0.0202 unit decrease,[0.015-0.026],"INS-IGF2, INS",Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2159843,Kidney
1400,INS,INS,Paternal,rs3842752-<b>A</b>,3 x 10-10,,NR,'-,0.018 unit increase,[0.012-0.024],"INS-IGF2, INS",Urea levels,serum urea measurement,GCST90019525,11:2159843,Kidney
1402,INS,INS,Paternal,rs11564722-<b>T</b>,9 x 10-23,,0.311,'-,0.0033 unit increase,[0.0025-0.0041],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,11:2157100,Kidney
1403,INS,INS,Paternal,rs11564722-<b>T</b>,1 x 10-21,,0.2396,'-,0.0038 unit increase,[0.003-0.0046],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008059,11:2157100,Kidney
1401,INS,INS,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Kidney
1418,INS,INS,Paternal,rs7948458-<b>C</b>,4 x 10-16,,NR,'-,0.0245 unit increase,[0.019-0.03],INS-IGF2,Cystatin C levels,cystatin C measurement,GCST90019504,11:2151600,Kidney
1419,INS,INS,Paternal,rs7948458-<b>C</b>,2 x 10-15,,NR,'-,0.024 unit decrease,[0.018-0.03],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2151600,Kidney
1424,INS,INS,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Kidney
1433,INS,INS,Paternal,rs3741205-<b>C</b>,3 x 10-12,,0.3997,'-,7.002 z score increase,NR,"IGF2-AS, INS-IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007876,11:2148654,Kidney
1434,INS,INS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Kidney
1435,INS,INS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Kidney
1442,INS,INS,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Kidney
1454,INS,INS,Paternal,rs7948458-<b>C</b>,5 x 10-17,,NR,'-,0.0253 unit increase,[0.019-0.031],INS-IGF2,Creatinine levels,creatinine measurement,GCST90019502,11:2151600,Kidney
1459,INS,INS-IGF2,Paternal,rs11564722-<b>T</b>,9 x 10-23,,0.311,'-,0.0033 unit increase,[0.0025-0.0041],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008058,11:2157100,Kidney
1460,INS,INS-IGF2,Paternal,rs11564722-<b>T</b>,1 x 10-21,,0.2396,'-,0.0038 unit increase,[0.003-0.0046],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST008059,11:2157100,Kidney
1475,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,4 x 10-16,,NR,'-,0.0245 unit increase,[0.019-0.03],INS-IGF2,Cystatin C levels,cystatin C measurement,GCST90019504,11:2151600,Kidney
1476,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-15,,NR,'-,0.024 unit decrease,[0.018-0.03],INS-IGF2,Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2151600,Kidney
1491,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,9 x 10-14,,NR,'-,0.0213 unit increase,[0.016-0.027],"INS-IGF2, INS",Creatinine levels,creatinine measurement,GCST90019502,11:2159843,Kidney
1492,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,1 x 10-12,,NR,'-,0.0202 unit decrease,[0.015-0.026],"INS-IGF2, INS",Estimated glomerular filtration rate,glomerular filtration rate,GCST90019506,11:2159843,Kidney
1481,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Kidney
1498,INS,INS-IGF2,Paternal,rs3741205-<b>C</b>,3 x 10-12,,0.3997,'-,7.002 z score increase,NR,"IGF2-AS, INS-IGF2",Estimated glomerular filtration rate,glomerular filtration rate,GCST007876,11:2148654,Kidney
1499,INS,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Kidney
1503,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,3 x 10-10,,NR,'-,0.018 unit increase,[0.012-0.024],"INS-IGF2, INS",Urea levels,serum urea measurement,GCST90019525,11:2159843,Kidney
1500,INS,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Kidney
1504,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Kidney
1512,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,5 x 10-17,,NR,'-,0.0253 unit increase,[0.019-0.031],INS-IGF2,Creatinine levels,creatinine measurement,GCST90019502,11:2151600,Kidney
1521,INS,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Kidney
2265,MAGEL2,MAGEL2,Paternal,rs850799-<b>G</b>,5 x 10-8,(Phosphatidylcholine with acyl-alkyl residue sum C42:3),NR,'-,0.285624 unit increase,[0.18-0.39],"NDN, MAGEL2",Serum metabolite concentrations in chronic kidney disease,"chronic kidney disease, serum metabolite measurement",GCST005648,15:23679185,Kidney
2364,MIMT1,MIMT1,Paternal,rs7249211-<b>G</b>,6 x 10-6,(men),0.29,'-,0.104 kg/m2 increase,[0.059-0.149],"MIMT1, AC044792.1",Urate levels in lean individuals,"urate measurement, underweight body mass index status",GCST002830,19:56906546,Kidney
2381,NDN,NDN,Paternal,rs850799-<b>G</b>,5 x 10-8,(Phosphatidylcholine with acyl-alkyl residue sum C42:3),NR,'-,0.285624 unit increase,[0.18-0.39],"NDN, MAGEL2",Serum metabolite concentrations in chronic kidney disease,"chronic kidney disease, serum metabolite measurement",GCST005648,15:23679185,Kidney
158,DLGAP2,DLGAP2,Paternal,rs145923053-<b>T</b>,2 x 10-8,(CTSS),0.02091,'-,0.009234 unit increase,NR,DLGAP2,Protein quantitative trait loci (liver),protein measurement,GCST011427,8:826793,Liver
159,DLGAP2,DLGAP2,Paternal,rs145923053-<b>T</b>,1 x 10-9,(GCN1),0.02091,'-,0.02939 unit increase,NR,DLGAP2,Protein quantitative trait loci (liver),protein measurement,GCST011427,8:826793,Liver
160,DLGAP2,DLGAP2,Paternal,rs145923053-<b>T</b>,2 x 10-8,(GSR),0.02091,'-,0.05072 unit increase,NR,DLGAP2,Protein quantitative trait loci (liver),protein measurement,GCST011427,8:826793,Liver
161,DLGAP2,DLGAP2,Paternal,rs145923053-<b>T</b>,1 x 10-10,(ACO2),0.02091,'-,0.458 unit increase,NR,DLGAP2,Protein quantitative trait loci (liver),protein measurement,GCST011427,8:826793,Liver
310,DNMT1,DNMT1,Paternal,rs10409243-<b>C</b>,1 x 10-16,,0.4,'-,8.29 z-score increase,'-,"S1PR2, DNMT1",Alanine aminotransferase levels,serum alanine aminotransferase measurement,GCST90011898,19:10222312,Liver
314,DNMT1,DNMT1,Paternal,rs10409243-<b>C</b>,2 x 10-8,,0.4,'-,5.59 z-score increase,'-,"S1PR2, DNMT1",Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,19:10222312,Liver
335,DSCAM,DSCAM,Paternal,rs41395652-<b>T</b>,1 x 10-8,(TKT),0.03659,'-,0.4395 unit increase,NR,DSCAM,Protein quantitative trait loci (liver),protein measurement,GCST011427,21:40353698,Liver
336,DSCAM,DSCAM,Paternal,rs56076602-<b>G</b>,9 x 10-6,,0.07774,2.7811,'-,NR,DSCAM,Thrombosis in response to liver transplant,"coronary thrombosis, GM11992",GCST011434,21:40679234,Liver
375,ERAP2,ERAP2,Paternal,rs3096168-<b>G</b>,8 x 10-12,,0.5,'-,6.84 z-score increase,'-,"ERAP2, AC009126.1",Aspartate aminotransferase levels,aspartate aminotransferase measurement,GCST90011899,5:96898508,Liver
602,GLIS3,GLIS3,Paternal,rs7043265-<b>?</b>,2 x 10-8,,0.2297,'-,0.007479 unit decrease,'-,GLIS3,Fibrosis-4 index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011736,9:4292012,Liver
603,GLIS3,GLIS3,Paternal,rs7043265-<b>?</b>,6 x 10-6,,0.2297,'-,0.007436 unit decrease,'-,GLIS3,Aspartate aminotransferase platelet ratio index in high alcohol intake,"liver fibrosis measurement, alcohol abuse",GCST90011735,9:4292012,Liver
882,HECW1,HECW1,Paternal,rs58394495-<b>T</b>,2 x 10-8,(CORO1B),0.01916,'-,0.1931 unit increase,NR,HECW1,Protein quantitative trait loci (liver),protein measurement,GCST011427,7:43330766,Liver
2385,NPAP1,NPAP1,Paternal,rs36032407-<b>A</b>,2 x 10-8,(PLD3),0.03659,'-,0.01542 unit increase,NR,"NPAP1, PWRN1, AC090983.2",Protein quantitative trait loci (liver),protein measurement,GCST011427,15:24678136,Liver
2875,SNRPN,SNRPN,Paternal,rs2201840-<b>?</b>,3 x 10-6,,NR,'-,'-,'-,"SNRPN, AC090983.2",Aspartate aminotransferase levels,aspartate aminotransferase measurement,GCST008174,15:24899980,Liver
2881,ST8SIA1,ST8SIA1,Paternal,rs2216228-<b>G</b>,4 x 10-6,,0.18,'-,0.45 unit increase,[NR],ST8SIA1,Non-alcoholic fatty liver disease histology (lobular),"non-alcoholic fatty liver disease, cirrhosis of liver",GCST000766,12:22212901,Liver
3204,ZFP90,ZFP90,Paternal,rs698718-<b>A</b>,3 x 10-11,,0.225108,'-,0.834304 unit increase,[0.6-1.07],"ZFP90, RPL35AP33",Liver fibrosis in non-alcoholic fatty liver disease,"non-alcoholic fatty liver disease, Hepatic fibrosis",GCST008469,16:68526282,Liver
3838,FAM50B,FAM50B,Paternal,rs75215148-<b>A</b>,2 x 10-8,(RAB14),0.0122,'-,0.02373 unit increase,NR,"TDGF1P4, FAM50B",Protein quantitative trait loci (liver),protein measurement,GCST011427,6:3906043,Liver
253,DLK1,DLK1,Paternal,rs72698726-<b>?</b>,7 x 10-6,,NR,'-,0.05109 unit decrease,[0.029-0.073],"AL132711.1, DLK1",Parental longevity (combined parental age at death),parental longevity,GCST003394,14:100722281,Longevity
497,GLI3,GLI3,Paternal,rs2049622-<b>?</b>,9 x 10-6,(EA),0.51,1.15,'-,[1.08-1.2],GLI3,Age-related macular degeneration,age-related macular degeneration,GCST001814,7:42136683,Longevity
185,DLGAP2,DLGAP2,Paternal,rs139288166-<b>?</b>,7 x 10-8,,0.03,4.3,'-,[2.53-7.31],DLGAP2,Toxicity response to radiotherapy in prostate cancer (rectal bleeding) (time to event),"Hematochezia, response to radiation, prostate carcinoma",GCST008381,8:755922,Male Reproductive System
254,DLK1,DLK1,Paternal,rs12893790-<b>G</b>,1 x 10-9,,0.815662,'-,0.0209852 unit increase,[0.014-0.028],"AL132711.1, DLK1",Total testosterone levels,testosterone measurement,GCST90012112,14:100712467,Male Reproductive System
604,GLIS3,GLIS3,Paternal,rs12336359-<b>C</b>,2 x 10-9,,0.405711,'-,0.0186014 unit increase,[0.013-0.025],GLIS3,Total testosterone levels,testosterone measurement,GCST90012113,9:4129657,Male Reproductive System
605,GLIS3,GLIS3,Paternal,rs34706136-<b>TG</b>,3 x 10-8,,0.351047,'-,0.0117008 unit increase,[0.0076-0.0158],GLIS3,Bioavailable testosterone levels,testosterone measurement,GCST90012104,9:4294708,Male Reproductive System
1268,IGF2,IGF2,Paternal,rs11564722-<b>T</b>,8 x 10-9,,0.239615,'-,0.00868151 unit increase,[0.0057-0.0117],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012114,11:2157100,Male Reproductive System
1269,IGF2,IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-11,,0.239755,'-,0.023258 unit increase,[0.016-0.03],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012113,11:2158635,Male Reproductive System
1272,IGF2,IGF2,Paternal,rs11602347-<b>G</b>,2 x 10-10,,NR,'-,0.0164 unit decrease,[0.011-0.021],INS-IGF2,Testosterone levels,testosterone measurement,GCST90019520,11:2155622,Male Reproductive System
1347,IGF2,INS-IGF2,Paternal,rs11564722-<b>T</b>,8 x 10-9,,0.239615,'-,0.00868151 unit increase,[0.0057-0.0117],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012114,11:2157100,Male Reproductive System
1348,IGF2,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-11,,0.239755,'-,0.023258 unit increase,[0.016-0.03],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012113,11:2158635,Male Reproductive System
1351,IGF2,INS-IGF2,Paternal,rs11602347-<b>G</b>,2 x 10-10,,NR,'-,0.0164 unit decrease,[0.011-0.021],INS-IGF2,Testosterone levels,testosterone measurement,GCST90019520,11:2155622,Male Reproductive System
1421,INS,INS,Paternal,rs11564722-<b>T</b>,8 x 10-9,,0.239615,'-,0.00868151 unit increase,[0.0057-0.0117],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012114,11:2157100,Male Reproductive System
1422,INS,INS,Paternal,rs775181992-<b>A</b>,1 x 10-11,,0.239755,'-,0.023258 unit increase,[0.016-0.03],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012113,11:2158635,Male Reproductive System
1425,INS,INS,Paternal,rs11602347-<b>G</b>,2 x 10-10,,NR,'-,0.0164 unit decrease,[0.011-0.021],INS-IGF2,Testosterone levels,testosterone measurement,GCST90019520,11:2155622,Male Reproductive System
1478,INS,INS-IGF2,Paternal,rs11564722-<b>T</b>,8 x 10-9,,0.239615,'-,0.00868151 unit increase,[0.0057-0.0117],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012114,11:2157100,Male Reproductive System
1479,INS,INS-IGF2,Paternal,rs775181992-<b>A</b>,1 x 10-11,,0.239755,'-,0.023258 unit increase,[0.016-0.03],INS-IGF2,Total testosterone levels,testosterone measurement,GCST90012113,11:2158635,Male Reproductive System
1482,INS,INS-IGF2,Paternal,rs11602347-<b>G</b>,2 x 10-10,,NR,'-,0.0164 unit decrease,[0.011-0.021],INS-IGF2,Testosterone levels,testosterone measurement,GCST90019520,11:2155622,Male Reproductive System
2167,LIN28B,LIN28B,Paternal,rs9391253-<b>?</b>,1 x 10-23,,NR,'-,0.058 unit increase,[0.046-0.069],LIN28B-AS1,Age at voice drop,age at voice drop,GCST003994,6:104919741,Male Reproductive System
2168,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,1 x 10-20,,NR,'-,0.0102481 years increase,[0.0081-0.0124],LIN28B-AS1,Male puberty timing (late vs. average onset facial hair),puberty onset measurement,GCST90012085,6:104916546,Male Reproductive System
2169,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,3 x 10-16,,NR,'-,0.00646028 years increase,[0.0049-0.008],LIN28B-AS1,Male puberty timing (late vs. average onset voice breaking),puberty onset measurement,GCST90012087,6:104916546,Male Reproductive System
2170,LIN28B,LIN28B,Paternal,rs9322822-<b>C</b>,2 x 10-52,,0.6785,'-,0.0487092 unit increase,[0.042-0.055],LIN28B-AS1,Bioavailable testosterone levels,testosterone measurement,GCST90012103,6:104921723,Male Reproductive System
2171,LIN28B,LIN28B,Paternal,rs9322822-<b>C</b>,9 x 10-27,,0.678953,'-,0.023054 unit increase,[0.019-0.027],LIN28B-AS1,Bioavailable testosterone levels,testosterone measurement,GCST90012104,6:104921723,Male Reproductive System
2172,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,3 x 10-52,,NR,'-,0.049468596 years increase,[0.043-0.056],LIN28B-AS1,Male puberty timing (age at voice breaking MTAG),puberty onset measurement,GCST90012088,6:104916546,Male Reproductive System
2173,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,7 x 10-13,,NR,'-,0.004984 years decrease,[0.0036-0.0064],LIN28B-AS1,Male puberty timing (early vs. average onset voice breaking),puberty onset measurement,GCST90012086,6:104916546,Male Reproductive System
2174,LIN28B,LIN28B,Paternal,rs11156429-<b>T</b>,1 x 10-15,,NR,'-,0.00712223 years decrease,[0.0054-0.0089],LIN28B-AS1,Male puberty timing (early vs. average onset facial hair),puberty onset measurement,GCST90012084,6:104916546,Male Reproductive System
2175,LIN28B,LIN28B,Paternal,rs7759938-<b>T</b>,2 x 10-13,,0.677632,'-,0.00999899 unit increase,[0.0073-0.0127],LIN28B-AS1,Total testosterone levels,testosterone measurement,GCST90012114,6:104931079,Male Reproductive System
2176,LIN28B,LIN28B,Paternal,rs1933801-<b>T</b>,8 x 10-33,,0.678113,'-,0.0375388 unit increase,[0.031-0.044],LIN28B-AS1,Total testosterone levels,testosterone measurement,GCST90012113,6:104917850,Male Reproductive System
2248,LIN28B,LIN28B-AS1,Paternal,rs9391253-<b>?</b>,1 x 10-23,,NR,'-,0.058 unit increase,[0.046-0.069],LIN28B-AS1,Age at voice drop,age at voice drop,GCST003994,6:104919741,Male Reproductive System
2249,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,1 x 10-20,,NR,'-,0.0102481 years increase,[0.0081-0.0124],LIN28B-AS1,Male puberty timing (late vs. average onset facial hair),puberty onset measurement,GCST90012085,6:104916546,Male Reproductive System
2250,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,3 x 10-16,,NR,'-,0.00646028 years increase,[0.0049-0.008],LIN28B-AS1,Male puberty timing (late vs. average onset voice breaking),puberty onset measurement,GCST90012087,6:104916546,Male Reproductive System
2251,LIN28B,LIN28B-AS1,Paternal,rs9322822-<b>C</b>,2 x 10-52,,0.6785,'-,0.0487092 unit increase,[0.042-0.055],LIN28B-AS1,Bioavailable testosterone levels,testosterone measurement,GCST90012103,6:104921723,Male Reproductive System
2252,LIN28B,LIN28B-AS1,Paternal,rs9322822-<b>C</b>,9 x 10-27,,0.678953,'-,0.023054 unit increase,[0.019-0.027],LIN28B-AS1,Bioavailable testosterone levels,testosterone measurement,GCST90012104,6:104921723,Male Reproductive System
2253,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,3 x 10-52,,NR,'-,0.049468596 years increase,[0.043-0.056],LIN28B-AS1,Male puberty timing (age at voice breaking MTAG),puberty onset measurement,GCST90012088,6:104916546,Male Reproductive System
2254,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,7 x 10-13,,NR,'-,0.004984 years decrease,[0.0036-0.0064],LIN28B-AS1,Male puberty timing (early vs. average onset voice breaking),puberty onset measurement,GCST90012086,6:104916546,Male Reproductive System
2255,LIN28B,LIN28B-AS1,Paternal,rs11156429-<b>T</b>,1 x 10-15,,NR,'-,0.00712223 years decrease,[0.0054-0.0089],LIN28B-AS1,Male puberty timing (early vs. average onset facial hair),puberty onset measurement,GCST90012084,6:104916546,Male Reproductive System
2256,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>T</b>,2 x 10-13,,0.677632,'-,0.00999899 unit increase,[0.0073-0.0127],LIN28B-AS1,Total testosterone levels,testosterone measurement,GCST90012114,6:104931079,Male Reproductive System
2257,LIN28B,LIN28B-AS1,Paternal,rs1933801-<b>T</b>,8 x 10-33,,0.678113,'-,0.0375388 unit increase,[0.031-0.044],LIN28B-AS1,Total testosterone levels,testosterone measurement,GCST90012113,6:104917850,Male Reproductive System
2559,PLAGL1,PLAGL1,Paternal,rs9399469-<b>A</b>,3 x 10-14,,0.622027,'-,0.0198083 unit increase,[0.015-0.025],PLAGL1,Bioavailable testosterone levels,testosterone measurement,GCST90012102,6:143997392,Male Reproductive System
3094,WT1,WTAP,Paternal,rs11752345-<b>T</b>,1 x 10-7,,NR,1.0968521,'-,NR,"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST90011808,6:159727316,Male Reproductive System
3095,WT1,WTAP,Paternal,rs963800-<b>C</b>,3 x 10-16,,NR,1.064,'-,[1.05-1.08],"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST011049,6:159729247,Male Reproductive System
3096,WT1,WTAP,Paternal,rs963800-<b>C</b>,6 x 10-6,,0.599,1.087,'-,[1.05-1.13],"SOD2, WTAP",Prostate cancer,prostate carcinoma,GCST011046,6:159729247,Male Reproductive System
3219,ZIM2,ZIM2,Paternal,rs7258285-<b>G</b>,3 x 10-6,,0.7,1.66,'-,[1.34-2.06],"AC006115.2, ZIM2-AS1",Prostate cancer,prostate carcinoma,GCST005786,19:56687205,Male Reproductive System
3234,ZIM2,ZIM2-AS1,Paternal,rs7258285-<b>G</b>,3 x 10-6,,0.7,1.66,'-,[1.34-2.06],"AC006115.2, ZIM2-AS1",Prostate cancer,prostate carcinoma,GCST005786,19:56687205,Male Reproductive System
182,DLGAP2,DLGAP2,Paternal,rs80058639-<b>?</b>,9 x 10-6,(MLM),NR,'-,'-,'-,DLGAP2,Response to paliperidone in schizophrenia (Multivariate),"schizophrenia, response to paliperidone, schizophrenia symptom severity measurement",GCST004043,8:1214070,Mental or Behavioural Disorder
187,DLGAP2,DLGAP2,Paternal,rs79367487-<b>A</b>,4 x 10-8,,0.19970534,'-,0.006329809 unit increase,[0.0041-0.0086],DLGAP2,Well-being spectrum (multivariate analysis),wellbeing measurement,GCST007341,8:1085058,Mental or Behavioural Disorder
188,DLGAP2,DLGAP2,Paternal,rs12681288-<b>A</b>,2 x 10-6,,NR,1.05,'-,[NR],DLGAP2,Schizophrenia,schizophrenia,GCST003048,8:1085152,Mental or Behavioural Disorder
189,DLGAP2,DLGAP2,Paternal,rs6988649-<b>T</b>,4 x 10-8,,0.202385001,'-,0.0064693824 unit increase,[0.0042-0.0088],DLGAP2,Depressive symptoms,depressive symptom measurement,GCST007340,8:1085729,Mental or Behavioural Disorder
190,DLGAP2,DLGAP2,Paternal,rs7818243-<b>C</b>,4 x 10-6,,0.28,'-,0.22 unit increase,[0.12-0.32],DLGAP2,Response to cognitive-behavioural therapy in anxiety disorder,"anxiety disorder, cognitive behavioural therapy",GCST008360,8:1181480,Mental or Behavioural Disorder
191,DLGAP2,DLGAP2,Paternal,rs3812479-<b>A</b>,6 x 10-9,,NR,'-,5.827 z score increase,'-,DLGAP2,Neuroticism,neuroticism measurement,GCST006476,8:1547781,Mental or Behavioural Disorder
192,DLGAP2,DLGAP2,Paternal,rs1971655-<b>T</b>,2 x 10-8,,0.492095,'-,5.6 z score increase,'-,"DLGAP2-AS1, DLGAP2",Feeling miserable,feeling miserable measurement,GCST006943,8:1571306,Mental or Behavioural Disorder
193,DLGAP2,DLGAP2,Paternal,rs7014992-<b>A</b>,2 x 10-8,,NR,'-,5.59 z score increase,'-,"DLGAP2, DLGAP2-AS1",Neuroticism,neuroticism measurement,GCST006476,8:1583881,Mental or Behavioural Disorder
194,DLGAP2,DLGAP2,Paternal,rs4875884-<b>T</b>,4 x 10-8,,NR,'-,5.486 z score decrease,'-,DLGAP2,Neuroticism,neuroticism measurement,GCST006476,8:1640059,Mental or Behavioural Disorder
195,DLGAP2,DLGAP2,Paternal,rs59811079-<b>G</b>,3 x 10-6,,0.716,1.0640675,'-,'-,DLGAP2,Bipolar disorder,bipolar disorder,GCST008103,8:1677566,Mental or Behavioural Disorder
197,DLGAP2,DLGAP2-AS1,Paternal,rs1971655-<b>T</b>,2 x 10-8,,0.492095,'-,5.6 z score increase,'-,"DLGAP2-AS1, DLGAP2",Feeling miserable,feeling miserable measurement,GCST006943,8:1571306,Mental or Behavioural Disorder
198,DLGAP2,DLGAP2-AS1,Paternal,rs7014992-<b>A</b>,2 x 10-8,,NR,'-,5.59 z score increase,'-,"DLGAP2, DLGAP2-AS1",Neuroticism,neuroticism measurement,GCST006476,8:1583881,Mental or Behavioural Disorder
257,DLK1,DLK1,Paternal,rs56011271-<b>T</b>,6 x 10-6,,0.9075,'-,0.833 unit increase,[0.47-1.19],"AL132711.1, DLK1",Nicotine dependence and major depression (severity of comorbidity),"nicotine dependence symptom count, depressive symptom measurement",GCST006631,14:100701395,Mental or Behavioural Disorder
258,DLK1,DLK1,Paternal,rs17099623-<b>C</b>,7 x 10-11,,0.212,'-,0.00860089 unit increase,[0.006-0.0112],"DLK1, AL132711.1",Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,14:100706787,Mental or Behavioural Disorder
259,DLK1,DLK1,Paternal,rs12881760-<b>C</b>,3 x 10-8,,0.649,'-,0.00849798 unit increase,[0.0055-0.0115],"AL132711.1, DLK1",Age of smoking initiation (MTAG),smoking initiation,GCST007462,14:100709998,Mental or Behavioural Disorder
348,DSCAM,DSCAM,Paternal,rs1734920-<b>?</b>,3 x 10-6,(females),'-,'-,'-,'-,"PCP4, DSCAM",Smoking initiation,smoking initiation,GCST002396,21:39972984,Mental or Behavioural Disorder
349,DSCAM,DSCAM,Paternal,rs2410205-<b>T</b>,2 x 10-8,,NR,'-,0.0076973 unit decrease,[0.005-0.0104],DSCAM,Worry/vulnerability (special factor of neuroticism),worry measurement,GCST007708,21:40045188,Mental or Behavioural Disorder
350,DSCAM,DSCAM,Paternal,rs2205129-<b>A</b>,1 x 10-8,,0.316141,'-,5.67 z score decrease,'-,DSCAM,Feeling nervous,feeling nervous measurement,GCST006948,21:40092507,Mental or Behavioural Disorder
351,DSCAM,DSCAM,Paternal,rs13051169-<b>T</b>,2 x 10-7,,NR,'-,1.72923 unit increase,[1.08-2.38],DSCAM,Systemising,systemising measurement,GCST008889,21:40297373,Mental or Behavioural Disorder
352,DSCAM,DSCAM,Paternal,rs9980603-<b>?</b>,3 x 10-7,(Dichotomous),0.58,1.53,'-,[NR],DSCAM,Anxiety in major depressive disorder,"unipolar depression, anxiety",GCST002202,21:40514656,Mental or Behavioural Disorder
418,GDAP1L1,GDAP1L1,Paternal,rs190457471-<b>A</b>,5 x 10-6,(liability model),0.004,'-,0.68 unit increase,[0.39-0.97],"OSER1-DT, GDAP1L1",Late-onset Alzheimer's disease,late-onset Alzheimers disease,GCST003815,20:44233181,Mental or Behavioural Disorder
420,GDAP1L1,GDAP1L1,Paternal,rs11907319-<b>T</b>,9 x 10-6,,0.8099,'-,14.3351 unit increase,[8.45-20.22],"GDAP1L1, FITM2",Response to ketamine in bipolar disorder or major depression (dissociation effects),"unipolar depression, response to ketamine, dissociation measurement, bipolar disorder",GCST007317,20:44294659,Mental or Behavioural Disorder
508,GLI3,GLI3,Paternal,rs1468452-<b>C</b>,9 x 10-6,(AA),NR,'-,0.129278 unit decrease,[0.072-0.186],GLI3,Maximum habitual alcohol consumption,alcohol consumption measurement,GCST008675,7:42214902,Mental or Behavioural Disorder
522,GLIS3,GLIS3,Paternal,rs10758593-<b>G</b>,5 x 10-9,,0.6011,1.0362694,'-,[1.02-1.05],GLIS3,Insomnia,insomnia measurement,GCST007988,9:4292083,Mental or Behavioural Disorder
619,GLIS3,GLIS3,Paternal,rs514716-<b>G</b>,1 x 10-8,(tau),NR,'-,0.071 unit decrease,[NR],GLIS3,Alzheimer's disease biomarkers,"Alzheimer's disease, t-tau measurement",GCST001951,9:3929424,Mental or Behavioural Disorder
620,GLIS3,GLIS3,Paternal,rs514716-<b>G</b>,3 x 10-9,(ptau),NR,'-,0.072 unit decrease,[NR],GLIS3,Alzheimer's disease biomarkers,"Alzheimer's disease, p-tau measurement",GCST001951,9:3929424,Mental or Behavioural Disorder
639,GLIS3,GLIS3,Paternal,rs13301469-<b>C</b>,8 x 10-7,,NR,1.08,'-,[NR],GLIS3,Schizophrenia,schizophrenia,GCST003048,9:3911353,Mental or Behavioural Disorder
640,GLIS3,GLIS3,Paternal,rs10974344-<b>T</b>,1 x 10-8,,0.393446973,'-,0.006813693 unit decrease,[0.0045-0.0091],GLIS3,Positive affect,wellbeing measurement,GCST007338,9:4140608,Mental or Behavioural Disorder
641,GLIS3,GLIS3,Paternal,rs10974344-<b>T</b>,7 x 10-9,,0.393446973,'-,0.008891059 unit decrease,[0.0059-0.0119],GLIS3,Neuroticism,neuroticism measurement,GCST007339,9:4140608,Mental or Behavioural Disorder
642,GLIS3,GLIS3,Paternal,rs10814852-<b>T</b>,2 x 10-8,,0.396711492,'-,0.005530694 unit decrease,[0.0036-0.0075],GLIS3,Depressive symptoms,depressive symptom measurement,GCST007340,9:4144772,Mental or Behavioural Disorder
643,GLIS3,GLIS3,Paternal,rs9298995-<b>A</b>,1 x 10-6,,0.406,'-,0.016965462 unit decrease,[0.01-0.024],GLIS3,Neuroticism,neuroticism measurement,GCST003770,9:4145340,Mental or Behavioural Disorder
644,GLIS3,GLIS3,Paternal,rs9298995-<b>A</b>,6 x 10-10,,0.406882458,'-,0.0057956423 unit decrease,[0.004-0.0076],GLIS3,Well-being spectrum (multivariate analysis),wellbeing measurement,GCST007341,9:4145340,Mental or Behavioural Disorder
645,GLIS3,GLIS3,Paternal,rs9298995-<b>?</b>,7 x 10-9,,NR,'-,'-,'-,GLIS3,Neuroticism,neuroticism measurement,GCST007084,9:4145340,Mental or Behavioural Disorder
646,GLIS3,GLIS3,Paternal,rs9298995-<b>A</b>,5 x 10-13,,0.39833,'-,7.218 z score decrease,'-,GLIS3,Neuroticism,neuroticism measurement,GCST005232,9:4145340,Mental or Behavioural Disorder
647,GLIS3,GLIS3,Paternal,rs13284170-<b>A</b>,5 x 10-9,,NR,'-,5.859 z score increase,'-,GLIS3,Neuroticism,neuroticism measurement,GCST006476,9:4145560,Mental or Behavioural Disorder
648,GLIS3,GLIS3,Paternal,rs13284170-<b>A</b>,8 x 10-9,,0.283182,'-,5.76 z score increase,'-,GLIS3,Neurociticism,neuroticism measurement,GCST006940,9:4145560,Mental or Behavioural Disorder
649,GLIS3,GLIS3,Paternal,rs13284170-<b>A</b>,2 x 10-10,,NR,'-,0.01649 unit increase,NR,GLIS3,Sensitivity to environmental stress and adversity,neuroticism measurement,GCST010123,9:4145560,Mental or Behavioural Disorder
650,GLIS3,GLIS3,Paternal,rs13299289-<b>T</b>,8 x 10-6,,0.251453,'-,4.47831 z score decrease,[NR],GLIS3,Eudaimonic well-being,wellbeing measurement,GCST006635,9:4145587,Mental or Behavioural Disorder
651,GLIS3,GLIS3,Paternal,rs2380937-<b>T</b>,1 x 10-9,,NR,'-,6.116 z score increase,'-,GLIS3,Neuroticism,neuroticism measurement,GCST006476,9:4145781,Mental or Behavioural Disorder
652,GLIS3,GLIS3,Paternal,rs2380937-<b>C</b>,5 x 10-9,,0.4011,'-,0.01119 unit decrease,[0.0074-0.0149],GLIS3,Neuroticism,neurotic disorder,GCST010017,9:4145781,Mental or Behavioural Disorder
653,GLIS3,GLIS3,Paternal,rs12348139-<b>T</b>,1 x 10-6,,'-,'-,0.05 unit decrease,[0.03-0.07],GLIS3,Nicotine dependence,nicotine dependence,GCST004294,9:4232743,Mental or Behavioural Disorder
775,DIRAS3,GNG12-AS1,Paternal,rs11209175-<b>C</b>,2 x 10-9,,NR,'-,0.01453 unit increase,[0.0098-0.0193],GNG12-AS1,Depressed affect,"unipolar depression, mood disorder",GCST006475,1:67909145,Mental or Behavioural Disorder
776,DIRAS3,GNG12-AS1,Paternal,rs11209175-<b>T</b>,9 x 10-10,,0.372461,'-,6.12 z score decrease,'-,GNG12-AS1,Feeling fed-up,"feeling ""fed-up"" measurement",GCST006947,1:67909145,Mental or Behavioural Disorder
785,GPR1,GPR1,Paternal,rs2058710-<b>A</b>,9 x 10-6,,NR,1.24,'-,[NR],GPR1-AS,Bipolar disorder and schizophrenia,"schizophrenia, bipolar disorder",GCST001567,2:206257058,Mental or Behavioural Disorder
788,GPR1,GPR1-AS,Paternal,rs2058710-<b>A</b>,9 x 10-6,,NR,1.24,'-,[NR],GPR1-AS,Bipolar disorder and schizophrenia,"schizophrenia, bipolar disorder",GCST001567,2:206257058,Mental or Behavioural Disorder
884,HECW1,HECW1,Paternal,rs17172199-<b>?</b>,1 x 10-6,,0.08,'-,0.28 unit decrease,'-,HECW1,Alzheimer's disease (cognitive decline),Alzheimer's disease,GCST001915,7:43337677,Mental or Behavioural Disorder
1528,IRAIN,IRAIN,Paternal,rs7402939-<b>C</b>,5 x 10-9,,0.624,1.0362694,'-,[1.02-1.05],"IRAIN, FAM169B",Insomnia,insomnia measurement,GCST007988,15:98640647,Mental or Behavioural Disorder
2145,LIN28B,LIN28B,Paternal,rs314280-<b>G</b>,1 x 10-9,,0.54824,1.01,'-,[1.00-1.03],LIN28B,Insomnia symptoms (never/rarely vs. usually),insomnia measurement,GCST007388,6:104952962,Mental or Behavioural Disorder
2146,LIN28B,LIN28B,Paternal,rs314281-<b>C</b>,6 x 10-13,,0.5469,1.0438414,'-,[1.03-1.06],LIN28B,Insomnia,insomnia measurement,GCST007988,6:104952730,Mental or Behavioural Disorder
2147,LIN28B,LIN28B,Paternal,rs13197753-<b>C</b>,4 x 10-10,(Male),0.5468,1.063,'-,[1.04-1.08],LIN28B-AS1,Insomnia,insomnia measurement,GCST007988,6:104924810,Mental or Behavioural Disorder
2148,LIN28B,LIN28B,Paternal,rs370771-<b>T</b>,1 x 10-11,,0.4692,'-,'-,'-,LIN28B,Insomnia,insomnia,GCST010097,6:104950211,Mental or Behavioural Disorder
2177,LIN28B,LIN28B,Paternal,rs314277-<b>?</b>,5 x 10-6,,'-,'-,'-,'-,LIN28B,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),"Alzheimer's disease, cognitive decline measurement, Cognitive impairment",GCST004253,6:104959787,Mental or Behavioural Disorder
2185,LIN28B,LIN28B,Paternal,rs314280-<b>G</b>,5 x 10-6,,0.545072,1.066,'-,[1.04-1.09],LIN28B,Trauma exposure,trauma exposure measurement,GCST009982,6:104952962,Mental or Behavioural Disorder
2186,LIN28B,LIN28B,Paternal,rs1475120-<b>G</b>,4 x 10-9,,0.452458,'-,0.0292 unit decrease,[0.017-0.041],LIN28B,Major depressive disorder,unipolar depression,GCST006041,6:104942078,Mental or Behavioural Disorder
2187,LIN28B,LIN28B,Paternal,rs314262-<b>A</b>,4 x 10-8,,0.54053353,'-,0.005054806 unit increase,[0.0032-0.0069],LIN28B,Well-being spectrum (multivariate analysis),wellbeing measurement,GCST007341,6:104946746,Mental or Behavioural Disorder
2188,LIN28B,LIN28B,Paternal,rs314272-<b>G</b>,3 x 10-7,(EA),NR,1.0570824,'-,[1.04-1.08],LIN28B,Schizophrenia,schizophrenia,GCST007201,6:105014129,Mental or Behavioural Disorder
2189,LIN28B,LIN28B,Paternal,rs1933802-<b>G</b>,1 x 10-19,,0.5464,1.0204082,'-,[1.02-1.02],LIN28B-AS1,Depression,unipolar depression,GCST007342,6:104918016,Mental or Behavioural Disorder
2190,LIN28B,LIN28B,Paternal,rs11758569-<b>A</b>,6 x 10-7,,0.156,'-,0.00748469 unit decrease,[0.0046-0.0104],LIN28B-AS1,Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,6:104910289,Mental or Behavioural Disorder
2191,LIN28B,LIN28B,Paternal,rs12526038-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,LIN28B-AS1,Smoking status,smoking status measurement,GCST007085,6:104898342,Mental or Behavioural Disorder
2192,LIN28B,LIN28B,Paternal,rs160593-<b>?</b>,3 x 10-10,,NR,1.0564348,'-,[1.04-1.07],LIN28B,Schizophrenia,schizophrenia,GCST009337,6:105018457,Mental or Behavioural Disorder
2193,LIN28B,LIN28B,Paternal,rs314283-<b>C</b>,2 x 10-8,,0.5639,'-,0.0121 unit increase,[0.008-0.0162],LIN28B,Depressive symptoms (MTAG),depressive symptom measurement,GCST005323,6:104991461,Mental or Behavioural Disorder
2194,LIN28B,LIN28B,Paternal,rs314272-<b>G</b>,1 x 10-6,,NR,1.0526316,'-,[NR],LIN28B,Schizophrenia,schizophrenia,GCST003048,6:105014129,Mental or Behavioural Disorder
2195,LIN28B,LIN28B,Paternal,rs160593-<b>G</b>,8 x 10-9,,NR,1.0559661,'-,[1.04-1.07],LIN28B,Schizophrenia,schizophrenia,GCST004946,6:105018457,Mental or Behavioural Disorder
2196,LIN28B,LIN28B,Paternal,rs314262-<b>A</b>,4 x 10-8,,0.54053353,'-,0.008068154 unit increase,[0.0052-0.011],LIN28B,Neuroticism,neuroticism measurement,GCST007339,6:104946746,Mental or Behavioural Disorder
2197,LIN28B,LIN28B,Paternal,rs314262-<b>A</b>,4 x 10-8,,0.54053353,'-,0.0051637557 unit increase,[0.0033-0.007],LIN28B,Depressive symptoms,depressive symptom measurement,GCST007340,6:104946746,Mental or Behavioural Disorder
2198,LIN28B,LIN28B,Paternal,rs160593-<b>G</b>,2 x 10-9,,NR,1.059322,'-,[1.04-1.08],LIN28B,Schizophrenia,schizophrenia,GCST007201,6:105018457,Mental or Behavioural Disorder
2199,LIN28B,LIN28B,Paternal,rs314289-<b>C</b>,4 x 10-8,,NR,'-,0.01296 unit decrease,NR,LIN28B,Sensitivity to environmental stress and adversity,neuroticism measurement,GCST010123,6:104983059,Mental or Behavioural Disorder
2200,LIN28B,LIN28B,Paternal,rs12528131-<b>A</b>,1 x 10-10,,0.4826,'-,6.42 z score decrease,'-,"LIN28B, LIN28B-AS1",Feeling guilty,guilt measurement,GCST006945,6:104941229,Mental or Behavioural Disorder
2201,LIN28B,LIN28B,Paternal,rs1933802-<b>G</b>,1 x 10-8,,NR,1.0204082,'-,'-,LIN28B-AS1,Bipolar disorder or major depressive disorder,"unipolar depression, bipolar disorder",GCST010416,6:104918016,Mental or Behavioural Disorder
2237,LIN28B,LIN28B-AS1,Paternal,rs13197753-<b>C</b>,4 x 10-10,(Male),0.5468,1.063,'-,[1.04-1.08],LIN28B-AS1,Insomnia,insomnia measurement,GCST007988,6:104924810,Mental or Behavioural Disorder
2258,LIN28B,LIN28B-AS1,Paternal,rs1933802-<b>G</b>,1 x 10-19,,0.5464,1.0204082,'-,[1.02-1.02],LIN28B-AS1,Depression,unipolar depression,GCST007342,6:104918016,Mental or Behavioural Disorder
2259,LIN28B,LIN28B-AS1,Paternal,rs11758569-<b>A</b>,6 x 10-7,,0.156,'-,0.00748469 unit decrease,[0.0046-0.0104],LIN28B-AS1,Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,6:104910289,Mental or Behavioural Disorder
2260,LIN28B,LIN28B-AS1,Paternal,rs12526038-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,LIN28B-AS1,Smoking status,smoking status measurement,GCST007085,6:104898342,Mental or Behavioural Disorder
2261,LIN28B,LIN28B-AS1,Paternal,rs1933802-<b>G</b>,1 x 10-8,,NR,1.0204082,'-,'-,LIN28B-AS1,Bipolar disorder or major depressive disorder,"unipolar depression, bipolar disorder",GCST010416,6:104918016,Mental or Behavioural Disorder
2262,LIN28B,LIN28B-AS1,Paternal,rs12528131-<b>A</b>,1 x 10-10,,0.4826,'-,6.42 z score decrease,'-,"LIN28B, LIN28B-AS1",Feeling guilty,guilt measurement,GCST006945,6:104941229,Mental or Behavioural Disorder
2530,WT1,PAWR,Paternal,rs7297018-<b>A</b>,4 x 10-6,,0.19,'-,'-,'-,PAWR,Attention deficit hyperactivity disorder and conduct disorder,"attention deficit hyperactivity disorder, conduct disorder",GCST000253,12:79668450,Mental or Behavioural Disorder
2671,RTL1,RTL1,Paternal,rs2180386-<b>A</b>,7 x 10-6,,0.38,'-,0.21 unit decrease,[NR],"RTL1, MEG8, AL117190.1",Developmental language disorder (linguistic errors),"linguistic error measurement, specific language impairment",GCST003397,14:100898928,Mental or Behavioural Disorder
2675,SGCE,SGCE,Paternal,rs1357318-<b>?</b>,1 x 10-8,,NR,1.06599,'-,[1.04-1.09],SGCE,Schizophrenia,schizophrenia,GCST009337,7:94638550,Mental or Behavioural Disorder
2884,ST8SIA1,ST8SIA1,Paternal,rs61921372-<b>C</b>,9 x 10-9,,0.571,'-,0.00649043 unit increase,[0.0043-0.0087],ST8SIA1,Smoking initiation (ever regular vs never regular) (MTAG),smoking status measurement,GCST007468,12:22392016,Mental or Behavioural Disorder
3040,WT1,WT1,Paternal,rs10767942-<b>?</b>,8 x 10-6,(count),NR,'-,'-,'-,"EIF3M, WT1-AS",Attention deficit hyperactivity disorder,attention deficit hyperactivity disorder,GCST000281,11:32500461,Mental or Behavioural Disorder
3067,WT1,WT1-AS,Paternal,rs10767942-<b>?</b>,8 x 10-6,(count),NR,'-,'-,'-,"EIF3M, WT1-AS",Attention deficit hyperactivity disorder,attention deficit hyperactivity disorder,GCST000281,11:32500461,Mental or Behavioural Disorder
3081,WT1-AS,WT1-AS,Paternal,rs10767942-<b>?</b>,8 x 10-6,(count),NR,'-,'-,'-,"EIF3M, WT1-AS",Attention deficit hyperactivity disorder,attention deficit hyperactivity disorder,GCST000281,11:32500461,Mental or Behavioural Disorder
3182,ZFAT,ZFAT,Paternal,rs17768250-<b>?</b>,7 x 10-7,,NR,2.3758,'-,NR,ZFAT,Response to SSRI (symptom remission),response to selective serotonin reuptake inhibitor,GCST007060,8:134558431,Mental or Behavioural Disorder
3183,ZFAT,ZFAT,Paternal,rs17768250-<b>?</b>,7 x 10-7,,NR,2.1933,'-,NR,ZFAT,Response to antidepressants (symptom remission),response to antidepressant,GCST007061,8:134558431,Mental or Behavioural Disorder
3184,ZFAT,ZFAT,Paternal,rs11166629-<b>?</b>,3 x 10-6,,'-,'-,'-,'-,ZFAT,Smoking quantity,smoking behaviour measurement,GCST002393,8:134624721,Mental or Behavioural Disorder
3207,ZFP90,ZFP90,Paternal,rs17689437-<b>?</b>,1 x 10-6,(risperidone),0.13,'-,'-,'-,ZFP90,Response to antipsychotic treatment in schizophrenia (reasoning),reasoning,GCST000885,16:68566448,Mental or Behavioural Disorder
3237,ZNF396,ZNF396,Paternal,rs2978362-<b>T</b>,2 x 10-8,,0.52156975,'-,0.0070359204 unit decrease,[0.0046-0.0095],"ZNF396, AC007998.1",Life satisfaction,wellbeing measurement,GCST007337,18:35379433,Mental or Behavioural Disorder
3842,FAM50B,FAM50B,Paternal,rs6906656-<b>A</b>,1 x 10-7,(Hispanic),NR,1.57,'-,'-,"TDGF1P4, FAM50B",Insomnia,insomnia,GCST005566,6:3919326,Mental or Behavioural Disorder
136,DIO3,DIO3OS,Paternal,rs11626434-<b>C</b>,2 x 10-16,,0.36,'-,0.053 unit increase,[0.039-0.067],"AL049836.2, DIO3OS",Free thyroxine concentration,thyroxine measurement,GCST006896,14:101532106,Metabolism
162,DLGAP2,DLGAP2,Paternal,rs113660214-<b>?</b>,2 x 10-6,,NR,'-,0.5166 unit decrease,[NR],DLGAP2,3-hydroxypropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxypropylmercapturic acid measurement",GCST002956,8:1027436,Metabolism
163,DLGAP2,DLGAP2,Paternal,rs11986808-<b>?</b>,3 x 10-7,(xanthurenate),NR,'-,0.19686499 unit decrease,[0.12-0.27],DLGAP2,Metabolite levels,xanthurenate measurement,GCST009391,8:1199246,Metabolism
164,DLGAP2,DLGAP2,Paternal,rs11779163-<b>?</b>,7 x 10-6,(oxalate),NR,'-,0.19865362 unit increase,[0.11-0.29],DLGAP2,Metabolite levels,oxalate measurement,GCST009391,8:1220295,Metabolism
165,DLGAP2,DLGAP2,Paternal,rs144606178-<b>?</b>,6 x 10-6,(Native Hawaiian),NR,'-,0.5584 unit decrease,[NR],DLGAP2,3-hydroxypropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxypropylmercapturic acid measurement",GCST002956,8:1351712,Metabolism
337,DSCAM,DSCAM,Paternal,rs2837671-<b>?</b>,9 x 10-6,(TAG 44:1),NR,'-,0.2572213 unit decrease,[0.14-0.37],DSCAM,Metabolite levels,triacylglycerol 44:1 measurement,GCST009391,21:40524015,Metabolism
338,DSCAM,DSCAM,Paternal,rs2837693-<b>?</b>,2 x 10-6,(TAG 48:4),NR,'-,0.2769407 unit decrease,[0.16-0.39],DSCAM,Metabolite levels,triacylglycerol 48:4 measurement,GCST009391,21:40538435,Metabolism
606,GLIS3,GLIS3,Paternal,rs10814819-<b>?</b>,3 x 10-6,(PC 34:3),NR,'-,0.21483028 unit increase,[0.12-0.3],GLIS3,Metabolite levels,phosphatidylcholine 34:3 measurement,GCST009391,9:4040327,Metabolism
607,GLIS3,GLIS3,Paternal,rs6415788-<b>T</b>,2 x 10-8,,0.6,'-,0.0107 unit decrease,[0.0069-0.0145],GLIS3,Urate levels,urate measurement,GCST011119,9:4118111,Metabolism
608,GLIS3,GLIS3,Paternal,rs10119187-<b>T</b>,8 x 10-10,,0.81,'-,0.048 unit increase,[0.032-0.064],GLIS3,Free thyroxine concentration,thyroxine measurement,GCST006896,9:4223660,Metabolism
883,HECW1,HECW1,Paternal,rs73099645-<b>?</b>,1 x 10-6,(Latino),NR,'-,0.6507 unit decrease,[NR],HECW1,3-hydroxy-1-methylpropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxy-1-methylpropylmercapturic acid measurement",GCST002957,7:43187042,Metabolism
1235,IGF2,IGF2,Paternal,rs11042751-<b>C</b>,8 x 10-17,,NR,'-,0.0234 unit increase,[0.018-0.029],IGF2,Urate levels,urate measurement,GCST90019524,11:2128634,Metabolism
1243,IGF2,IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Metabolism
1244,IGF2,IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Metabolism
1271,IGF2,IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Metabolism
1290,IGF2,IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Metabolism
1310,IGF2,IGF2,Paternal,rs7482894-<b>T</b>,4 x 10-14,,0.65,'-,0.0147 unit increase,[0.011-0.019],"H19, IGF2",Urate levels,urate measurement,GCST011119,11:2100034,Metabolism
1315,IGF2,IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Metabolism
1322,IGF2,IGF2-AS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Metabolism
1323,IGF2,IGF2-AS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Metabolism
1350,IGF2,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Metabolism
1368,IGF2,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Metabolism
1369,IGF2,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Metabolism
1373,IGF2,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Metabolism
1390,IGF2,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Metabolism
1401,INS,INS,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Metabolism
1424,INS,INS,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Metabolism
1434,INS,INS,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Metabolism
1435,INS,INS,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Metabolism
1442,INS,INS,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Metabolism
1481,INS,INS-IGF2,Paternal,rs7948458-<b>C</b>,2 x 10-11,,NR,'-,0.0202 unit increase,[0.014-0.026],INS-IGF2,Urate levels,urate measurement,GCST90019524,11:2151600,Metabolism
1499,INS,INS-IGF2,Paternal,rs35506085-<b>A</b>,2 x 10-8,,0.1887,'-,0.028758 mg/dL decrease,[0.019-0.039],"INS-IGF2, IGF2-AS",Urate levels,urate measurement,GCST008971,11:2144346,Metabolism
1500,INS,INS-IGF2,Paternal,rs3741210-<b>A</b>,1 x 10-8,,0.6584,'-,0.0193 mg/dL increase,[0.013-0.026],"IGF2-AS, INS-IGF2",Urate levels,urate measurement,GCST008972,11:2148310,Metabolism
1504,INS,INS-IGF2,Paternal,rs3842752-<b>A</b>,2 x 10-16,,NR,'-,0.0234 unit increase,[0.018-0.029],"INS-IGF2, INS",Urate levels,urate measurement,GCST90019524,11:2159843,Metabolism
1521,INS,INS-IGF2,Paternal,rs3842748-<b>C</b>,1 x 10-17,,0.23,'-,0.0193 unit increase,[0.015-0.024],"INS-IGF2, INS",Urate levels,urate measurement,GCST011119,11:2160165,Metabolism
1531,IRAIN,IRAIN,Paternal,rs8035887-<b>?</b>,4 x 10-7,(EA),NR,'-,0.6866 unit decrease,[NR],"FAM169B, IRAIN",3-hydroxy-1-methylpropylmercapturic acid levels in smokers,"smoking behavior, 3-hydroxy-1-methylpropylmercapturic acid measurement",GCST002957,15:98618223,Metabolism
2364,MIMT1,MIMT1,Paternal,rs7249211-<b>G</b>,6 x 10-6,(men),0.29,'-,0.104 kg/m2 increase,[0.059-0.149],"MIMT1, AC044792.1",Urate levels in lean individuals,"urate measurement, underweight body mass index status",GCST002830,19:56906546,Metabolism
2657,RHOBTB3,RHOBTB3,Paternal,rs17085064-<b>?</b>,6 x 10-6,(glutamate),NR,'-,0.1610073 unit increase,[0.091-0.231],"GLRX, RHOBTB3",Metabolite levels,glutamate measurement,GCST009391,5:95785831,Metabolism
3053,WT1,WT1,Paternal,rs12292135-<b>G</b>,2 x 10-9,,0.684313,'-,0.0126524 unit increase,[0.0085-0.0168],WT1-AS,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,11:32448758,Metabolism
3072,WT1,WT1-AS,Paternal,rs12292135-<b>G</b>,2 x 10-9,,0.684313,'-,0.0126524 unit increase,[0.0085-0.0168],WT1-AS,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,11:32448758,Metabolism
3086,WT1-AS,WT1-AS,Paternal,rs12292135-<b>G</b>,2 x 10-9,,0.684313,'-,0.0126524 unit increase,[0.0085-0.0168],WT1-AS,Apolipoprotein A1 levels,apolipoprotein A 1 measurement,GCST010241,11:32448758,Metabolism
3097,WT1,WTIP,Paternal,rs16969368-<b>?</b>,3 x 10-6,(TAG 58:11),NR,'-,0.5476408 unit decrease,[0.32-0.78],WTIP,Metabolite levels,triacylglycerol 58:10 measurement,GCST009391,19:34494550,Metabolism
3098,WT1,WTIP,Paternal,rs16969368-<b>?</b>,7 x 10-6,(TAG 58:12),NR,'-,0.5265684 unit decrease,[0.3-0.76],WTIP,Metabolite levels,triacylglycerol 58:12 measurement,GCST009391,19:34494550,Metabolism
3099,WT1,WTIP,Paternal,rs16969368-<b>?</b>,3 x 10-6,(TAG 60:12),NR,'-,0.5479422 unit decrease,[0.32-0.78],WTIP,Metabolite levels,triacylglycerol 60:12 measurement,GCST009391,19:34494550,Metabolism
3100,WT1,WTIP,Paternal,rs16969368-<b>?</b>,5 x 10-6,(TAG 58:10),NR,'-,0.5285057 unit decrease,[0.3-0.76],WTIP,Metabolite levels,triacylglycerol 58:10 measurement,GCST009391,19:34494550,Metabolism
3197,ZFP90,ZFP90,Paternal,rs142674134-<b>?</b>,5 x 10-10,(AGRP),NR,'-,1.67397 unit increase,[1.15-2.2],"ZFP90, RPL35AP33",Blood protein levels,Agouti-related protein measurement,GCST009696,16:68521135,Metabolism
166,DLGAP2,DLGAP2,Paternal,rs12793607-<b>?</b> x rs9650538-<b>?</b>,8 x 10-9,,NR,'-,'-,'-,AP002387.1 x DLGAP2,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,11:71418270|8:997830,Nervous System
167,DLGAP2,DLGAP2,Paternal,rs4923680-<b>?</b> x rs11778949-<b>?</b>,9 x 10-8,,NR,'-,'-,'-,NDUFA12 x DLGAP2,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,12:94955273|8:1049463,Nervous System
168,DLGAP2,DLGAP2,Paternal,rs1713428-<b>?</b> x rs11785306-<b>?</b>,7 x 10-8,,NR,'-,'-,'-,RNA5SP382 - KLHL33 x DLGAP2,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,14:20420021|8:1303819,Nervous System
169,DLGAP2,DLGAP2,Paternal,rs1078321-<b>G</b>,9 x 10-6,,0.420485,'-,0.302747 unit increase,[0.17-0.44],DLGAP2,Neuritic plaque,neuritic plaque measurement,GCST008829,8:1072377,Nervous System
170,DLGAP2,DLGAP2,Paternal,rs112455974-<b>A</b>,4 x 10-7,,NR,1.97,'-,[1.72-2.25],DLGAP2,Stroke,stroke,GCST011176,8:1624708,Nervous System
171,DLGAP2,DLGAP2,Paternal,rs117603268-<b>G</b>,7 x 10-7,,0.025,'-,0.17 unit increase,NR,DLGAP2,Tau burden,t-tau measurement,GCST011624,8:871593,Nervous System
313,DNMT1,DNMT1,Paternal,rs7937007-<b>?</b> x rs10407514-<b>?</b>,6 x 10-8,,NR,'-,'-,'-,"AC107884.1, SYT9 x DNMT1",Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,11:7445125|19:10144436,Nervous System
343,DSCAM,DSCAM,Paternal,rs727333-<b>C</b>,4 x 10-14,,0.62,3.846154,'-,[2.78-5.56],DSCAM,Intracranial aneurysm,brain aneurysm,GCST007354,21:40331020,Nervous System
344,DSCAM,DSCAM,Paternal,rs2085759-<b>?</b> x rs2837504-<b>?</b>,1 x 10-7,,NR,'-,'-,'-,LINC02511 x DSCAM,Total amyloid (SNP x SNP interaction),amyloid-beta measurement,GCST010339,4:136823860|21:40206658,Nervous System
339,DSCAM,DSCAM,Paternal,rs2249498-<b>?</b>,5 x 10-7,,'-,'-,'-,'-,DSCAM,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A,"Charcot-Marie-Tooth disease type 1A, foot muscle strength measurement",GCST008539,21:40059947,Nervous System
418,GDAP1L1,GDAP1L1,Paternal,rs190457471-<b>A</b>,5 x 10-6,(liability model),0.004,'-,0.68 unit increase,[0.39-0.97],"OSER1-DT, GDAP1L1",Late-onset Alzheimer's disease,late-onset Alzheimers disease,GCST003815,20:44233181,Nervous System
419,GDAP1L1,GDAP1L1,Paternal,rs75172958-<b>?</b>,3 x 10-6,,NR,'-,1748.7869 unit decrease,NR,GDAP1L1,Cerebrospinal fluid sTREM-2 levels,soluble triggering receptor expressed on myeloid cells 2 measurement,GCST009246,20:44247666,Nervous System
498,GLI3,GLI3,Paternal,rs2237425-<b>?</b> x rs7016311-<b>?</b>,8 x 10-8,,NR,'-,'-,'-,GLI3 x RN7SL318P - AC007718.1,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,7:42027757|8:5312987,Nervous System
499,GLI3,GLI3,Paternal,rs150749209-<b>T</b>,3 x 10-6,,NR,'-,4.66 z score decrease,'-,"LINC01448, GLI3",Longitudinal brain connectivity change (Louvain modularity),brain connectivity measurement,GCST009730,7:42454375,Nervous System
550,GLIS3,GLIS3,Paternal,rs4237150-<b>?</b>,3 x 10-9,,NR,'-,'-,'-,GLIS3,Circulating leptin levels or type 2 diabetes,"leptin measurement, type II diabetes mellitus",GCST010272,9:4290085,Nervous System
612,GLIS3,GLIS3,Paternal,rs12346050-<b>?</b> x rs12937078-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,GLIS3 x MSI2,Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,9:3836445|17:57422619,Nervous System
613,GLIS3,GLIS3,Paternal,rs7861718-<b>?</b>,7 x 10-13,,'-,'-,'-,'-,GLIS3,Brain morphology (min-P),"brain measurement, neuroimaging measurement",GCST010699,9:3924447,Nervous System
614,GLIS3,GLIS3,Paternal,rs7861718-<b>?</b>,3 x 10-8,,'-,'-,'-,'-,GLIS3,Brain morphology (MOSTest),"brain measurement, neuroimaging measurement",GCST010703,9:3924447,Nervous System
615,GLIS3,GLIS3,Paternal,rs7861718-<b>?</b>,2 x 10-11,,'-,'-,'-,'-,GLIS3,Subcortical volume (MOSTest),"neuroimaging measurement, brain volume measurement",GCST010702,9:3924447,Nervous System
616,GLIS3,GLIS3,Paternal,rs7861718-<b>?</b>,2 x 10-13,,'-,'-,'-,'-,GLIS3,Subcortical volume (min-P),"neuroimaging measurement, brain volume measurement",GCST010698,9:3924447,Nervous System
617,GLIS3,GLIS3,Paternal,rs624290-<b>C</b>,1 x 10-6,,0.106,'-,0.044 unit decrease,[0.026-0.062],GLIS3,Cerebrospinal T-tau levels,t-tau measurement,GCST004071,9:3928115,Nervous System
618,GLIS3,GLIS3,Paternal,rs514716-<b>C</b>,3 x 10-8,,0.125,'-,0.049 unit decrease,[0.031-0.067],GLIS3,Cerebrospinal P-tau181p levels,p-tau measurement,GCST004070,9:3929424,Nervous System
619,GLIS3,GLIS3,Paternal,rs514716-<b>G</b>,1 x 10-8,(tau),NR,'-,0.071 unit decrease,[NR],GLIS3,Alzheimer's disease biomarkers,"Alzheimer's disease, t-tau measurement",GCST001951,9:3929424,Nervous System
620,GLIS3,GLIS3,Paternal,rs514716-<b>G</b>,3 x 10-9,(ptau),NR,'-,0.072 unit decrease,[NR],GLIS3,Alzheimer's disease biomarkers,"Alzheimer's disease, p-tau measurement",GCST001951,9:3929424,Nervous System
770,DIRAS3,GNG12-AS1,Paternal,rs1808596-<b>?</b>,2 x 10-10,,'-,'-,'-,'-,"CTBP2P8, WLS, GNG12-AS1",Brain morphology (MOSTest),"brain measurement, neuroimaging measurement",GCST010703,1:68162260,Nervous System
771,DIRAS3,GNG12-AS1,Paternal,rs1808596-<b>?</b>,1 x 10-8,,'-,'-,'-,'-,"CTBP2P8, WLS, GNG12-AS1",Cortical surface area (MOSTest),"cortical surface area measurement, neuroimaging measurement",GCST010701,1:68162260,Nervous System
772,DIRAS3,GNG12-AS1,Paternal,rs1556401-<b>?</b> x rs12741473-<b>?</b>,2 x 10-8,,NR,'-,'-,'-,"KIAA1217 x GNG12-AS1, WLS",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,10:24405786|1:68116316,Nervous System
885,HECW1,HECW1,Paternal,rs55704525-<b>G</b>,3 x 10-7,,0.01,'-,0.3463 unit increase,[NR],HECW1,Cerebrospinal fluid AB1-42 levels,"beta-amyloid 1-42 measurement, cerebrospinal fluid biomarker measurement",GCST003072,7:43528967,Nervous System
886,HECW1,HECW1,Paternal,rs10245574-<b>?</b>,3 x 10-6,,'-,'-,'-,'-,HECW1,Caudal anterior-cingulate cortex volume,caudal anterior cingulate cortex volume measurement,GCST009175,7:43544922,Nervous System
884,HECW1,HECW1,Paternal,rs17172199-<b>?</b>,1 x 10-6,,0.08,'-,0.28 unit decrease,'-,HECW1,Alzheimer's disease (cognitive decline),Alzheimer's disease,GCST001915,7:43337677,Nervous System
1227,IGF2,IGF2,Paternal,rs4529869-<b>A</b>,3 x 10-6,,0.5051,'-,0.0293 unit decrease,[0.017-0.042],IGF2,Periventricular white matter hyperintensities,white matter hyperintensity measurement,GCST010726,11:2123215,Nervous System
2177,LIN28B,LIN28B,Paternal,rs314277-<b>?</b>,5 x 10-6,,'-,'-,'-,'-,LIN28B,Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction),"Alzheimer's disease, cognitive decline measurement, Cognitive impairment",GCST004253,6:104959787,Nervous System
2178,LIN28B,LIN28B,Paternal,rs17065417-<b>A</b>,1 x 10-8,,0.89,1.38,'-,[1.23-1.54],LIN28B,Neuroblastoma,neuroblastoma,GCST001660,6:104958399,Nervous System
2179,LIN28B,LIN28B,Paternal,rs17065417-<b>C</b>,5 x 10-9,"(European American, conditioned on rs72990858)",0.9,1.4285715,'-,[1.25-1.67],LIN28B,Sporadic neuroblastoma,neuroblastoma,GCST004510,6:104958399,Nervous System
2560,PLAGL1,PLAGL1,Paternal,rs6928827-<b>A</b>,9 x 10-6,(EA),0.1263,'-,'-,'-,PLAGL1,Anti-saccade response,antisaccade response measurement,GCST005025,6:143994082,Nervous System
2594,RASGRF1,RASGRF1,Paternal,rs62013236-<b>C</b>,9 x 10-17,,NR,1.106,'-,NR,"CTSH, RASGRF1",Multiple sclerosis,multiple sclerosis,GCST009597,15:78955140,Nervous System
2658,RHOBTB3,RHOBTB3,Paternal,rs12917426-<b>?</b> x rs9314160-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"LINC02351 x RHOBTB3, GLRX",Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,15:98368760|5:95820753,Nervous System
2673,SGCE,SGCE,Paternal,rs4330611-<b>?</b> x rs7174784-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,SGCE x AC087762.1,Neurofibrillary tangles (SNP x SNP interaction),neurofibrillary tangles measurement,GCST010343,7:94642686|15:100761839,Nervous System
3058,WT1,WT1,Paternal,rs2067666-<b>?</b> x rs11085752-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS - EIF3M x TIMM29 - SMARCA4,Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,11:32476809|19:10954733,Nervous System
3074,WT1,WT1-AS,Paternal,rs2067666-<b>?</b> x rs11085752-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS - EIF3M x TIMM29 - SMARCA4,Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,11:32476809|19:10954733,Nervous System
3088,WT1-AS,WT1-AS,Paternal,rs2067666-<b>?</b> x rs11085752-<b>?</b>,4 x 10-8,,NR,'-,'-,'-,WT1-AS - EIF3M x TIMM29 - SMARCA4,Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,11:32476809|19:10954733,Nervous System
3119,ZDBF2,ZDBF2,Paternal,rs181263645-<b>G</b>,4 x 10-6,,0.936876333,'-,0.286888 unit decrease,[0.17-0.41],"ACER2P1, ZDBF2",Short-term memory (digit-span task),short-term memory,GCST007471,2:206401557,Nervous System
3120,ZDBF2,ZDBF2,Paternal,rs7874270-<b>?</b> x rs10196764-<b>?</b>,8 x 10-8,,NR,'-,'-,'-,AL355672.1 - AL592227.1 x ZDBF2 - ACER2P1,Diffuse plaques (SNP x SNP interaction),diffuse plaque measurement,GCST010341,9:11443473|2:206364804,Nervous System
3179,ZFAT,ZFAT,Paternal,rs13273819-<b>?</b>,4 x 10-6,,0.43,'-,0.08 unit increase,[0.021-0.139],"ZFAT, AC105180.2",Short-term memory (visuospatial task),memory performance,GCST006254,8:134433010,Nervous System
3180,ZFAT,ZFAT,Paternal,rs4909605-<b>?</b> x rs1941492-<b>?</b>,1 x 10-7,,NR,'-,'-,'-,ZFAT x AP005205.1 - AP005205.3,Neuritic plaques (SNP x SNP interaction),neuritic plaque measurement,GCST010342,8:134485918|18:6661947,Nervous System
3181,ZFAT,ZFAT,Paternal,rs1036819-<b>C</b>,5 x 10-9,,0.261,'-,'-,'-,"ZFAT-AS1, ZFAT",Cerebrospinal fluid t-tau:AB1-42 ratio,t-tau:beta-amyloid 1-42 ratio measurement,GCST007130,8:134599702,Nervous System
3186,ZFAT,ZFAT-AS1,Paternal,rs1036819-<b>C</b>,5 x 10-9,,0.261,'-,'-,'-,"ZFAT-AS1, ZFAT",Cerebrospinal fluid t-tau:AB1-42 ratio,t-tau:beta-amyloid 1-42 ratio measurement,GCST007130,8:134599702,Nervous System
3212,ZIM2,ZIM2,Paternal,rs10520571-<b>?</b> x rs7250785-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"ADAMTSL3 x ZNF71, ZIM2-AS1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,15:83947580|19:56615360,Nervous System
3213,ZIM2,ZIM2,Paternal,rs7250785-<b>?</b> x rs12642242-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x AC096773.1 - AC093772.1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615360|4:127094149,Nervous System
3214,ZIM2,ZIM2,Paternal,rs7254537-<b>?</b> x rs7997628-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x DCT - TGDS",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|13:94565598,Nervous System
3215,ZIM2,ZIM2,Paternal,rs7254537-<b>?</b> x rs678113-<b>?</b>,5 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x IGDCC3",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|15:65365146,Nervous System
3216,ZIM2,ZIM2,Paternal,rs7254537-<b>?</b> x rs243018-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x AC007381.1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|2:60359572,Nervous System
3217,ZIM2,ZIM2,Paternal,rs7254537-<b>?</b> x rs17666-<b>?</b>,3 x 10-10,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x DPYSL2",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|8:26657942,Nervous System
3218,ZIM2,ZIM2,Paternal,rs115442558-<b>?</b>,7 x 10-6,,NR,1.26,'-,[1.14-1.39],"ZNF71, ZIM2-AS1",Non-lobar intracerebral hemorrhage (MTAG),non-lobar intracerebral hemorrhage,GCST008876,19:56617586,Nervous System
3227,ZIM2,ZIM2-AS1,Paternal,rs10520571-<b>?</b> x rs7250785-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"ADAMTSL3 x ZNF71, ZIM2-AS1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,15:83947580|19:56615360,Nervous System
3228,ZIM2,ZIM2-AS1,Paternal,rs7250785-<b>?</b> x rs12642242-<b>?</b>,2 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x AC096773.1 - AC093772.1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615360|4:127094149,Nervous System
3229,ZIM2,ZIM2-AS1,Paternal,rs7254537-<b>?</b> x rs7997628-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x DCT - TGDS",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|13:94565598,Nervous System
3230,ZIM2,ZIM2-AS1,Paternal,rs7254537-<b>?</b> x rs678113-<b>?</b>,5 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x IGDCC3",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|15:65365146,Nervous System
3231,ZIM2,ZIM2-AS1,Paternal,rs7254537-<b>?</b> x rs243018-<b>?</b>,1 x 10-9,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x AC007381.1",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|2:60359572,Nervous System
3232,ZIM2,ZIM2-AS1,Paternal,rs7254537-<b>?</b> x rs17666-<b>?</b>,3 x 10-10,,NR,'-,'-,'-,"ZNF71, ZIM2-AS1 x DPYSL2",Total PHF-tau (SNP x SNP interaction),PHF-tau measurement,GCST010340,19:56615673|8:26657942,Nervous System
3233,ZIM2,ZIM2-AS1,Paternal,rs115442558-<b>?</b>,7 x 10-6,,NR,1.26,'-,[1.14-1.39],"ZNF71, ZIM2-AS1",Non-lobar intracerebral hemorrhage (MTAG),non-lobar intracerebral hemorrhage,GCST008876,19:56617586,Nervous System
3826,ZFAT-AS1,ZFAT-AS1,Paternal,rs1036819-<b>C</b>,5 x 10-9,,0.261,'-,'-,'-,"ZFAT-AS1, ZFAT",Cerebrospinal fluid t-tau:AB1-42 ratio,t-tau:beta-amyloid 1-42 ratio measurement,GCST007130,8:134599702,Nervous System
3841,FAM50B,FAM50B,Paternal,rs11242880-<b>?</b>,1 x 10-6,,'-,'-,'-,'-,"FAM50B, PXDC1",Isthmus-cingulate cortex volume,isthmus cingulate cortex volume measurement,GCST009212,6:3769511,Nervous System
3844,PXDC1,PXDC1,Paternal,rs11242880-<b>?</b>,1 x 10-6,,'-,'-,'-,'-,"FAM50B, PXDC1",Isthmus-cingulate cortex volume,isthmus cingulate cortex volume measurement,GCST009212,6:3769511,Nervous System
137,DIO3,DIO3OS,Paternal,"rs10142332-<b>G</b>, rs12435279-<b>C</b>, rs12586651-<b>T</b>",3 x 10-7,,0.155,'-,'-,'-,AL049836.2 - DIO3OS; AL049836.2 - DIO3OS; AL049836.2 - DIO3OS,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,14:101519289|14:101522626|14:101519591,Orthopaedic
172,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>T</b>",1 x 10-7,,0.185,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Orthopaedic
173,DLGAP2,DLGAP2,Paternal,"rs4876094-<b>C</b>, rs10111688-<b>C</b>",4 x 10-7,,0.355,'-,'-,'-,DLGAP2; DLGAP2,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,8:1309780|8:1310504,Orthopaedic
501,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>G</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",3 x 10-10,,0,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Orthopaedic
502,GLI3,GLI3,Paternal,"rs10279985-<b>T</b>, rs4724101-<b>C</b>, rs7790090-<b>T</b>, rs3801234-<b>C</b>, rs6949528-<b>A</b>, rs3801236-<b>C</b>, rs6955604-<b>G</b>",2 x 10-6,,0.123,'-,'-,'-,GLI3; GLI3; GLI3; GLI3; GLI3; GLI3; GLI3,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:42232361|7:42230723|7:42232050|7:42217585|7:42222253|7:42221225|7:42217285,Orthopaedic
632,GLIS3,GLIS3,Paternal,rs564816-<b>C</b>,3 x 10-7,,0.04,'-,'-,[NR],GLIS3,Methotrexate phramacokinetics (acute lymphoblastic leukemia),response to antineoplastic agent,GCST000523,9:4015370,Orthopaedic
887,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>A</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",3 x 10-15,,0.011,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Orthopaedic
888,HECW1,HECW1,Paternal,"rs17207421-<b>A</b>, rs11979957-<b>A</b>, rs2240983-<b>G</b>, rs12702043-<b>G</b>, rs1860755-<b>G</b>, rs17801421-<b>A</b>, rs2024269-<b>T</b>",8 x 10-15,,0.23,'-,'-,'-,HECW1; HECW1; HECW1; HECW1; HECW1; HECW1; HECW1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,7:43435480|7:43441841|7:43441038|7:43441857|7:43434275|7:43434488|7:43434218,Orthopaedic
2365,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
2366,MIMT1,MIMT1,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
2533,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
2534,PEG3,PEG3,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
3220,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>T</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",1 x 10-16,,0.001,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
3221,ZIM2,ZIM2,Paternal,"rs8113561-<b>G</b>, rs382592-<b>C</b>, rs10408898-<b>G</b>, rs10401139-<b>C</b>, rs2870477-<b>G</b>, rs1860565-<b>G</b>, rs11881055-<b>A</b>, rs2159551-<b>C</b>, rs8102497-<b>A</b>",4 x 10-9,,0.188,'-,'-,'-,MIMT1 - AC044792.1; MIMT1; MIMT1 - AC044792.1; AC006115.2; ZIM2; PEG3; ZIM2; PEG3; ZIM2; MIMT1 - AC044792.1; PEG3; ZIM2; MIMT1 - AC044792.1,Core binding factor acute myeloid leukemia,acute myeloid leukemia,GCST008413,19:56866899|19:56848432|19:56868336|19:56808849|19:56833545|19:56823654|19:56863695|19:56833599|19:56858687,Orthopaedic
174,DLGAP2,DLGAP2,Paternal,rs28367414-<b>?</b>,3 x 10-6,,'-,'-,'-,'-,DLGAP2,Clostridium difficile infection in multiple myeloma,"clostridium difficile infection, multiple myeloma",GCST005686,8:1470728,Orthopaedic
176,DLGAP2,DLGAP2,Paternal,rs4976875-<b>G</b>,6 x 10-6,,0.723421,1.07678,'-,[1.04381-1.11078],DLGAP2,Osteoarthritis (self-reported),osteoarthritis,GCST005811,8:1242438,Orthopaedic
314,DNMT1,DNMT1,Paternal,rs10409243-<b>C</b>,2 x 10-8,,0.4,'-,5.59 z-score increase,'-,"S1PR2, DNMT1",Serum alkaline phosphatase levels,alkaline phosphatase measurement,GCST90011900,19:10222312,Orthopaedic
347,DSCAM,DSCAM,Paternal,rs191124187-<b>C</b>,3 x 10-6,,0.01,10.71,'-,[3.95-29.03],DSCAM,Hallux valgus,Hallux valguso,GCST009846,21:40531924,Orthopaedic
374,ERAP2,ERAP2,Paternal,rs2910686-<b>?</b>,2 x 10-21,(subset analysis),NR,'-,'-,'-,"AC009126.1, ERAP2","Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:96916885,Orthopaedic
376,ERAP2,ERAP2,Paternal,rs4869314-<b>G</b>,3 x 10-9,,NR,1.14,'-,[1.09-1.19],"AC009126.1, ERAP2",Arthritis (juvenile idiopathic),juvenile idiopathic arthritis,GCST90010715,5:96893521,Orthopaedic
377,ERAP2,ERAP2,Paternal,rs2910686-<b>C</b>,5 x 10-17,"(conditioned on rs30187, EA)",0.44,1.17,'-,'-,"AC009126.1, ERAP2",Ankylosing spondylitis,ankylosing spondylitis,GCST005529,5:96916885,Orthopaedic
624,GLIS3,GLIS3,Paternal,rs12344176-<b>T</b>,3 x 10-6,,0.78,'-,0.225 unit decrease,[0.13-0.32],GLIS3,Osteolysis in total hip arthroplasty (time to prosthesis revision),"periprosthetic osteolysis, total hip arthroplasty, disease progression measurement",GCST007550,9:3940862,Orthopaedic
625,GLIS3,GLIS3,Paternal,rs10116772-<b>C</b>,4 x 10-8,,0.6,1.03,'-,[1.02-1.04],GLIS3,Osteoarthritis of the hip or knee (with total joint replacement),"osteoarthritis, hip, osteoarthritis, knee",GCST005571,9:4290541,Orthopaedic
626,GLIS3,GLIS3,Paternal,rs10116772-<b>C</b>,3 x 10-8,,0.6002,1.03,'-,[1.02-1.04],GLIS3,Osteoarthritis of the hip or knee,"osteoarthritis, hip, osteoarthritis, knee",GCST005573,9:4290541,Orthopaedic
627,GLIS3,GLIS3,Paternal,rs10974438-<b>A</b>,1 x 10-8,,0.65,1.03,'-,[1.02-1.05],GLIS3,Osteoarthritis,osteoarthritis,GCST007093,9:4291928,Orthopaedic
628,GLIS3,GLIS3,Paternal,rs10758594-<b>G</b>,2 x 10-8,,0.58,1.04,'-,[1.03-1.06],GLIS3,Osteoarthritis of the hip or knee,"osteoarthritis, hip, osteoarthritis, knee",GCST007092,9:4295583,Orthopaedic
774,DIRAS3,GNG12-AS1,Paternal,rs17130567-<b>G</b>,2 x 10-9,,0.254436,'-,0.10955559 unit decrease,[0.074-0.146],"WLS, GNG12-AS1",Medication use (drugs affecting bone structure and mineralization),Drugs affecting bone structure and mineralization use measurement,GCST007935,1:68198164,Orthopaedic
889,HECW1,HECW1,Paternal,rs7810100-<b>T</b>,6 x 10-7,,0.183686,1.08533,'-,[1.04798-1.124],HECW1,Osteoarthritis (self-reported),osteoarthritis,GCST005811,7:43176015,Orthopaedic
2266,MAGEL2,MAGEL2,Paternal,rs11161318-<b>?</b>,2 x 10-29,,NR,'-,'-,'-,"MAGEL2, MKRN3",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,15:23643119,Orthopaedic
2371,MKRN3,MKRN3,Paternal,rs11161318-<b>?</b>,2 x 10-29,,NR,'-,'-,'-,"MAGEL2, MKRN3",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,15:23643119,Orthopaedic
2659,RHOBTB3,RHOBTB3,Paternal,rs8751-<b>?</b>,1 x 10-10,,NR,'-,'-,'-,"RHOBTB3, GLRX",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,5:95814112,Orthopaedic
3837,FAM50B,FAM50B,Paternal,rs9503803-<b>?</b>,2 x 10-28,,NR,'-,'-,'-,"TDGF1P4, FAM50B",Adolescent idiopathic scoliosis,adolescent idiopathic scoliosis,GCST006287,6:3915216,Orthopaedic
175,DLGAP2,DLGAP2,Paternal,rs2404618-<b>T</b>,7 x 10-6,,0.465822007,1.0544931,'-,[1.030451547-1.07909551],DLGAP2,Lung cancer,lung carcinoma,GCST004748,8:1514102,Respiratory
183,DLGAP2,DLGAP2,Paternal,rs182302106-<b>G</b>,2 x 10-6,(AA),0.999,'-,0.45 unit increase,'-,DLGAP2,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,8:1507009,Respiratory
345,DSCAM,DSCAM,Paternal,rs9981861-<b>G</b>,4 x 10-6,,NR,1.33,'-,[0.82-2.15],DSCAM,Non-small cell lung cancer (survival),non-small cell lung carcinoma,GCST000871,21:40043117,Respiratory
464,GLI3,GLI3,Paternal,rs10233459-<b>G</b>,4 x 10-6,(African),0.05,1.57,'-,[1.30‐1.91],GLI3,Asthma,asthma,GCST005212,7:42001387,Respiratory
509,GLI3,GLI3,Paternal,rs6956494-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,"GLI3, LINC01448",Lung function (FVC),vital capacity,GCST007081,7:42248153,Respiratory
623,GLIS3,GLIS3,Paternal,rs10974465-<b>T</b>,6 x 10-6,,0.161054917,1.122095,'-,[1.067564608-1.179410829],GLIS3,Squamous cell lung carcinoma,squamous cell lung carcinoma,GCST004750,9:4326243,Respiratory
629,GLIS3,GLIS3,Paternal,rs183726757-<b>T</b>,5 x 10-6,(AA),1,'-,2.616 unit increase,NR,"RFX3-AS1, GLIS3",Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,9:3795100,Respiratory
654,GLIS3,GLIS3,Paternal,rs1570203-<b>A</b>,5 x 10-6,,0.5296,'-,0.0108 unit increase,[0.0061-0.0155],GLIS3,Lung function (FVC),vital capacity,GCST007429,9:4120648,Respiratory
655,GLIS3,GLIS3,Paternal,rs1570203-<b>A</b>,6 x 10-20,,0.5296,'-,0.0214 unit increase,[0.017-0.026],GLIS3,FEV1,forced expiratory volume,GCST007432,9:4120648,Respiratory
656,GLIS3,GLIS3,Paternal,rs1570203-<b>A</b>,4 x 10-18,,0.5296,'-,0.0221 unit increase,[0.017-0.027],GLIS3,Peak expiratory flow,peak expiratory flow,GCST007430,9:4120648,Respiratory
657,GLIS3,GLIS3,Paternal,rs1570203-<b>A</b>,6 x 10-25,,0.5296,'-,0.0246 unit increase,[0.02-0.029],GLIS3,Lung function (FEV1/FVC),FEV/FEC ratio,GCST007431,9:4120648,Respiratory
658,GLIS3,GLIS3,Paternal,rs4740752-<b>G</b>,6 x 10-6,,0.36,1.08,'-,[1.04-1.12],GLIS3,Chronic obstructive pulmonary disease x ever smoker interaction (main effect),chronic obstructive pulmonary disease,GCST90016586,9:4123044,Respiratory
659,GLIS3,GLIS3,Paternal,rs4740752-<b>G</b>,9 x 10-6,,0.36,1.07,'-,[1.04-1.1],GLIS3,Chronic obstructive pulmonary disease in ever smokers,"smoking status measurement, chronic obstructive pulmonary disease",GCST90016588,9:4123044,Respiratory
660,GLIS3,GLIS3,Paternal,rs4740752-<b>G</b>,7 x 10-6,,0.36,1.08,'-,[1.04-1.12],GLIS3,Chronic obstructive pulmonary disease in never smokers,"smoking status measurement, chronic obstructive pulmonary disease",GCST90016589,9:4123044,Respiratory
661,GLIS3,GLIS3,Paternal,rs4740752-<b>G</b>,2 x 10-9,,0.36,'-,'-,[NR],GLIS3,Chronic obstructive pulmonary disease x ever smoker interaction (2df),"smoking status measurement, chronic obstructive pulmonary disease",GCST90016585,9:4123044,Respiratory
662,GLIS3,GLIS3,Paternal,rs4741893-<b>?</b>,6 x 10-11,,NR,'-,'-,'-,GLIS3,Lung function (FVC),vital capacity,GCST007081,9:4123284,Respiratory
663,GLIS3,GLIS3,Paternal,rs7872188-<b>T</b>,2 x 10-10,,0.4017,'-,0.026 unit decrease,[0.018-0.034],GLIS3,Lung function (FEV1),forced expiratory volume,GCST004183,9:4124377,Respiratory
664,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,9 x 10-13,,0.42,1.07,'-,[1.05-1.09],GLIS3,Chronic obstructive pulmonary disease,chronic obstructive pulmonary disease,GCST007692,9:4143749,Respiratory
665,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,4 x 10-10,,0.42,1.08,'-,[1.05-1.11],GLIS3,Chronic obstructive pulmonary disease in non-current smokers,"smoking status measurement, chronic obstructive pulmonary disease",GCST90016594,9:4143749,Respiratory
666,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,6 x 10-10,,0.42,'-,'-,[NR],GLIS3,Chronic obstructive pulmonary disease x current smoker interaction (2df),"smoking status measurement, chronic obstructive pulmonary disease",GCST90016590,9:4143749,Respiratory
667,GLIS3,GLIS3,Paternal,rs10114763-<b>T</b>,4 x 10-10,,0.42,1.08,'-,[1.05-1.11],GLIS3,Chronic obstructive pulmonary disease x current smoker interaction (main effect),chronic obstructive pulmonary disease,GCST90016591,9:4143749,Respiratory
668,GLIS3,GLIS3,Paternal,rs10974345-<b>?</b>,5 x 10-33,,NR,'-,'-,'-,GLIS3,Lung function (FEV1/FVC),FEV/FEC ratio,GCST007080,9:4144203,Respiratory
890,HECW1,HECW1,Paternal,rs9648078-<b>A</b>,6 x 10-8,,0.056,'-,0.2747 unit increase,[0.18-0.37],HECW1,"Obstructive sleep apnea trait (apnea hypopnea index, change over time)",sleep apnea measurement,GCST009461,7:43280814,Respiratory
891,HECW1,HECW1,Paternal,rs4509217-<b>A</b>,1 x 10-6,,0.068,'-,0.2493 unit increase,[0.15-0.35],HECW1,"Obstructive sleep apnea trait (apnea hypopnea index, change over time)",sleep apnea measurement,GCST009461,7:43321409,Respiratory
2202,LIN28B,LIN28B,Paternal,rs370771-<b>?</b>,3 x 10-17,,NR,'-,'-,'-,LIN28B,Lung function (FVC),vital capacity,GCST007081,6:104950211,Respiratory
2540,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,4 x 10-6,,NR,'-,'-,'-,PLAGL1,Asthma (adult onset),adult onset asthma,GCST009842,6:143977063,Respiratory
2561,PLAGL1,PLAGL1,Paternal,rs150612539-<b>C</b>,2 x 10-6,(AA),1,'-,0.441 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:143952786,Respiratory
2562,PLAGL1,PLAGL1,Paternal,rs150029151-<b>A</b>,2 x 10-6,(AA),1,'-,0.432 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:144025056,Respiratory
2563,PLAGL1,PLAGL1,Paternal,rs192748541-<b>A</b>,1 x 10-6,(AA),1,'-,0.434 unit increase,'-,PLAGL1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:144052556,Respiratory
2564,PLAGL1,PLAGL1,Paternal,rs6900923-<b>C</b>,5 x 10-10,,NR,'-,'-,'-,PLAGL1,Adult onset asthma and/or BMI,"adult onset asthma, body mass index",GCST009868,6:143977063,Respiratory
2877,SNRPN,SNRPN,Paternal,rs3867498-<b>?</b>,1 x 10-6,(FEV1slope),NR,'-,'-,'-,"AC090983.2, SNRPN",Pulmonary function,pulmonary function measurement,GCST000106,15:24833640,Respiratory
2878,SNRPN,SNRPN,Paternal,rs72693656-<b>T</b>,8 x 10-6,,0.48,'-,'-,'-,"SNRPN, AC090983.2",Non-tuberculous mycobacterial pulmonary disease,pulmonary non-tuberculous mycobacterial infection,GCST010983,15:24861407,Respiratory
2882,ST8SIA1,ST8SIA1,Paternal,rs184061709-<b>G</b>,3 x 10-6,(AA),1,'-,0.38 unit increase,'-,ST8SIA1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,12:22309344,Respiratory
2883,ST8SIA1,ST8SIA1,Paternal,rs182272664-<b>A</b>,2 x 10-6,(AA),0.999,'-,0.383 unit increase,'-,ST8SIA1,Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,12:22312006,Respiratory
3065,WT1,WT1,Paternal,rs11031736-<b>?</b>,1 x 10-8,,NR,'-,'-,'-,"THEM7P, WT1",Lung function (FVC),vital capacity,GCST007081,11:32350208,Respiratory
3211,ZIM2,ZIM2,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Respiratory
3226,ZIM2,ZIM2-AS1,Paternal,rs10404342-<b>?</b>,8 x 10-6,,'-,'-,'-,'-,"ZNF71, ZIM2-AS1",IgE levels in asthmatics,"serum IgE measurement, asthma",GCST002122,19:56620870,Respiratory
3836,FAM50B,FAM50B,Paternal,rs187885921-<b>C</b>,4 x 10-6,(AA),0.999,'-,0.366 unit increase,'-,"TDGF1P4, FAM50B",Post bronchodilator FEV1/FVC ratio,"response to bronchodilator, FEV/FEC ratio",GCST003264,6:3894081,Respiratory
3840,FAM50B,FAM50B,Paternal,rs187885921-<b>C</b>,5 x 10-6,(AA),0.999,'-,1.821 unit increase,NR,"TDGF1P4, FAM50B",Post bronchodilator FEV1,"forced expiratory volume, response to bronchodilator",GCST003262,6:3894081,Respiratory
196,DLGAP2,DLGAP2,Paternal,rs12547340-<b>G</b>,4 x 10-6,,0.79,'-,0.016 dioptres increase,[0.0082-0.0238],DLGAP2,Refractive astigmatism,Astigmatism,GCST007160,8:1199028,Sensory System
261,DLK1,DLK1,Paternal,rs4905998-<b>?</b>,3 x 10-10,,'-,'-,'-,'-,"DLK1, AL132711.1",Refractive error,Abnormality of refraction,GCST010002,14:100715444,Sensory System
260,DLK1,DLK1,Paternal,rs200197449-<b>?</b>,2 x 10-6,"(AA, adjusted for duration of diabetes and glycemic control)",NR,1.44,'-,[NR],"AL132711.1, DLK1",Proliferative diabetic retinopathy (vs no DR),proliferative diabetic retinopathy,GCST007291,14:100689809,Sensory System
339,DSCAM,DSCAM,Paternal,rs2249498-<b>?</b>,5 x 10-7,,'-,'-,'-,'-,DSCAM,Foot plantar flexion strength in Charcot-Marie-Tooth disease 1A,"Charcot-Marie-Tooth disease type 1A, foot muscle strength measurement",GCST008539,21:40059947,Sensory System
353,DSCAM,DSCAM,Paternal,rs7277023-<b>?</b>,5 x 10-8,,'-,'-,'-,'-,DSCAM,Refractive error,Abnormality of refraction,GCST010002,21:40543432,Sensory System
510,GLI3,GLI3,Paternal,rs7710527-<b>?</b> x rs10278194-<b>?</b>,6 x 10-9,,NR,'-,'-,'-,"FER, AC116428.1 x GLI3 - LINC01448",Age-related hearing impairment (SNP x SNP interaction),age-related hearing impairment,GCST002487,5:109166792|7:42324206,Sensory System
511,GLI3,GLI3,Paternal,rs7793034-<b>?</b>,1 x 10-10,,'-,'-,'-,'-,GLI3,Refractive error,Abnormality of refraction,GCST010002,7:42075917,Sensory System
669,GLIS3,GLIS3,Paternal,rs7047871-<b>T</b>,1 x 10-17,,0.69,'-,8.54 z score decrease,NR,GLIS3,Intraocular pressure,intraocular pressure measurement,GCST007998,9:4050113,Sensory System
670,GLIS3,GLIS3,Paternal,rs7048915-<b>?</b>,4 x 10-9,,'-,'-,'-,'-,GLIS3,Refractive error,Abnormality of refraction,GCST010002,9:4206388,Sensory System
671,GLIS3,GLIS3,Paternal,rs7026684-<b>A</b>,2 x 10-9,,0.37,'-,1.94 unit decrease,[1.31-2.57],GLIS3,Central corneal thickness,central corneal thickness,GCST005667,9:4215308,Sensory System
672,GLIS3,GLIS3,Paternal,rs7026684-<b>?</b>,4 x 10-14,,NA,'-,1.85 unit increase,[1.38-2.32],GLIS3,Central corneal thickness,central corneal thickness,GCST90000654,9:4215308,Sensory System
673,GLIS3,GLIS3,Paternal,rs1570204-<b>?</b>,3 x 10-8,,NR,'-,0.0741 unit decrease,[0.048-0.1],GLIS3,Intraocular pressure,intraocular pressure measurement,GCST006394,9:4216751,Sensory System
674,GLIS3,GLIS3,Paternal,rs1570204-<b>T</b>,7 x 10-31,,0.6521,'-,0.168 unit decrease,[0.14-0.2],GLIS3,Intraocular pressure,intraocular pressure measurement,GCST005580,9:4216751,Sensory System
675,GLIS3,GLIS3,Paternal,rs736893-<b>G</b>,1 x 10-14,,'-,1.18,'-,[NR],GLIS3,Glaucoma (primary angle closure),primary angle closure glaucoma,GCST003467,9:4217028,Sensory System
676,GLIS3,GLIS3,Paternal,rs736893-<b>G</b>,1 x 10-11,(Asian),'-,1.17,'-,[NR],GLIS3,Glaucoma (primary angle closure),primary angle closure glaucoma,GCST003467,9:4217028,Sensory System
677,GLIS3,GLIS3,Paternal,rs6476827-<b>C</b>,1 x 10-10,,0.66,'-,0.086 unit decrease,[0.061-0.111],GLIS3,Intraocular pressure,intraocular pressure measurement,GCST006412,9:4220832,Sensory System
678,GLIS3,GLIS3,Paternal,rs6476827-<b>C</b>,5 x 10-33,,0.6617,'-,0.174 unit decrease,[0.14-0.2],GLIS3,Intraocular pressure,intraocular pressure measurement,GCST005580,9:4220832,Sensory System
679,GLIS3,GLIS3,Paternal,rs2224492-<b>?</b>,4 x 10-16,,NR,'-,0.11 unit decrease,[NR],GLIS3,Intraocular pressure,intraocular pressure measurement,GCST005170,9:4237546,Sensory System
1255,IGF2,IGF2,Paternal,rs7948458-<b>A</b>,2 x 10-36,,0.19,'-,0.016 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012795,11:2151600,Sensory System
1256,IGF2,IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-10,,NR,'-,0.0153 mm decrease,[0.011-0.02],INS-IGF2,Corneal curvature,corneal topography,GCST90012799,11:2151600,Sensory System
1299,IGF2,IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-6,,0.51,'-,0.015 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012797,11:2151600,Sensory System
1300,IGF2,IGF2,Paternal,rs7948458-<b>A</b>,1 x 10-5,,0.2,'-,0.014 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012796,11:2151600,Sensory System
1334,IGF2,INS-IGF2,Paternal,rs7948458-<b>A</b>,2 x 10-36,,0.19,'-,0.016 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012795,11:2151600,Sensory System
1335,IGF2,INS-IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-10,,NR,'-,0.0153 mm decrease,[0.011-0.02],INS-IGF2,Corneal curvature,corneal topography,GCST90012799,11:2151600,Sensory System
1375,IGF2,INS-IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-6,,0.51,'-,0.015 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012797,11:2151600,Sensory System
1376,IGF2,INS-IGF2,Paternal,rs7948458-<b>A</b>,1 x 10-5,,0.2,'-,0.014 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012796,11:2151600,Sensory System
1409,INS,INS,Paternal,rs7948458-<b>A</b>,2 x 10-36,,0.19,'-,0.016 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012795,11:2151600,Sensory System
1410,INS,INS,Paternal,rs7948458-<b>A</b>,5 x 10-10,,NR,'-,0.0153 mm decrease,[0.011-0.02],INS-IGF2,Corneal curvature,corneal topography,GCST90012799,11:2151600,Sensory System
1446,INS,INS,Paternal,rs7948458-<b>A</b>,5 x 10-6,,0.51,'-,0.015 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012797,11:2151600,Sensory System
1447,INS,INS,Paternal,rs7948458-<b>A</b>,1 x 10-5,,0.2,'-,0.014 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012796,11:2151600,Sensory System
1465,INS,INS-IGF2,Paternal,rs7948458-<b>A</b>,2 x 10-36,,0.19,'-,0.016 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012795,11:2151600,Sensory System
1466,INS,INS-IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-10,,NR,'-,0.0153 mm decrease,[0.011-0.02],INS-IGF2,Corneal curvature,corneal topography,GCST90012799,11:2151600,Sensory System
1506,INS,INS-IGF2,Paternal,rs7948458-<b>A</b>,5 x 10-6,,0.51,'-,0.015 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012797,11:2151600,Sensory System
1507,INS,INS-IGF2,Paternal,rs7948458-<b>A</b>,1 x 10-5,,0.2,'-,0.014 mm decrease,'-,INS-IGF2,Corneal curvature,corneal topography,GCST90012796,11:2151600,Sensory System
2203,LIN28B,LIN28B,Paternal,rs314263-<b>C</b>,8 x 10-9,,0.3224,'-,0.081 unit increase,[0.052-0.11],LIN28B,Intraocular pressure,intraocular pressure measurement,GCST005580,6:104944870,Sensory System
2204,LIN28B,LIN28B,Paternal,rs7759938-<b>C</b>,5 x 10-9,,0.3244,'-,0.0828 unit increase,[0.053-0.112],LIN28B-AS1,Intraocular pressure,intraocular pressure measurement,GCST005580,6:104931079,Sensory System
2205,LIN28B,LIN28B,Paternal,rs111307712-<b>?</b>,4 x 10-9,,NR,'-,0.1168 unit decrease,[0.078-0.156],LIN28B-AS1,Intraocular pressure,intraocular pressure measurement,GCST006394,6:104931801,Sensory System
2263,LIN28B,LIN28B-AS1,Paternal,rs7759938-<b>C</b>,5 x 10-9,,0.3244,'-,0.0828 unit increase,[0.053-0.112],LIN28B-AS1,Intraocular pressure,intraocular pressure measurement,GCST005580,6:104931079,Sensory System
2264,LIN28B,LIN28B-AS1,Paternal,rs111307712-<b>?</b>,4 x 10-9,,NR,'-,0.1168 unit decrease,[0.078-0.156],LIN28B-AS1,Intraocular pressure,intraocular pressure measurement,GCST006394,6:104931801,Sensory System
2595,RASGRF1,RASGRF1,Paternal,rs4778879-<b>G</b>,4 x 10-11,,0.44,'-,0.102 unit decrease,[0.073-0.131],RASGRF1,Refractive error,Abnormality of refraction,GCST001858,15:79080533,Sensory System
2596,RASGRF1,RASGRF1,Paternal,rs6495367-<b>A</b>,2 x 10-24,,0.4075,'-,10.202 z score decrease,[NR],RASGRF1,Spherical equivalent or myopia (age of diagnosis),"age at onset, Myopia, refractive error measurement",GCST006291,15:79083005,Sensory System
2597,RASGRF1,RASGRF1,Paternal,rs6495367-<b>A</b>,4 x 10-8,,0.46,'-,'-,'-,RASGRF1,Spherical equivalent (joint analysis main effects and education interaction),"self reported educational attainment, refractive error measurement",GCST003455,15:79083005,Sensory System
2598,RASGRF1,RASGRF1,Paternal,rs6495367-<b>A</b>,5 x 10-6,(European ancestry),0.42,'-,'-,'-,RASGRF1,Spherical equivalent (joint analysis main effects and education interaction),"self reported educational attainment, refractive error measurement",GCST003455,15:79083005,Sensory System
2599,RASGRF1,RASGRF1,Paternal,rs13380104-<b>T</b>,3 x 10-12,,0.4178,'-,0.0937 unit decrease,[0.067-0.12],RASGRF1,Spherical equivalent,refractive error measurement,GCST006289,15:79086479,Sensory System
2600,RASGRF1,RASGRF1,Paternal,rs13380104-<b>?</b>,4 x 10-18,,NR,1.066,'-,[1.051-1.082],RASGRF1,Myopia,Myopia,GCST003997,15:79086479,Sensory System
2601,RASGRF1,RASGRF1,Paternal,rs1007365-<b>?</b>,1 x 10-9,,0.42,1.1828623,'-,[1.12-1.25],RASGRF1,High myopia,Myopia,GCST009962,15:79087150,Sensory System
2602,RASGRF1,RASGRF1,Paternal,rs1961579-<b>?</b>,8 x 10-84,,'-,'-,'-,'-,RASGRF1,Refractive error,Abnormality of refraction,GCST010002,15:79088174,Sensory System
2603,RASGRF1,RASGRF1,Paternal,rs1961579-<b>G</b>,3 x 10-37,,'-,'-,0.14 unit increase,[0.12-0.16],RASGRF1,Spherical equivalent,refractive error measurement,GCST010378,15:79088174,Sensory System
2604,RASGRF1,RASGRF1,Paternal,rs1961579-<b>A</b>,2 x 10-9,(EA),0.4206,'-,0.0895 unit decrease,[0.06-0.119],RASGRF1,Spherical equivalent,refractive error measurement,GCST006289,15:79088174,Sensory System
2605,RASGRF1,RASGRF1,Paternal,rs28415942-<b>T</b>,7 x 10-10,,0.54,1.26,'-,NR,"ANKRD34C-AS1, RASGRF1",High myopia,Myopia,GCST010994,15:79092508,Sensory System
2885,ST8SIA1,ST8SIA1,Paternal,rs144311425-<b>?</b>,9 x 10-26,,'-,'-,'-,'-,ST8SIA1,Refractive error,Abnormality of refraction,GCST010002,12:22402094,Sensory System
3222,ZIM2,ZIM2,Paternal,rs2072501-<b>?</b>,8 x 10-19,,NR,'-,0.3 unit increase,[0.22-0.38],"ZNF71, ZIM2-AS1",Ebbinghaus illusion (overestimation),visual perception measurement,GCST011568,19:56621600,Sensory System
3235,ZIM2,ZIM2-AS1,Paternal,rs2072501-<b>?</b>,8 x 10-19,,NR,'-,0.3 unit increase,[0.22-0.38],"ZNF71, ZIM2-AS1",Ebbinghaus illusion (overestimation),visual perception measurement,GCST011568,19:56621600,Sensory System
3847,CMTM1,CMTM1,Paternal,rs542982358-<b>?</b>,2 x 10-9,,NR,'-,0.7239 unit increase,[0.48-0.96],"MAF, CMTM1",Macular thickness,macula measurement,GCST006976,16:79576551,Sensory System
359,ERAP2,ERAP2,Paternal,rs2910686-<b>C</b>,2 x 10-8,(conditioned on rs27432),0.44,1.12,'-,'-,"AC009126.1, ERAP2",Psoriasis,psoriasis,GCST005527,5:96916885,Skin
374,ERAP2,ERAP2,Paternal,rs2910686-<b>?</b>,2 x 10-21,(subset analysis),NR,'-,'-,'-,"AC009126.1, ERAP2","Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)","ankylosing spondylitis, psoriasis, ulcerative colitis, Crohn's disease, sclerosing cholangitis",GCST005537,5:96916885,Skin
144,DLGAP2,DLGAP2,Paternal,rs13263535-<b>G</b>,3 x 10-13,,'-,'-,0.0062 unit increase,[0.0044-0.008],DLGAP2,Daytime nap,daytime rest measurement,GCST011494,8:1225131,Sleep
521,GLIS3,GLIS3,Paternal,rs12336359-<b>C</b>,9 x 10-9,,0.4037,'-,0.01448 unit increase,[0.0095-0.0194],GLIS3,Sleep duration,sleep duration,GCST007982,9:4129657,Sleep
522,GLIS3,GLIS3,Paternal,rs10758593-<b>G</b>,5 x 10-9,,0.6011,1.0362694,'-,[1.02-1.05],GLIS3,Insomnia,insomnia measurement,GCST007988,9:4292083,Sleep
1528,IRAIN,IRAIN,Paternal,rs7402939-<b>C</b>,5 x 10-9,,0.624,1.0362694,'-,[1.02-1.05],"IRAIN, FAM169B",Insomnia,insomnia measurement,GCST007988,15:98640647,Sleep
2145,LIN28B,LIN28B,Paternal,rs314280-<b>G</b>,1 x 10-9,,0.54824,1.01,'-,[1.00-1.03],LIN28B,Insomnia symptoms (never/rarely vs. usually),insomnia measurement,GCST007388,6:104952962,Sleep
2146,LIN28B,LIN28B,Paternal,rs314281-<b>C</b>,6 x 10-13,,0.5469,1.0438414,'-,[1.03-1.06],LIN28B,Insomnia,insomnia measurement,GCST007988,6:104952730,Sleep
2147,LIN28B,LIN28B,Paternal,rs13197753-<b>C</b>,4 x 10-10,(Male),0.5468,1.063,'-,[1.04-1.08],LIN28B-AS1,Insomnia,insomnia measurement,GCST007988,6:104924810,Sleep
2148,LIN28B,LIN28B,Paternal,rs370771-<b>T</b>,1 x 10-11,,0.4692,'-,'-,'-,LIN28B,Insomnia,insomnia,GCST010097,6:104950211,Sleep
2237,LIN28B,LIN28B-AS1,Paternal,rs13197753-<b>C</b>,4 x 10-10,(Male),0.5468,1.063,'-,[1.04-1.08],LIN28B-AS1,Insomnia,insomnia measurement,GCST007988,6:104924810,Sleep
3154,ZFAT,ZFAT,Paternal,rs4909296-<b>T</b>,3 x 10-8,,0.4839,'-,0.00935643 unit decrease,[0.006-0.0127],ZFAT,Chronotype,chronotype measurement,GCST007576,8:134578267,Sleep
3842,FAM50B,FAM50B,Paternal,rs6906656-<b>A</b>,1 x 10-7,(Hispanic),NR,1.57,'-,'-,"TDGF1P4, FAM50B",Insomnia,insomnia,GCST005566,6:3919326,Sleep
262,DLK1,DLK1,Paternal,rs12881545-<b>G</b>,3 x 10-7,,0.326561,'-,0.011 unit decrease,[0.0071-0.0149],"DLK1, AL132711.1",Serum 25-Hydroxyvitamin D levels,vitamin D measurement,GCST90000616,14:100709875,Vitamin
